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ABSTRACT 
 
PROTEIN-PROTEIN INTERACTIONS OF HUMAN MITOCHONDRIAL AMIDOXIME-
REDUCING COMPONENT IN MAMMALIAN CELLS 
 
 
 
By 
John A. Thomas 
December 2016 
 
Dissertation supervised by Partha Basu 
Newly discovered pterin-molybdoenzymes mammalian proteins, mARC1, and mARC2, 
are though to activate pro-drug, metabolize mutated base pairs, and producing nitric 
oxide from nitrite. However, the physiological function of the mARC proteins remain 
unclear. It is hypothesized that identifying partner proteins through protein-protein 
interactions can provide evidence to their physiological function. This study aimed to 
further investigate the potential function of mARC proteins through the identification of 
protein-protein interaction in human cell lysate, utilizing co-immunoprecipitation, 
crosslinking reagent, and pull-down assays. Several proteins (e.g. mitogen-activated 
protein kinase 5, phosphatidylinositol 4-phospahte 3-kinase C2 domain-containing 
subunit beta, ADP/ATP translocase 1, and myotubularin) were identified as interacting 
partners of mARC1, and mARC2. These interacting proteins are affiliated with various 
KEGG signaling pathways. From the interacting proteins we infer, mARC1 and mARC2 
may be involved in the regulation of nitric oxide signaling under hypoxic. Reverse co-
immunoprecipitation experiments using select proteins from the pathways detected 
mARC proteins. The investigation was then expanded to include pig liver mitochondrial 
fraction and rat liver cell lysate, in which all experimental conditions identified mARC 
proteins using reverse co-immunoprecipitation.  
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Chapter 1: Introduction 
1.1 Molybdenum-containing Enzymes and their Classes 
Molybdenum is an essential trace element in all forms of life.[1] Molybdenum-
containing enzymes play important roles in a vast array of metabolic processes in all 
forms of life. Enzymes requiring molybdenum cofactor for full functionality are capable 
of redox reactions involving carbon, sulfur, and nitrogen metabolism.[2-4] These 
enzymes require molybdenum to be ligated by a cofactor, resulting in two general 
categories for molybdenum cofactors, iron-molybdenum cofactor (FeMoco) and pterin-
based molybdenum cofactor (Moco).[5-9] Reactions involving Moco-containing enzymes 
can be characterized into either the transformation of species utilizing hydroxylation or 
oxygen atom transfer to/from a substrate involving two electrons.[2, 5, 10-12] Moco is 
commonly comprised of a molybdenum atom directly coordinated by a dithiolene ligand 
which is appended to a pyranopterin (Figure 1.1) or metal binding pterin.[13]  
  
Figure 1.1: The general structure of pyranopterin 
cofactor for molybdenum containing enzymes. 
Molybdenum atom is covalently bound to the ene-
dithiolate. R = H, monophosphate, guanidine 
dinucleotide, or cytosine dinucleotide. 
 2 
 
The two molybdenum-containing enzyme categories, FeMoco, and Moco can be 
further divided into different families based on active site structure. An example of a 
FeMoco containing enzyme is nitrogenase, the enzyme is involved in dinitrogen 
fixation.[14-17] Moco-containing enzymes, can further be divided into three families; 
sulfite oxidases (SO), xanthine oxidases (XO), and dimethyl sulfoxide reductases 
(DMSOR).[18] SO and XO family proteins contain a simple molybdopterin (MPT)-type 
cofactor.[5] They differ in the third Mo-S ligand in which SO contains an enzyme-derived 
cysteine and XO contains a sulphido ligand.[5] In DMSOR family of enzymes, two 
pyranopterin cofactors coordinate the molybdenum center, each having an additional 
guanosine monophosphate.[5] It has been proposed that there may be a fourth family in 
this category, mitochondrial amidoxime reducing-component (mARC), which may 
contain a structurally unique active site when compared to the other three families.[19] 
However, it has been recently accepted that mARC is indeed a part of the sulfite oxidase 
family.[8] Pterin-based molybdenum enzymes are generally mononuclear, where the 
molybdenum atom is coordinated by the pterin. In addition, the molybdenum is also 
coordinated by a sulfur, oxygen or selenium donor. The pterin-based molybdenum 
cofactor families typically function via oxygen atom transfer reactions or hydroxylation, 
and during catalysis the molybdenum center shifts between a fully oxidized and a 
reduced state. Figure 1.2 shows a comprehensive tree of the categories and families of 
molybdenum containing enzymes as well as the corresponding enzyme commission (EC) 
 3 
 
number and the Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathways 
involved. 
 
Figure 1.2: Categories of molybdenum containing enzymes. The families, enzyme 
function and corresponding metabolisms are listed. 
Molybdenum-containing 
Enzyme
Iron-molybdenum 
Cofactors
Pterin-based 
Molybdenum Cofactors
Nitrogenase
EC:1.18.6.1
Nitrogen Metabolism
Sulfite Oxidase
mARC
EC:1.8.3.1
Sulfur Metabolism
Xanthine Oxidase
EC:1.17.1.4,1.17.3.2
Purine Metabolism, 
Caffeine Metabolism, 
Drug Metabolism
Dimethyl sulfoxide 
Reductase
EC:1.8.5.3
Sulfur Metabolism
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1.2 Mammalian Molybdenum-containing Enzymes 
There are four mammalian molybdenum containing enzymes known. They 
include SO, XO, aldehyde oxidase (AO), and mARC.[11, 18, 20] The structural differences 
of the cofactor in these enzymes can be seen in Figure 1.3. The four proteins can be 
categorized into two or potentially three families. SO belongs to the SO family which 
contains a conserved cysteine ligated to the molybdenum center.[18] Xanthine 
oxidoreductase and AO belong to the xanthine oxidase family which contains a sulfido 
group bound the to the molybdenum center.[18] The active site in AO and XO can be 
superimposed, demonstrating a high degree of similarity.[21] The Moco-containing 
 
Figure 1.3: The structural differences in the 
mammalian molybdenum enzymes cofactors. A. 
Moco for sulfite oxidase family enzymes, B. Moco 
for xanthine oxidase family enzymes. 
B
A
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enzyme, mARC, is suggested to belong to the SO family based on the conserved cysteine 
residue or may potentially represent a new type of molybdenum-containing enzyme.[22] 
SO and XO are among the more well-known mammalian molybdenum containing 
enzymes with defined physiological roles in cysteine and purine metabolism.[2] The 
physiological roles of AO and mARC enzymes remain unclear; both proteins have been 
proposed to function in pro-drug activation.[23, 24] Aldehyde oxidases have a broad 
substrate specificity corresponding to compounds containing carboxylic acids and 
heterocycles, transforming substrates into hydroxylated derivatives.[23] The mARC 
enzymes have been shown to reduce substrates containing amidoxime groups into their 
active drug forms; these include antiprotozoal, anti-inflammatories, anti-cancer, and 
antidepressants.[24] 
The four mammalian molybdenum containing enzymes all have markedly 
different catabolic properties. SO catalyzes the oxidation of sulfite to sulfate. XO catalyzes 
the formation of hypoxanthine to xanthine and xanthine to uric acid.[18] AO catalyzes 
the oxidation of aldehydes to carboxylic acids.[2] Recently, mARC proteins have been 
found to metabolize compounds with N-hydroxylated side groups.[24, 25] These types 
of compounds are regularly used as pro-drugs (Figure 1.4 shows three pro-drugs. A more 
complete set of examples can be found in Figure 1.8). Interestingly, mARC proteins can 
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reduce nitrite to nitric oxide, which is a potent signaling molecule in mammalian 
systems.[26] 
1.3 Molybdenum-containing Enzymes and their Involvement in Mammalian Nitric 
Oxide 
There are two distinct nitric oxide synthesis pathways in mammalian systems. The 
first pathway is the nitric oxide synthase (NOS)-dependent pathway in which arginine is 
metabolized to form nitric oxide. The NOS pathway requires oxygen to catalyze the 
reaction. Under oxygen-limiting conditions, however, the body can produce nitric oxide 
using a second pathway involving the conversion of nitrite to nitric oxide. Nitrate is more 
available than nitrite in mammalian systems and requires the aid of oral commensal 
bacteria to generate nitrite from nitrate.[27] The subsequent reduction of nitrite to nitric 
oxide occurs in the mitochondria of cells. Nitric oxide is an important signaling molecule 
in multiple pathways. Figure 1.5 demonstrates two different pathways for nitric oxide 
 
Figure 1.4: Three example pro-drugs that mARC has been 
shown to be able to catalyze the activation by reducing the 
amidoxime functional groups. 
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production. The first is the normal oxygen conditions under which NOS can catalyze the 
formation of nitric oxide from arginine. The second pathway is under the hypoxic 
conditions when mARC proteins can be used to reduce nitrite into nitric oxide and the 
subsequent pathways associated with nitric oxide. Investigating the mammalian nitrite 
reductase pathways is of great interest for human health and disease, as the effects of 
nitrite are largely mediated by its reduction to nitric oxide. 
 
Figure 1.5: (Left) NOS pathway for nitric oxide production in which L-arginine or N-omega-
hydroxy-L-arginine can be oxidized by nNOS, iNOS, or eNOS to form L-citrulline and nitric 
oxide under normal oxygen conditions. (Right) Formation of nitric oxide by mARC proteins; 
nitrite is reduced by mARC proteins but requires cytochrome b5 (Cb5) and cytochrome b5 
reductase (Cb5R) as well as NADH. Nitric oxide has been found to be associated with different 
pathways in mammalian systems. 
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In mammals there are a several sources of nitric oxide namely, L-arginine, S-
nitrosothiols, nitrate and nitrite. The oxidation of L-arginine catalyzed by NOS is a well-
characterized pathways for nitric oxide production.[28-31] There are three distinct 
isozymes that have been identified in mammalian systems, neuronal NOS (nNOS or 
NOS-1), inducible NOS (iNOS or NOS-2), and endothelial NOS (eNOS or NOS-3).[32-34] 
It was found that if all three proteins were knocked out in mice, they displayed a shorter 
life expectancy, with increased risk of cardiovascular disease including hypertension, 
cardiac hypertrophy, diastolic heart failure, arteriosclerosis, and myocardial infarction; 
demonstrating the importance of nitric oxide production in mammalian systems.[35] The 
full functioning NOS proteins require five cofactors to effectively catalyze the formation 
of nitric oxide from L-arginine; tetrahydrobiopterin, flavin adenine dinucleotide, flavin 
mononucleotide, calmodulin, and iron protoporphyrin IX.[32, 36] The monomeric NOS 
isozyme is incapable of producing nitric oxide, producing instead oxygen.[36] NOS 
enzymes require substrates NADPH, L-arginine, and oxygen in order to produce NADP+, 
L-citrulline, and nitric oxide.[32] It is imperative that the NOS proteins form dimers in 
order to bind the tetrahydrobiopterin cofactor and the substrate L-arginine subsequently 
forming nitric oxide.[37]  
In addition to the oxidation of L-arginine to form nitric oxide, S-nitrosothiols are 
utilized to regulate protein expression for nitric oxide production and can also provide a 
source of nitric oxide.[38] S-nitrosothiols can be formed two ways; exogenously by a S-
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nitrosothiol donor (i.e., S-nitrosoglutathione) or endogenously by NOS proteins.[39] 
Furthermore, donor S-nitrosylated proteins can transfer the nitric oxide group to acceptor 
S-nitrosylation protein complexes.[40] While nitric oxide has a very short half-life (2 ms) 
in plasma, S-nitrosoproteins have half-lives of approximately one hour.[39] The release 
of nitric oxide from S-nitrosothiols have been shown to be achieved several ways in vitro; 
trace amounts of transition metal ions (Cu2+ or Fe2+), flash photolysis, as well as the 
addition of dithiothreitol, or vitamin C.[41-43] 
Nitrate can undergo a reductive process in which nitrite is formed by microbial 
nitrate reductase, and subsequently nitrite can be reduced to nitric oxide by different 
mammalian enzymes. Although many proteins and catalysts are known, this latter 
pathway is not well understood in mammalian cells at a molecular level. Nitrate and 
nitrite are now considered to be biological reservoir of nitric oxide, however, all the key 
enzymes influencing the process have yet to be understood.[38, 44] There is no known 
mammalian nitrate reductase, although several mammalian enzymes can reduce nitrate 
to nitrite with millimolar (mM) binding, which is orders of magnitude lower than the 
micromolar (μM) Km determined for bacterial and plant enzymes.[45] Thus, mammalian 
nitrate reduction is catalytically less efficient. Our assertion is that the nitrate to nitrite 
transformation is likely to be achieved by commensal bacterial nitrate reductase, a 
process we have been investigating for years.[46, 47] Several in vitro studies have 
indicated that nitrite to nitric oxide reduction is achieved by essentially three different 
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types of biomolecules: members of the globin family (e.g., hemoglobin, myoglobin and 
neuroglobin), pterin-containing molybdenum enzymes (e.g., XO; AO; SO) and nitrite 
anhydrase enzymes (e.g., carbonic reductase). Under specific conditions, these pterin-
containing enzymes have been reported to be able to catalyze the reduction of nitrate and 
nitrite to nitric oxide (Table 1.1).[26, 48-50] Hemoglobin and myoglobin are iron and 
oxygen-binding proteins are capable of catalyzing the formation of produce nitric oxide. 
Hemoglobin, which is used in oxygen transport, has demonstrated potential to produce 
nitric oxide from nitrite at a max rate under the conditions of 40-60% saturation at a pH 
of 6.4.[51-53] The second protein, myoglobin, is capable of producing nitric oxide from 
nitrite; deoxymyoglobin has been shown to reduce nitrite at a rate of 36 times faster than 
deoxyhemoglobin.[54] Hemoglobin and myoglobin are oxygen-sensing proteins that aid 
in the scavenging of nitric oxide, but under conditions of hypoxia the roles change to 
nitric oxide producers; inducing vasodilation and increasing blood flow to tissue.[55-57] 
Xanthine oxidoreductase is capable of producing nitric oxide from both nitrate and nitrite 
in anoxic tissue.[58, 59] Under hypoxic conditions mitochondrial cytochrome c oxidase 
Table 1.1: The in vitro enzymatic properties of some known mammalian 
proteins capable of reducing nitrite to nitric oxide. 
Protein Name Reducing Substrate, pH 
𝒌𝒄𝒂𝒕
𝑵𝑶𝟐
−
 
(s-1) 
𝒌𝒎
𝑵𝑶𝟐
−
 
(mM) 
𝒌𝑵𝑶𝟐
−
 
(M-1s-1) 
Aldehyde oxidase [48] Aldehyde, pH 7.4 0.47 4.1 115 
Mitochondrial 
amidoxime reducing-
component [26] 
NADH, pH 7.4 0.1 9.5 11 
Sulfite oxidase [50] 
Sulfite, pH 7.4 
Phenosafranine, pH 7.4 
0.002 
1.9 
1.6 
80 
1.3 
26 
Xanthine oxidase 
[48,49] 
Aldehyde, pH 7.4 0.41 2.2 186 
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has been shown to produces nitric oxide depending on the pH of the system.[60] Xanthine 
oxidoreductase and mitochondrial cytochrome c oxidase potentially demonstrate a role 
in increasing blood flow to ischemic tissue.[60-62]  
Organic nitro compounds have been shown to be reduced to nitric oxide by 
aldehyde dehydrogenase 2 under normoxic conditions.[62, 63] Although aldehyde 
dehydrogenase 2 has been shown to reduce nitroglycerin, the proteins physiological 
function have eluded researchers.[62, 63] Interestingly, the activity and expression of 
aldehyde dehydrogenase 2 in the vascular system when there is a tolerance to organic 
nitrates.[64, 65] The final proteins that have demonstrated their capabilities to reduce 
nitrate and nitrite to nitric oxide are cytochrome P450 reductase and cytochrome 
P450.[66] 
Nitric oxide is an important signaling molecule in the vascular endothelium, 
nervous and immune systems, aiding in the regulation of behavior, gastrointestinal 
motility, and defense mechanisms against infectious disease and tumors.[67-73] The 
signaling molecule stimulates soluble guanylyl cyclase (sGC) and promotes the 
formation of cyclic guanosine monophosphate (cGMP) through a signaling cascade 
referred to as cGMP-PKG signaling pathway.[74-78] The signaling cascade is used in 
smooth muscle cell relaxation by activating protein kinase G (PKG) and increases the 
reuptake of calcium into the sarcoplasmic reticulum, reducing cytosolic calcium 
concentrations, resulting in the activation of potassium channels.[79-83] Myosin light 
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chain kinase is a calcium/calmodulin-dependent enzyme, the decrease concentration of 
cytosolic calcium prevents the phosphorylation of myosin and subsequently causes the 
relaxation of smooth muscle.[84-88] In addition to being a key signaling molecule in 
muscle relaxation, in the presence of electron acceptors, nitric oxide can form S-
nitrosylated proteins by reacting with deprotonated cysteines.[89] S-nitrosylations aids 
in the regulation and function of G protein-coupled receptors, as well as help to modulate 
pathways within vascular cells.[40, 90] The activity of G protein-coupled receptors kinase 
2 regulates the phosphorylation of β-adrenoceptors, this system can be regulated by nitric 
oxide and S-nitrosylation. In some cases S-nitrosylation helps prevent the reduction of β-
adrenergic signaling in vivo by mediating the phosphorylation of β-adrenoceptors and 
avoiding the receptors desensitization.[90, 91] Activation of β1 and β2-adrenoceptors in 
heart tissue increases muscular contraction; while the opposite occurs in blood vessels, 
activation of β-adrenoceptors results in vasodilation.[92-98] Thus, NO-cGMP signaling 
cascade is therapeutically relevant for treating cardiovascular disorders with therapies 
targeting sGC.[99] 
1.4 Novel Mammalian Enzyme: mARC 
The newly discovered pterin molybdenum-containing enzyme, mitochondrial 
amidoxime-reducing component (mARC) has been shown in vitro to reduce nitrite to 
nitric oxide more efficiently than any other human molybdenum containing enzymes.[26] 
As previously stated, mARC proteins are proposed to belong to the SO family of 
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molybdenum containing enzymes.[2, 100] There are two isoforms of mARC proteins that 
have been annotated in humans with an overall sequence identity/similarity of 66/80%, 
mARC1 and mARC2 (UniProt ID: Q5VT66, Q969Z3) (Figure 1.6).[19] The number of 
amino acids in both mARC proteins is very similar (mARC1: 337 amino acids, and 
mARC2: 335 amino acids).[22] The proteins contain similar domains; amino-terminal 
mitochondrial signal sequence, a predicted β-barrell domain, and a MOSC domain near 
the carboxyl terminus.[101] Even though mARC is a mitochondrial protein it has been 
found through cellular staining to be also located outside the mitochondria, as it is 
anchored to the outer mitochondrial membrane and may detach.[102, 103] Both mARC 
 
Figure 1.6: Sequence alignment of human mARC1 and mARC2 proteins. Similar domains in 
mARC proteins are highlighted; mitochondrial signaling sequence (red), MOSC, N-terminal β-
barrel sequence (blue), molybdenum cofactor sulfurase, C-terminal (green), and conserved 
cysteines (purple) which may coordinate to Moco. 
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proteins are capable of reducing N-oxygenated species, although the rate of the reaction 
are not high. These proteins require cytochrome b5, and cytochrome b5 reductase ancillary 
proteins to perform reduction.[24, 25, 104, 105] The physiological function of mARC 
enzymes is uncertain at a cellular level, but an in vitro study demonstrated that they may 
be utilized in the pro-drug metabolism by catalyzing the reduction of amidoxime 
functional groups to amidines.[46, 106-109] There is also evidence that mARC proteins 
can function in lipid synthesis, nitrite reduction to for nitric oxide and the detoxification 
of N-hydroxylated nucleotides.[19, 26, 105, 110] The expression of mARC1 and mARC2 
is found throughout the body with varying degrees of expression of each protein in 
selected tissue (Figure 1.7). Using a method referred to as intensity based absolute 
quantitation (iBAQ) in which the sum of all peptide peak intensities are divided by the 
number of theoretically observed tryptic peptides the relative abundances of mARC1 and 
mARC2 proteins were quantitated in different tissues.[111] Figure 1.7 shows that mARC2 
is expressed to a higher degree in similar tissues as mARC1. This may indicate that the 
physiological roles of mARC1 and mARC2 may be different. In the kidneys and liver, 
both involved in detoxification of harmful metabolites, mARC2 showed a higher 
expression than mARC1; indicating that one potential role of these proteins is the 
catabolism of harmful substrates. In addition, mARC2 was found to be expressed in the 
heart while mARC1 was not. To this end, the physiological function of mARC proteins 
 15 
 
in humans is unknown and this investigation seeks to provide clarity in the physiological 
role of mARC.
  
 
16 
  
 
Figure 1.7: Protein expression of mARC1. Expression of mARC1 in females (left), males (center), and the iBAQ intensities for tissue (right). 
(proteomicsdb.org/)[112] 
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Figure 1.8: Protein expression of mARC2 in humans. Expression of mARC2 in females (left), males (center), and the iBAQ intensities for 
tissue (right). (proteomicsdb.org/)[112] 
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The presence of NADH, cytochrome b5, and cytochrome b5 reductase has been 
shown to be important to the activity of mARC proteins.[19, 25, 105, 108, 113] In in vitro 
studies, during the regeneration step, the catalytic center of the mARC enzyme receives 
electrons from NADH via electron transfer partner proteins, cytochrome b5, and 
cytochrome b5 reductase, without which mARC proteins’ function is impaired. Given the 
slow rate of the reaction, it is not clear whether cytochrome b5, and cytochrome b5 
reductase are the physiological electron transfer partners with mARC. There are two 
isoforms of cytochrome b5 encoded by different genes, type A and type B.[114, 115] Type 
A cytochrome b5 is localized as membrane-bound in microsomes as well as a soluble 
form.[114, 116] The type B isoform is localized to the mitochondrial outer membrane.[117-
119] The catalytic properties of mARC have been achieved in vitro using both types of 
cytochrome b5.[120] However, a knockout study demonstrated that type B-cytochrome b5 
is required for the N-reductive pathways.[25, 105] 
As previously stated mARC proteins may have an involvement in several different 
pathways, but the exact physiological role of mARC proteins is not well understood.[22] 
There is the potential that mARC proteins may be involved in nitric oxide production in 
humans. Under aerobic conditions, mitochondrial fractions of different tissue containing 
heterologously expressed mARC1 and mARC2 have been shown to produce nitric oxide 
from Nω-hydroxy-L-arginine.[113] Under hypoxic conditions mARC proteins coupled 
with the ancillary proteins cytochrome b5, and cytochrome b5 reductase have been 
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identified to reduce nitrite into nitric oxide.[26] As previously stated nitric oxide is a 
potent signaling molecule and affects several different mammalian pathways, suggesting 
that mARC proteins may be involved in signaling cascades.  
Human mARC proteins may also participate in the metabolic detoxification of N-
hydroxylated nucleobases and nucleosides such as N-hydroxycytosine, N-
hydroxyadenine, cytidine, and adenine.[19, 110] The down-regulation of mARC2 in colon 
tumors demonstrated a significant role of mARC-mediated detoxification of mutagenic 
DNA bases.[121] This suggests that mARC proteins may be involved in the detoxification 
and prevention of accumulation of mutagenic substances within the cells. 
It has also been found that the expression of mARC2 and N-reductive activity were 
increased in adipose tissue, suggesting that mARC2 may be regulated under lipogenic 
conditions within differentiation of murine cells into mature adipocytes.[22, 105, 122, 123] 
The down-regulation of mARC2 was found to impact lipid synthesis in cells 
negatively.[105] It has also been observed that the expression of mARC proteins and N-
reductive activity were affected by fasting and a high-fat-diet in mice, suggesting that 
mARC proteins may be involved lipid metabolism within cells.[116] 
Currently, mARC proteins are exploited for their potential in pro-drug 
metabolism to reduce amidoxime to amidines.[22] Compounds containing amidine 
functional groups are used in several types of treatment including; factor Xa inhibitors, 
thrombin inhibitors, factor VIIa inhibitors, urokinase-type plasminogen activators, anti-
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microbial agents (i.e. parasitic, bacterial, malaria), and antiplatelet GPIIb/IIIa-receptor 
antagonist.[124-131] The issue with compounds containing amidines is their strong 
basicity and under physiological conditions can readily be protonated, resulting in a low 
bioavailability within the body.[132, 133] By converting the amidines to amidoxime 
functional groups the compounds can no longer be protonated, and the basicity is also 
greatly reduced, allowing for a bioreversible compound that utilizes enzymes like mARC 
proteins to catalyze the reduction of the pro-drug into the active form.[22] The mARC 
protein system has been tested and showed success in several model substrates, pro-
drugs including anti-cancer and antiprotozoal agents, transforming drug metabolites, 
and the reduction of mutated nucleotides and harmful metabolites (Figure 1.8).[19, 26, 
107-110, 113, 116, 126, 134, 135] Thus, the physiological function of mARC proteins 
remains unknown in human systems, but studies have demonstrated that they may be 
involved in nitric oxide production, detoxification of mutated base pairs, and lipid 
metabolism. By understanding the metabolic properties of the mARC system, 
physiological functions may be proposed.  
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Figure 1.9: Substrates that have been evaluated using the mARC system. 
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1.5 Specific Aims of Study 
 The global objective of this study is to understand potential the physiological role 
of mARC1 and mARC2 through identifying interacting proteins through protein-protein 
interaction in vitro experiments. Protein-protein interactions can provide insight into the 
physiological function of mARC proteins. One of the issues with performing protein-
protein interaction studies is the number of falsely identified proteins (false 
positives).[136] The experimental conditions, cell types, and reagents used affect the 
protein-protein interactions. To collect a more comprehensive the data set for this study, 
three different methods to identify protein-protein interactions were used; 
chemical/photoactivated crosslinking, co-immunoprecipitation, and pull-down assay. 
Interactions were probed in human embryonic kidney (HEK-293) cell lysate using 
purified mARC1 and mARC2 overexpressed in Escherichia coli. Proteins were selected for 
reverse co-immunoprecipitation specifically looking for mARC1 and mARC2 for the 
selected proteins. Reverse co-immunoprecipitation experiments were carried out in HEK-
293 cells lysate as well rat liver tissue lysate and pig mitochondrial lysate. By identifying 
potential interacting partners of mARC proteins, a better understanding of the 
physiological function can be probed.  
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Chapter 2: Sample Preparation and Experimental Methods  
 All reagents, materials, and kits used in the subsequent experiments can be found 
in Appendix I, Table A1. 
2.1 Lysate Preparation and Recombinant mARC Protein 
HEK-293 cells were grown, harvested, and lysed at the University of Pittsburgh, 
Pittsburgh, PA, by Dr. Courtney Sparacino-Watkins. The cells used were modified to 
overexpress mARC2 with a green fluorescent protein (GFP) tag, as reported in the 
literature.[26] Rat liver tissue was supplied by Dr. Courtney Sparacino-Watkins 
University of Pittsburgh, Pittsburgh, PA. Purified mARC1 and mARC2 were supplied by 
Dr. Courtney Sparacino-Watkins University of Pittsburgh, Pittsburgh, PA, following a 
procedure previously published.[26] Pig liver mitochondrial fractions were supplied by 
Dr. Antje Havemeyer of the Institute of Pharmaceutical Chemistry, Christian-Albrechts 
University of Kiel, Kiel.  
HEK-293 cells were lysed by resuspending the cell pellet in 5 mL of Pierce Lysis 
Buffer and sonicating them with 5 cycles of 3-second pulses on ice. The lysis buffer 
contains a mild detergent capable of releasing proteins in the membrane fraction. The 
soluble cell fraction was collected by centrifuging at 11,250xg for 15 minutes at 4°C. Rat 
liver tissue was washed using the PierceTM Lysis Buffer (Appendix I). The liver was then 
diced into smaller pieces using a stainless steel razor blade. The pieces were resuspended 
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in 5 mL of lysis buffer (Appendix I) and sonicated for 5 cycles of 3-second pulses on ice. 
The soluble cell fraction was collected by centrifuging at 11,250xg for 15 minutes at 4°C. 
2.2 Experimental Methods to Identify Interacting Proteins with mARC Protein 
Three different methods to identify protein-protein interactions were used to 
identify potentially affiliated partners with mARC1 and mARC2. Each type of 
experiment had experimental and control conditions to improve the results interpreted. 
The experimental conditions used purified mARC proteins and HEK-293 cell lysate to 
identify interacting partners. The control conditions were to ensure there were no false 
positives identified by the affinity purification methods and used either purified mARC 
proteins or HEK-293 cell lysate. In Table 3.3 the experimental and control conditions are 
listed. All experimental and control conditions (co-immunoprecipitation, crosslinking, 
Table 2.1: Experimental and control conditions for each method used to 
identify protein-protein interactions.  
Experimental Control 
Co-immunoprecipitation 
† mARC1 + HEK-293 Lysate 
‡ mARC2 + HEK-293 Lysate 
†‡ HEK-293 Lysate 
† Purified mARC1 
‡ Purified mARC2 
Crosslinking 
† mARC1 + HEK-293 Lysate 
‡ mARC2 + HEK-293 Lysate 
† Reduced mARC1 + HEK-293 Lysate 
‡ Reduced mARC2 + HEK-293 Lysate 
†‡ HEK-293 Lysate 
Pull-down 
† mARC1 + HEK-293 Lysate 
‡ mARC2 + HEK-293 Lysate 
†‡ HEK-293 Lysate 
† Purified mARC1 
‡ Purified mARC2 
Reverse Co-
Immunoprecipitation 
†‡ HEK-293 Lysate 
†‡ Pig Liver 
†‡ Rat Liver 
†‡ HEK-293 Lysate 
† Conditions used for mARC1 
‡ Conditions used for mARC2 
†‡ Conditions used for mARC1 and mARC2 
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pull-down assay and associated mass spectrometric analyses) were performed in 
triplicate to improve the robustness of the data. 
2.2.1 Co-immunoprecipitation of Interacting proteins with mARC Proteins 
The mARC antibodies used for co-immunoprecipitation can be found in Table 2.1. 
A stock of 1X coupling buffer (0.01 M sodium phosphate, 0.15 M sodium chloride, pH 
7.2) was prepared from the 20X coupling buffer (0.20 M sodium phosphate, 3 M sodium 
chloride, pH 7.2)(Appendix I) by diluting 3 mL of buffer into 57 mL of ultra-pure water. 
The AminoLink® Plus Coupling Resin, aldehyde-activated agarose beads, and coupling 
buffer were equilibrated to room temperature. The AminoLink® Coupling Resin was 
resuspended, and 50 µL was pipetted into labeled spin column tubes. Using a table top 
centrifuge (1,000xg), the supernatant was removed. The resin was washed with 200 µL 
aliquots of 1X coupling buffer, centrifuged to remove supernatant and repeated once 
Table 2.2: Antibodies that were used in the co-immunoprecipitation and reverse co-
immunoprecipitation. 
Antibody Gene Name Type Company Catalog Number 
MAP3K5 (ASK1) 
Monoclonal Santa Cruz Biotechnology, Santa 
Cruz, California 
sc-5194 
PIK3C2B 
Monoclonal Santa Cruz Biotechnology, Santa 
Cruz, California 
sc-100407 
SLC25A4 (ANT 1/2) 
Polyclonal Santa Cruz Biotechnology, Santa 
Cruz, California 
sc-9299 
MTM1 
Monoclonal Santa Cruz Biotechnology, Santa 
Cruz, California 
sc-377309 
GAPDH Monoclonal Invitrogen, Waltham, Massachusetts 39-8600 
mARC1 (MOSC1) 
Polyclonal Abcam, Cambridge, United 
Kingdom 
ab103191 
mARC2 (MOSC2) 
Polyclonal Abcam, Cambridge, United 
Kingdom 
ab111685 
mARC2 (MOSC2)* 
Polyclonal Abcam, Cambridge, United 
Kingdom 
ab197195 
*Used previously and was not able to purify mARC2 based on mass spectrometry data. 
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more. Antibody (50 µg) was added to the resin, and the volume was adjusted to 200 µL 
using 1X coupling buffer. The antibody was coupled to the AminoLink® Coupling Resin 
by adding 3 µL of 5 M sodium cyanoborohydride solution in the fume hood. The reaction 
was allowed to proceed for 120 minutes at room temperature on a rotator. The 
supernatant was removed using centrifugation at 1,000xg. The reaction mixture was 
rinsed with 200 µL 1X coupling buffer, centrifuged, and the process was repeated once 
more. The reaction was quenched by adding 200 µL of quenching buffer (Appendix I), 
the supernatant was removed through centrifuging. Quenching buffer was again added 
(200 µL) with 3 µL of sodium cyanoborohydride and incubated for 15 minutes at room 
temperature on a rotator. The supernatant was removed by centrifuging, and the resin 
was washed twice with 200 µL of 1X coupling buffer. The resin was then washed a total 
of 6 times with 150 µL of the wash buffer (Appendix I). The bait/prey interaction mixture 
was prepared by adding 50 µg of purified mARC protein to 1 mg of protein in HEK-293 
cell lysate. The resin was washed twice using 200 µL of IP lysis/wash buffer (Appendix 
I), and centrifuged to remove supernatant. The reaction was added to the resin and 
incubated overnight at 4°C on a rotator to ensure the mixture remains suspended. The 
flow through was removed by centrifuging and the resin was washed three times with 
200 µL of IP lysis/wash buffer. The bait/prey proteins were eluted from the resin by 
adding 25 µL of the elution buffer (Appendix I) and incubating at room temperature for 
5 minutes. Elution was repeated a total of 3 times resulting in ~75 µL if flow-through. 
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2.2.2 Crosslinking of Interacting proteins with mARC Proteins 
The Sulfo-SBED Label Transfer Reagent (Appendix I, Figure A.1A) was purchased 
from Thermo Fisher Scientific, Waltham, MA. The No-WeighTM microtubes contained 
1.12 mg of Sulfo-SBED Label Transfer Reagent and were reconstituted in 22 µL of DMSO. 
The K-BLoC (Appendix I, Figure A.1B) compound was a customized to bind to the active 
site in mARC and bind the non-specific crosslinking reagent transforming it into a site 
specific complex. was reconstituted in phosphate buffer (0.01 M sodium phosphate, 0.15 
M sodium chloride, pH 7.2). K-BLoC and Sulfo-SBED crosslinker were reacted by adding 
5 mg of K-BLoC and 11 µL of the reconstituted Sulfo-SBED crosslinker and incubated for 
30 minutes at room temperature; the resulting complex will be referred to as LTR-K-BLoC 
complex (Appendix I, Figure A.1C). The precipitate was seperated from the soluble 
fraction by centrifugation. To bind the LTR-K-BLoC complex to purified mARC proteins, 
200 µg was added to 50 µg of protein. They were incubated together for 15 minutes at 
room temperature. The LTR-K-BLoC complex binding to mARC1 was confirmed after 
buffer exchange, using intact protein mass spectrometry. The buffer exchange was 
carried out using ZebaTM Micro Spin Desalting Columns. The storage solution was 
removed by centrifuging using a table top centrifuge. The resin was then rinsed 3 times 
with 50 µL of 50 mM triethylammonium acetate. The sample was added to the final 
volume of 12 µL and 3 µL of 50 mM triethylammonium acetate was added as a stacking 
layer to aid in flow-through. The column was centrifuged at 1000xg for 2 minutes, and 
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the sample was collected. Excess LTR-K-BLoC complex was removed using ZebaTM Micro 
Spin Desalting Columns. The storage solution was removed by centrifuging using a table 
top centrifuge. The sample was added to the final volume of 12 µL and 3 µL of ultrapure 
water was added as a stacking layer to aid in flow-through. The column was centrifuged 
at 1,000xg for 2 minutes, and the sample was collected. Once the mARC complex was 
desalted, 1 mg of HEK-293 cell lysate was incubated for 5 minutes at room temperature. 
The sample was then placed on ice under a long-wave UV lamp for 15 minutes to bond 
interacting partners through the photoactive aryl azide covalently. Three biological 
replicates from mARC1 and mARC2 interacting with HEK-293 cell lysate were reduced 
by adding 10 µL of 50 mM dithiothreitol (DTT) and incubated for 15 minutes to reduce 
the disulfide bond present in the Sulfo-SBED crosslinker. Immobilized Streptavidin was 
resuspended, and 50 µL aliquots were placed into each spin column. The resin was rinsed 
using 250 µL of TBS buffer and inverted several times. The supernatant was removed 
using centrifugation at 1,000xg for 30 seconds. This process was repeated a total of three 
times. The bait/prey crosslinked samples were then incubated with the streptavidin resin 
for 1 hour at 4°C. The unbound proteins were rinsed from the resin using centrifugation 
at 1,000xg for 30 seconds. The resin was washed by adding 250 µL of wash buffer and 
inverted several times to resuspended the slurry. The eluent was removed using 
centrifugation at 1,000xg for 30 seconds. This process was repeated a total of four times. 
Proteins were eluted from the Streptavidin resin by first neutralizing the pH of the sample 
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by adding 10 µL of the neutralization buffer. Then 250 µL of elution buffer was added to 
the samples and inverted several times. Samples were incubated for 5 minutes at room 
temperature and then collected using centrifugation at 1,000xg for 30 seconds.  
2.2.3 Pull-down Assay of Interacting proteins with mARC Proteins 
The bait proteins, i.e., mARC1 and mARC2, were overexpressed and purified 
using a polyhistidine tag as previously discussed in Chapter 2.1.[26] The bait protein was 
immobilized onto HisPurTM Cobalt Resin by pipetting 50 uL of the slurry resin into spin 
columns. The resin was rinsed using 400 uL of wash solution (1:1 tris-buffered saline:lysis 
buffer, 10 mM imidazole)(Appendix I) and inverting the spin columns. The caps were 
then removed and placed into a tabletop centrifuge to remove buffer. There was a total 
of 5 washing steps to prepare the cobalt resin. The purified mARC1 and mARC2 were 
added to the PierceTM spin columns to the final concentration of 50 µg of protein. The 
samples were then incubated at 4°C for 60 min using a rotator to maintain suspension of 
the resin. Both caps were removed, and the supernatant was removed using a table top 
centrifuge. The resin was rinsed using 400 µL of wash buffer and inverted several times. 
Again, the supernatant was removed using a table top centrifuge. This wash process was 
repeated a total of 5 times. The HEK-293 cell lysate was added to the spin columns to the 
final amount of 1 mg of proteins. Samples were then incubated at 4°C overnight on a 
rotating platform. The supernatant was then removed using a table top centrifuge. The 
samples were then washed with 400 µL of the wash buffer a total of 5 times. Bait and prey 
 30 
 
protein were then eluted from the resin by adding 250 µL of 290 mM imidazole elution 
buffer (Appendix I). Samples were incubated at room temperature for 5 min on a rotating 
platform. The bait and prey protein was collected in sample tubes using a table top 
centrifuge.  
2.3 Mass Spectrometry Method for Protein Analysis 
 All mass spectrometric data collection and analyses was performed at Duquesne 
University, Pittsburgh, PA at the Agilent Technologies Center of Excellence, supported 
by NSF DBI 0821401 
2.3.1 In-solution Trypsin Digestion 
 Tryptic peptides were produced by first adding equal volumes of 2,2,2-
trifluoroethanol (TFE) to samples with 5 µL of 200 mM dithiothreitol (DTT). Samples 
were then incubated at 56°C for 1 hour to denature and reduce proteins. A 10 µL aliquot 
of 200 mM iodoacetamide (IAM) was added to each sample and incubated at room 
temperature and covered for 1 hour. Samples were dried using a Forma Speed Vac and 
resuspended in 50 µL of 100 mM ammonium bicarbonate buffer. Digestion occurred by 
adding 5 µg of trypsin and incubated at 36°C overnight. The pH of the solution was 
adjusted by adding 2 µL of formic acid and vortexed to cease the digestion. The samples 
were again dried and then reconstituted in 95% water, 5% acetonitrile, and 0.1% formic 
acid for LC-MS/MS analysis. 
 
 31 
 
2.3.2 Liquid Chromatography Mass Spectrometry (LC-MS/MS) Peptide Analysis 
The protein mass spectrometric analysis was performed using a quadrupole-time-
of-flight (Q-TOF) LC-MS system (Agilent Technologies, Santa Clara, CA) equipped with 
a 1200 Series binary liquid chromatography, Dual AJS ESI source, and a 6530 Q-TOF mass 
spectrometer. The instrument was operated under the MassHunter Data Acquisitions 
software (version B.05.01 build 5.01.5125.1, Agilent Technologies, Santa Clara, CA).  
Tryptic digested peptides were separated on a Aeris™ 3.6 μm WIDEPORE XB-C18 200 
Å, LC Column 150 x 2.1 mm (00F-4482-AN, Phenomenex, Torrance, CA) using a gradient 
of 5% acetonitrile, 95% water, and 0.1% formic acid to 80% acetonitrile 10% water, 10% 
2,2,2-trifluoroethanol, and 0.1% formic acid using the time table and flow rates in Table 
2.2. The source parameters were set to the values in Table 2.3. Fragmentor voltage, 
skimmer voltage, and OCT RF Vpp were set to 200 V, 65 V, and 750 V, respectively. The 
MS settings used were the following: precursor ion selection, medium (4 m/z); mass 
range, 120−1700 m/z; acquisition rate MS, 7 scans/sec; acquisition rate MS/MS, 4 scans/s 
(m/z 59-3000). The collision energy was adjusted based on the charge of the precursor 
(Table 2.4). Reference mass correction was enabled using reference mass of 121.05087300, 
and 922.00979800 m/z. 
2.3.2 Intact Protein Mass Spectrometry  
The intact protein mass spectrometric analysis was performed using a 
quadrupole-time-of-flight (Q-TOF) LC-MS system (Agilent Technologies, Santa Clara, 
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CA) equipped with a 1200 Series binary liquid chromatography, Dual AJS ESI source, 
and a 6530 Q-TOF mass spectrometer. The instrument was operated under the 
MassHunter Data Acquisitions software (version B.05.01 build 5.01.5125.1, Agilent 
Technologies, Santa Clara, CA).  Intact proteins were injected using a 10 µL injection 
volume with a 3-second needle wash and set with an isocratic gradient of 5% acetonitrile, 
95% water, 0.1% formic acid with 5 minutes run time using a flow rate of 0.450 mL/min. 
The source parameters were set to the values in Table 2.3. Fragmentor voltage, skimmer 
voltage, and OCT RF Vpp were set to 400 V, 65 V and 750 V, respectively. The MS settings 
used were the mass range, 100−3200 m/z; acquisition rate MS, 7.00 scans/sec. 
 
Table 2.3: Binary pump gradient table used for LC-MS/MS analysis. 
Time A [%] B [%] Flow [mL/min] Max Pressure [bar] 
0.00 100.0 0.0 0.450 400.00 
35.00 70.0 30.0 0.450 400.00 
40.00 0.0 100.0 0.450 400.00 
42.00 0.0 100.0 0.450 400.00 
43.00 100.0 0.0 0.450 400.00 
45.00 100.0 0.0 0.450 400.00 
 
Table 2.4: Dual AJS ESI source parameters 
for LC-MS/MS analysis. 
Dual AJS ESI Value 
Gas Temperature 340°C 
Drying Gas 10 L/min 
Nebulizer 45 psig 
Sheath Gas Temperature 400°C 
Sheath Gas Flow 11 L/min 
Voltage Capillary 3500 V 
Nozzle Voltage 1000 V 
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2.4 Bioinformatics Software for Peptide and Protein Identification 
2.4.1 Spectrum Mills Proteomic Workbench (Rev B.04.01.141) 
Our research group has previously published a proteomic research paper in a 
peer-reviewed journal using the similar parameters as will be discussed.[137] Collision-
induced dissociation (CID) data were searched against a custom homo sapiens databases 
that were created using the UniProt (uniprot.org) database, and all protein identifiers 
used in this investigation were denoted by their UniProt numbers and gene name. Peak 
lists were created with the Spectrum Mills Proteomic Workbench Data Extractor program 
with the following attributions. Scans with the same precursor ±1.4 m/z were merged 
within a time frame of ±30 seconds. Precursor ions needed to have a minimum signal to 
noise value of 25. Charges up to a maximum of 7 were assigned to the precursor ion, and 
the 12C peak was determined by the Data Extractor. The custom database was searched 
for tryptic peptides with a mass tolerance of ±1.2 Da for the precursor ions and a tolerance 
of ±0.7 Da for the product ions. Two missed cleavages were allowed. A Spectrum Mills 
auto validation was performed first in the protein details followed by peptide mode using 
a.) in protein details mode; protein score ≥20, peptide score (scored percent intensity 
Table 2.5: Collision energy to 
generate product ions. 
Charge Slope Offset 
2 3 2 
3 3.6 -4.8 
>3 3.6 -4.8 
Unknown 3.6 -4.8 
1 3.5 6 
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[SPI]) charge +2 (>6.0, >60.0%), peptide charge +1 (>6.0, >70.0%), peptide charge +3 (>8.0, 
>70.0%), peptide charge +4 (>8.0, >70%), peptide charge +5 (>12.0, >70.0%), peptide charge 
+2 (>6.0, >90.0%), and rank 1 minus rank 2 score threshold >2.0 for all rules the last which 
was set to >1.0; b.) in peptide mode: precursor charge +2 (>11.0, >60.0%), peptide charge 
+1 (>13.0, >70%), peptide charge +3 (>13.0, >70.0%), peptide charge +4 (>13.0, >70.0%), 
peptide charge +5 (>15.0, >70.0%), and rank 1 minus rank 2 score threshold >2. All protein 
hits found in a distinct database search by Spectrum Mill are non-redundant. 
2.4.2 Agilent MassHunter Qualitative Analysis with BioConfirm (Version B.06.00, 
Build 6.0.633.0) 
Once proteins were identified using Spectrum Mills Proteomic Workbench the 
BioConfirm software package was used to investigate the identified proteins further 
using high-resolution mass spectrometry data. Once the files were loaded into the 
software “Find by Molecular Feature” was used to identify the compound in the samples 
meeting the criteria found in Table 2.5. The protein sequences from each protein 
identified were loaded into the software using trypsin as the digestion reagent allowing 
Table 2.6: BioConfirm "Find by Molecular Feature" parameters 
used to identify compounds from mass spectrometry data. 
Find by molecular Feature Parameter 
Target Data type Small molecules (chromatographic) 
Restrict m/z to 350.00-2000.00 m/z 
Use Peaks with height ≥100 counts  
Ion Species H+, Na+, K+ 
Peak Space tolerance 0.0025 m/z, plus 7.0 ppm 
Isotope Model Peptides 
Maximum charge state 15 
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for up to 2 missed cleavages, global modifications were set to alkylation (iodoacetamide), 
and variable modifications were set to deamidation and oxidation. The compounds 
identified from “Find by Molecular Feature” were then analyzed using “Define and 
Match Sequences” with the MS tolerance of 10.00 ppm, and the MS/MS tolerance of 50.00 
ppm. 
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Chapter 3: Results and Discussion for Proteins Interacting with mARC1 and mARC2 
3.1 K-BLoC, LTR-K-BLoC Complex, and mARC1 Native Intact Protein Mass 
Spectrometry 
Mass spectrometric analysis was used to identify LTR-K-BLoC complex binding 
to mARC1. A bottom-up approach was used first to identify the starting materials K-
BLoC, and Sulfo-SBED reagent, then the LTR-K-BLoC complex, and finally intact mARC1 
with LTR-K-BLoC bound. 
The K-BLoC compound (179.22 MW) was identified by mass spectrometry as seen 
in Figure 3.1. The highest abundant peak at 180.1105 m/z (M+H)+ suggests the protonated 
form of K-BLC. The second most abundant peak at 163.0838 m/z indicates a loss of a –OH 
group suggesting the reduced form of K-BLoC may also be present. 
Analysis of Sulfo-SBED label transfer reagent was performed under the same 
instrument parameters. Upon the addition of DMSO the NHS-ester side chain is 
 
Figure 3.1: Mass spectrum for K-BLC compound. 
 
(M+H)+
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removed, activating one of the reactive group. In Figure 3.2 of the mass spectrometry 
analysis of Sulfo-SBED label transfer reagent, there are four compounds present from the 
m/z range of 675 to 885. The most abundant peak at 681.2291 m/z is proposed to be 
activated Sulfo-SBED reagent with the loss of the NHS-ester. The peak present at 703.2108 
m/z denotes a mass shift of ~22 m/z from the activated Sulfo-SBED reagent suggesting a 
sodium adduct. The peaks present at 858.2019 and 880.1828 m/z are proposed to be the 
starting/unactivated form of Sulfo-SBED, without and with a sodium adduct. 
Once the Sulfo-SBED label transfer reagent was activated by removal of the NHS-
ester side chain, it was anticipated to bind to the lysine side chain of the K-BLoC 
compound. Figure 3.3 is the mass spectrometry analysis of the LTR-K-BLoC complex. 
The peaks present at 681.2266 and 703.2084 m/z are the activated Sulfo-SBED without and 
with sodium adduct. The peaks of interest are present at 842.3227 and 864.3047 m/z which 
 
Figure 3.2: Mass spectrum for Sulfo-SBED label transfer reagent. 
 
(M+H)+
(M+Na)+
(M-NHS ester)+
(M-NHS ester+Na)+
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are suggested to be the bound Sulfo-SBED and K-BLoC compound (LTR-K-BLoC 
complex). 
To identify the interaction of the LTR-K-BLoC complex and mARC proteins, native 
intact protein mass spectrometry was used. Figure 3.4 show the purified mARC1 
analyzed intact (A) and the deconvoluted results (B). The calculated MW of the 
cytoplasmic portion (41-337 AA) of mARC1 is 33,635.80 Da, and the molybdopterin 
cofactor is 519.26 Da. Adding the protein and the cofactor the calculated mass is 34,155.06 
Da. The calculated value and observed (34,146.42 Da) from the deconvoluted results 
agree reasonably with a 0.025% difference. After incubating with the LTR-K-BLoC 
complex and deconvoluting the results (Figure 3.5) there is a noticeable split of the intact 
mARC1 peak. The unreacted mARC1 appears at 34,144.47 Da, but four other peaks 
appear to have emerged. The calculated MW of mARC1, the cofactor, and the LTR-K-
 
Figure 3.3: Mass spectrum for LTR-K-BLC complex. 
(M)+
(M+Na)+
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BLoC complex is 34,997.38 Da. The peak of interest is 34,982.86 Da; the difference is 
approximately 0.041% difference (or ~14.5 Da) which may be a loss of nitrogen or possibly 
oxygen in the complexed protein. 
 
 
Figure 3.4: Mass spectrum for intact mARC1 unreacted with LTR-K-BLoC complex. A. Mass 
spectrum gathered from the analysis of intact mARC1, B. the deconvoluted results of intact 
mARC1. 
A
B
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3.2 Data Mining mARC1 and mARC2 Protein-protein Interactions 
 Very few interaction studies have been performed using mARC1 and mARC2. 
Using STRING database (string-db.org/), reported protein-protein interactions were 
compiled for mARC1 and mARC2.[138] Interactions in the database classified under 8 
categories (neighborhood, gene fusion, co-occurrence, experiments, databases, data 
 
Figure 3.5: Mass spectrum for intact mARC1 reacted with LTR-K-BLoC complex. A. Mass 
spectrum gathered from the analysis of intact mARC1 reacted with LTR-K-BLoC complex, B. the 
deconvoluted results of intact mARC1 reacted with LTR-K-BLoC complex. 
A
B
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mining, and homology). Each interaction is scored with a confidence score, which was 
set to ≥0.5 for mARC1 and mARC2 interactions. The confidence score is calculated by 
combining the probabilities of various evidence and correcting for the random 
observations of interaction.[139] STRING database also categorizes the interacting 
proteins into functional networks (e.g., GOTerm biological process, GOTerm molecular 
function, and KEGG pathways). The categories are ranked by false discovery rate; 
nothing was reported with a score of ≥0.03 for biological process, ≥0.01 molecular 
function, and ≥0.01 KEGG pathway. The false discovery rate was calculated using a 
statistical enrichment test referred to as LRpath.[140, 141] This form of statistical 
comparison uses logistic regression so the data can remain on a continuous scale and 
results can be interpreted similarly to the Fisher’s Exact test.[140, 141] 
 There were 20 proteins that were reported in the STRING database to be shown as 
interacting with mARC1. There were 8 of the 20 were identified from data mining, and 
12 identified from experiments (i.e. co-immunoprecipitation, and affinity capture-MS 
assay) for mARC1. The 20 proteins can be found in Table 3.1 and labeled according to 
their associated categories, functional networks, and scores.  
There are 12 GOTerm biological processes involving the interacting proteins. 
Interestingly, the three biological processes with the lowest false discovery rate are: small 
molecules metabolic, single-organism metabolic, and oxidation-reduction processes. 
Based on this information, 8 of the interacting proteins are involved in the oxidation-
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reduction process, and mARC1 is known to reduce compound with amidoxime groups 
suggesting its potential physiological involvement. There are also 3 biological processes, 
respiratory electron transport chain, mitochondrial electron transport, and mitochondrial 
ATP synthesis coupled electron transport. All of which are involved in electron transfer 
processes, suggesting mARC may function as a redox protein.  
There are 4 GOTerm molecular functions identified for the interacting proteins. 
The top two molecular functions are oxidoreductase activity, and oxidoreductase activity 
acting on NAD(P)H. Again strengthening the proposal that mARC1 may be involved in 
reductive processes as its biological function. 
Of the 20 interacting proteins identified with mARC1, 9 were affiliated with 7 
different KEGG pathways identified for interacting proteins with mARC1. The pathway 
with the lowest false discovery score is oxidative phosphorylation. Interestingly enough 
the next 4 pathways identified are different disease pathways, non-alcoholic fatty liver 
disease, Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease. There were 
8 potential interacting proteins with mARC2 predicted through data mining. The 8 
proteins can be found in Table 3.2 and labeled according to their associated categories, 
functional networks, and scores. There were 4 GOTerm biological processes that were 
reported for interacting proteins with mARC2, molybdopterin cofactor biosynthetic 
proteins, small molecule, water-soluble vitamin, and single-organism metabolic process. 
The interactions of molybdopterin proteins (MOCS1, MOCS2, GPHN) may be involved 
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in the maturation process of mARC2. Similar to mARC1, cytochrome b5 reductase has 
also been proposed to interact with mARC proteins because it is involved in the reductive 
system. 
The information provided regarding the GOTerm molecule function and KEGG 
pathways provides almost no information regarding the potential physiological function 
of mARC2. Xanthine dehydrogenase contains a molybdopterin cofactor binding domain 
similar to that in mARC2. The MOCS1 and MOCS2 proteins are both involved in the 
sulfur relay system and the folate biosynthesis pathways. The sulfur relay system is a 
signaling system involved in cell cycles processes like cell proliferation, apoptosis, and 
DNA repair.
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Table 3.1: Proteins identified in the STRING database as interacting proteins with mARC1.  
UniProt ID (Gene 
Name), Protein 
Name 
Category 
(Score) 
GOTerm Biological Process (False Discovery Rate) 
GOTerm 
Molecular 
Function (False 
Discovery Rate) 
KEGG Pathway (False Discovery 
Rate) 
P15313 (ATP6V1B1), 
V-type proton 
ATPase subunit B, 
kidney isoform[20] 
Experiments 
(0.644) 
small molecule metabolic process (0.00878); single-
organism metabolic process (0.00878); purine 
nucleotide metabolic process (0.024); ATP metabolic 
process (0.0252); organonitrogen compound 
metabolic process (0.0341) 
 
Oxidative phosphorylation 
(0.0000516); Metabolic pathways 
(0.00512); Phagosome (0.0163) 
Q9UKI2 
(CDC42EP3), Cdc42 
effector protein 
3[142-152] 
Data mining 
(0.675) 
   
Q6BCY4 (CYB5R2), 
NADH-cytochrome 
b5 reductase 2[105] 
Data mining 
(0.567) 
small molecule metabolic process (0.00878); single-
organism metabolic process (0.00878); oxidation-
reduction process (0.00878) 
oxidoreductase 
activity (0.0055); 
oxidoreductase 
activity, acting on 
NAD(P)H (0.0055) 
 
Q52LR7 (EPC2), 
Enhancer of 
polycomb homolog 
2[49, 153] 
Data mining 
(0.526) 
single-organism metabolic process (0.00878) 
  
Q96DN0 (ERP27), 
Endoplasmic 
reticulum resident 
protein 27[105] 
Data mining 
(0.517) 
   
Q15031 (LARS2), 
Probable leucine--
tRNA ligase, 
mitochondrial[154] 
Data mining 
(0.596) 
small molecule metabolic process (0.00878); single-
organism metabolic process (0.00878); 
organonitrogen compound metabolic process 
(0.0341) 
  
Q9P015 (MRPL15), 
39S ribosomal 
protein L15, 
mitochondrial[20] 
Experiments 
(0.644) 
single-organism metabolic process (0.00878); 
organonitrogen compound metabolic process 
(0.0341) 
  
 
  
 
45 
 
  
Table 3.1: Continued  
UniProt ID (Gene 
Name), Protein 
Name 
Category 
(Score) 
GOTerm Biological Process (False Discovery Rate) 
GOTerm 
Molecular 
Function (False 
Discovery Rate) 
KEGG Pathway (False Discovery 
Rate) 
Q9NYK5 (MRPL39), 
39S ribosomal 
protein L39, 
mitochondrial[20] 
Experiments, 
Data mining 
(0.695) 
single-organism metabolic process (0.00878); 
organonitrogen compound metabolic process 
(0.0341) 
  
O96000 (NDUFB10), 
NADH 
dehydrogenase 
[ubiquinone] 1 beta 
subcomplex subunit 
10[20, 155] 
Experiments, 
Data mining 
(0.676) 
small molecule metabolic process (0.00878); single-
organism metabolic process (0.00878); oxidation-
reduction process (0.00878); respiratory electron 
transport chain (0.0202); mitochondrial electron 
transport, NADH to ubiquinone (0.024); purine 
nucleotide metabolic process (0.024); energy 
derivation by oxidation of organic compounds 
(0.024); mitochondrial ATP synthesis coupled 
electron transport (0.0252); cellular respiration 
(0.0252); ATP metabolic process (0.0252); oxidative 
phosphorylation (0.0286); organonitrogen compound 
metabolic process (0.0341) 
oxidoreductase 
activity (0.0055); 
oxidoreductase 
activity, acting on 
NAD(P)H 
(0.0055); NADH 
dehydrogenase 
(ubiquinone) 
activity (0.0114) 
Oxidative phosphorylation(0.0000516); 
Non-alcoholic fatty liver disease 
(0.00133); Parkinson s disease 
(0.00133); Alzheimer s disease 
(0.00154); Huntington s disease 
(0.00181); Metabolic pathways 
(0.00512) 
O95168 (NDUFB4), 
NADH 
dehydrogenase 
[ubiquinone] 1 beta 
subcomplex subunit 
4[5, 14, 20] 
Experiments 
(0.644) 
small molecule metabolic process (0.00878); single-
organism metabolic process (0.00878); oxidation-
reduction process (0.00878); respiratory electron 
transport chain (0.0202); mitochondrial electron 
transport, NADH to ubiquinone (0.024); purine 
nucleotide metabolic process (0.024); energy 
derivation by oxidation of organic compounds 
(0.024); mitochondrial ATP synthesis coupled 
electron transport (0.0252); cellular respiration 
(0.0252); ATP metabolic process (0.0252); oxidative 
phosphorylation (0.0286); organonitrogen compound 
metabolic process (0.0341) 
oxidoreductase 
activity (0.0055); 
oxidoreductase 
activity, acting on 
NAD(P)H 
(0.0055); NADH 
dehydrogenase 
(ubiquinone) 
activity (0.0114) 
Oxidative phosphorylation 
(0.0000516); Non-alcoholic fatty liver 
disease (0.00133); Parkinson s disease 
(0.00133); Alzheimer s disease 
(0.00154); Huntington s disease 
(0.00181); Metabolic pathways 
(0.00512) 
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Table 3.1: Continued 
UniProt ID (Gene 
Name), Protein 
Name 
Category 
(Score) 
GOTerm Biological Process (False Discovery Rate) 
GOTerm 
Molceular 
Function (False 
Discovery Rate) 
KEGG Pathway (False Discovery 
Rate) 
O43181 (NDUFS4), 
NADH 
dehydrogenase 
[ubiquinone] iron-
sulfur protein 4, 
mitochondrial[20] 
Experiments 
(0.644) 
small molecule metabolic process (0.00878); single-
organism metabolic process (0.00878); oxidation-
reduction process (0.00878); respiratory electron 
transport chain (0.0202); mitochondrial electron 
transport, NADH to ubiquinone (0.024); purine 
nucleotide metabolic process (0.024); energy 
derivation by oxidation of organic compounds 
(0.024); mitochondrial ATP synthesis coupled 
electron transport (0.0252); cellular respiration 
(0.0252); ATP metabolic process (0.0252); oxidative 
phosphorylation (0.0286); organonitrogen compound 
metabolic process (0.0341) 
oxidoreductase 
activity (0.0055); 
oxidoreductase 
activity, acting on 
NAD(P)H 
(0.0055); NADH 
dehydrogenase 
(ubiquinone) 
activity (0.0114) 
Oxidative phosphorylation(0.0000516); 
Non-alcoholic fatty liver disease 
(0.00133); Parkinson s disease 
(0.00133); Alzheimer s disease 
(0.00154); Huntington s disease 
(0.00181); Metabolic pathways 
(0.00512) 
Q9H0N0 (RAB6C), 
Ras-related protein 
Rab-6C[14, 20] 
Experiments 
(0.644) 
   
P31040 (SDHA), 
Succinate 
dehydrogenase 
[ubiquinone] 
flavoprotein 
subunit, 
mitochondrial[20] 
Experiments, 
Data mining 
(0.655) 
small molecule metabolic process (0.00878); single-
organism metabolic process (0.00878); oxidation-
reduction process (0.00878); respiratory electron 
transport chain (0.0202); energy derivation by 
oxidation of organic compounds (0.024); cellular 
respiration (0.0252) 
oxidoreductase 
activity (0.0055) 
Oxidative phosphorylation 
(0.0000516); Non-alcoholic fatty liver 
disease (0.00133); Parkinson s disease 
(0.00133); Alzheimer s disease 
(0.00154); Huntington s disease 
(0.00181); Metabolic pathways 
(0.00512) 
Q8IWL2 (SFTPA1), 
Pulmonary 
surfactant-
associated protein 
A1[156, 157] 
Data mining 
(0.53) 
  
Phagosome (0.0163) 
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Table 3.1: Continued 
UniProt ID (Gene Name), 
Protein Name 
Category 
(Score) 
GOTerm Biological Process (False Discovery 
Rate) 
GOTerm 
Molceular 
Function (False 
Discovery Rate) 
KEGG Pathway (False Discovery 
Rate) 
O00330 (PDHX), Pyruvate 
dehydrogenase protein X 
component, 
mitochondrial[11, 20] 
Experiments, 
Data mining 
(0.662) 
small molecule metabolic process (0.00878); 
single-organism metabolic process (0.00878) 
 
Metabolic pathways (0.00512) 
Q8IWL1 (SFTPA2), 
Pulmonary surfactant-
associated protein A2[156, 
157] 
Data mining 
(0.527) 
  
Phagosome (0.0163) 
Q96AG3 (SLC25A46), 
Solute carrier family 25 
member 46[20] 
Experiments 
(0.644) 
   
P0CG48 (UBC), 
Polyubiquitin-C[158] 
Experiments 
(0.86) 
small molecule metabolic process (0.00878); 
single-organism metabolic process (0.00878); 
oxidation-reduction process (0.00878); energy 
derivation by oxidation of organic compounds 
(0.024) 
  
P47989 (XDH), Xanthine 
dehydrogenase/oxidase[49, 
105, 159-161] 
Data mining 
(0.52) 
small molecule metabolic process (0.00878); 
single-organism metabolic process (0.00878); 
oxidation-reduction process (0.00878); purine 
nucleotide metabolic process (0.024); 
organonitrogen compound metabolic process 
(0.0341) 
oxidoreductase 
activity (0.0055); 
molybdopterin 
cofactor binding 
(0.0114) 
Metabolic pathways (0.00512) 
Q9UPT8 (ZC3H4), Zinc 
finger CCCH domain-
containing protein 4[20] 
Experiments 
(0.644) 
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Table 3.2: Proteins identified in the STRING database as interacting proteins with mARC2.  
UniProt ID (Gene Name), 
Protein Name 
Category 
(Score) 
GOTerm Biological Process (False Discovery 
Rate) 
GOTerm 
Molecular 
Function (False 
Discovery Rate) 
KEGG Pathway (False Discovery 
Rate) 
Q15031 (LARS2), Probable 
leucine-tRNA ligase, 
mitochondrial[154] 
Texting 
mining (0.636) 
small molecule metabolic process (0.00489), 
single-organism metabolic process (0.0147) 
  
Q96DN0 (ERP27), 
Endoplasmic reticulum 
resident protein 27[105] 
Texting 
mining (0.500) 
   
Q6BCY4 (CYB5R2), 
NADH-cytochrome b5 
reductase 2[105] 
Texting 
mining (0.560) 
small molecule metabolic process (0.00489), 
single-organism metabolic process (0.0147) 
  
Q52LR7 (EPC2), Enhancer 
of polycomb homolog 
2[162] 
Texting 
mining (0.566) 
single-organism metabolic process (0.0147)   
O96007 (MOCS2), 
Molybdopterin synthase 
catalytic subunit[49, 160, 
163] 
Texting 
mining (0.842) 
Mo-molybdopterin cofactor biosynthetic process 
(0.00000325), small molecule metabolic process 
(0.00489), water-soluble vitamin metabolic 
process (0.0138), single-organism metabolic 
process (0.0147) 
 Sulfur relay system (0.00222), Folate 
biosynthesis (0.00224) 
Q9NP27 (MOCS1), 
Molybdenum cofactor 
synthesis-step 1 protein A 
splice type I[49] 
Texting 
mining (0.882) 
Mo-molybdopterin cofactor biosynthetic process 
(0.00000325), small molecule metabolic process 
(0.00489), water-soluble vitamin metabolic 
process (0.0138), single-organism metabolic 
process (0.0147) 
 Sulfur relay system (0.00222), Folate 
biosynthesis (0.00224) 
P47989 (XDH), Xanthine 
dehydrogenase oxidase[49, 
105, 160, 164, 165] 
Texting 
mining (0.505) 
small molecule metabolic process (0.00489), 
single-organism metabolic process (0.0147) 
molybdopterin 
cofactor binding 
(0.00707) 
 
Q9NQX3 (GPHN), 
Gephyrin[49] 
Neighborhood, 
Data mining 
(0.758) 
Mo-molybdopterin cofactor biosynthetic process 
(0.00000325), small molecule metabolic process 
(0.00489), water-soluble vitamin metabolic 
process (0.0138), single-organism metabolic 
process (0.0147) 
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3.3 Experimental and Control Conditions to Identify Interacting Partners with mARC 
Proteins 
3.3.1 Co-immunoprecipitation 
 Co-immunoprecipitation experiments utilize antigen-antibody reactions to 
precipitate the targeted bait protein as well as interacting partners.[166] Monoclonal and 
polyclonal antibodies have their advantages and challenges in co-immunoprecipitation 
experiments. While monoclonal antibodies target specific epitopes within protein 
sequences resulting in reduced background noise and cross-reactivity, polyclonal 
antibodies allow for sequence flexibility in the target site tolerating sequence variability 
leading to a more robust detection of the target proteins.[166] The advantages of co-
immunoprecipitation include high specificity based on the characteristics of the antibody, 
and compatibility with downstream analysis, in which mass spectrometric techniques 
will be used.[167, 168] In contrast the disadvantages to co-immunoprecipitation include 
the limitation of the specificity of the antibody used, and often a considerable amount of 
protein extract (100-1000 µg) of protein is required for identification downstream.[166-
168] Co-immunoprecipitation experiments have been used in several instances to identify 
interacting partners. Luethy et al. used co-immunoprecipitation to study protein-protein 
interactions of pyruvate dehydrogenase complex (PDC) in pea seedlings.[169] PDC is a 
large (5000-7000 kDa) multi-component complex comprised of three major enzymes 
(pyruvate dehydrogenase, E1 dihydrolipoamide transacetylase, E2; and 
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dihydrolipoamide dehydrogenase, E3) with multiple subunits of each enzyme.[169] A 
highly specific antibody to PDC-E1α subunit was found to precipitate subunits E1β, E2, 
and E3 when separated on SDS-PAGE.[169] Using a novel approach in which co-
immunoprecipitation was linked with crosslinking Huang et al. examined interacting 
proteins with protein kinase B (Akt) in mouse neuroblastoma cells.[170] Akt is a 
serine/threonine-specific protein kinase that is essential for multiple cellular 
processes.[170] They were able to crosslink the Akt antibody to agarose bead, incubate 
with cell lysate containing Akt protein, then chemically crosslinking interacting proteins 
to Akt using dithiobis[succinimidylpropionate].[170] Using this method they were able 
to identify ten interacting proteins with Akt, with only one of which that was able to be 
detected without the added crosslinking step.[170] The previous examples are only a few 
of the successful experiments utilizing co-immunoprecipitation to studying interacting 
partners with target proteins. 
3.3.2 Crosslinking 
 Chemical crosslinking involves the process of covalently binding interacting 
proteins together using a reagent with two reactive groups separated by a spacer/linker 
region.[171] The benefits of crosslinking allow for transient interactions between proteins 
to be probed by “locking” the interactions.[166] Crosslink reagents have been customized 
to meet the users’ needs by varying the chemical activity, length of that spacer, water 
solubility, cell membrane permeability, and cleavability.[167] Crosslinking is coupled 
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with including, but not limited to affinity purification, mass spectrometric identification, 
and SDS-PAGE.[172, 173] A disadvantage to using crosslinking reagents is the 
nonspecific interactions that may occur when other proteins are in the vicinity of the bait 
protein.[166] These nonspecific interactions may not be in direct contact with the bait 
protein. Downstream analysis of proteins or peptides can often be more difficult by the 
addition of chemical crosslinking reagents.[167] One such example of chemical 
crosslinking utilizes formaldehyde as the crosslinking reagent to investigate protein-
protein interactions within yeast cells.[174] In this study Hall et al. wished to develop a 
way of investigating interactions within the cells using formaldehyde to crosslink 
transcriptional activator proteins chemically.[174] They were able to demonstrate the 
direct interaction of VP16 activation domain and TATA-binding protein, transcription 
factor II B, and SAGA histone acetylase complex.[174] Li et al. performed a 
comprehensive protein-protein interaction study of DmsD maturation protein in E. coli 
strains by utilizing affinity chromatography, co-precipitation, and crosslinking.[175] The 
study used the same crosslinking reagent as was used in this investigation, Sulfo-SBED 
label transfer reagent. They were able to identify six chaperones and molybdenum 
cofactor biosynthesis proteins through this method.[175] The use of crosslinking reagents 
aids in the stabilization of protein interactions by covalently linking partners together, 
allowing for the strong and weak interacting partners to be identified. 
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3.3.3 Pull-down 
 The pull-down assay usually utilizes a fusion tagged (i.e. GST, MBP, CBP, poly-
His, or biotin) bait protein which demonstrates a high affinity for an enzyme and 
substrate, receptor and ligand, antibody and antigen.[166] The bait protein can often be 
overexpressed and purified using the resin compatible with the fusion tag. The drawback 
to pull-down assays is a significant amount of DNA manipulation is required to 
overexpress tagged bait protein.[167] Matsunami et al. utilized pull-down assays to 
identify interacting partners of FlgA-FlgI complex in E. coli OrigamiTM 2.[176] FlgI protein 
was overexpressed with an N-terminal poly-histidine tag to investigate the isolation of 
the complex using metal affinity chromatography.[176] Pull-down assays are not limited 
to poly-histidine tags, Wei et al. utilized a GST-tag to affinity purify interacting proteins 
in the ATP-binding cassette transport system in Bifidobacterium longum NCC2705.[177] 
There are four subunits in the system, FruE, FruK, FruF, and FruG. Using the GST-tag 
they were able to identify interactions between external-side membrane subunits FruF 
and FruG with FruE which shows a high correlation with the proposed model for 
bacterial ABC sugar transporters.[177] Pull-down assays can utilize a wide array of 
affinity tags to affinity purify bait and target proteins to identify interacting partners with 
high compatibility with downstream analysis methods. 
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3.3.4 Protein-protein Interactions of mARC1 and mARC2 Results 
Utilizing the antibodies listed in Table 2.1 a total of 176 proteins were identified 
in mARC1 and 83 proteins were identified in mARC2 control and in the co-
immunoprecipitation experiments. Figure 3.6A show the proteins that were identified in 
control samples as well as in experimental conditions in mARC1 and mARC2 samples. 
In mARC1 samples, 85 proteins were identified as unique when compared to the controls 
conditions, and 23 proteins were identified as unique in mARC2 conditions.  
Using the trifunctional crosslinking reagent (Appendix I, Figure A.1A) a total of 
124 proteins were identified in mARC1 and 25 proteins identified in mARC2 control and 
in experimental conditions in the crosslinking experiments. Figure 3.6B show the 
proteins that were identified in control, and experimental conditions in mARC1 and 
mARC2 samples. In mARC1 samples 106 proteins were identified as unique when 
compared to the controls conditions and in mARC2 13 proteins were identified as unique.  
A total of 181 proteins were identified in mARC1 and 112 proteins identified in 
mARC2 control and experimental conditions in the crosslinking experiments. Figure 3.6C 
show the proteins that were identified in control, and experimental conditions in mARC1 
and mARC2 samples. In mARC1 samples 27 proteins were identified as unique when 
compared to the control conditions, and in mARC2 samples 18 proteins were identified 
as unique.  
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Pull-down experiments including mARC1 and mARC2 proteins had the most 
proteins identified from other protein-protein interaction methods. This may suggest an 
increase number of false positives interacting with the Co-NTA resin. The crosslinking 
experiments in both mARC1 and mARC2 yielded the lowest number of proteins 
identified, suggesting a reduced number of false positive interactions and potentially a 
 
Figure 3.6: Venn diagrams depicting the number of proteins that were identified in control 
conditions compared to experimental conditions. A. Co-immunoprecipitation experiments, B. 
Crosslinking experiments, C. Pull-down experiments. The complete list of proteins identified for 
all experiments can be found in Appendix II, Table A.1 for mARC1 samples and Appendix II, 
Table A.2 for mARC2 samples. 
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more reliable method for analyzing protein-protein interactions using the method used 
for this investigation. The co-immunoprecipitation experiments yielded a number of 
proteins between the pull-down crosslinking experiments, but there was difficulty 
disguising interacting partners due to the lack of specificity of the mARC1 and mARC2 
antibodies. 
3.4 Bioinformatics Results and Discussion for Protein-protein Interactions 
3.4.1 Reducing Falsely Identified Interacting Proteins with mARC Proteins 
One of the issues with performing any protein-protein interaction studies is false 
positives identified from the mass spectrometric analysis. To minimize the number of 
false positives, the following criteria were set: BioConfirm score of ≥10, ≥2 MS/MS spectra 
per peptide, ≥2 unique peptides per protein, and absent in the controls (Figure 3.7). The 
number of total proteins meeting these criteria significantly reduced the number of 
 
Figure 3.7: Workflow for reducing the potential false positive interactions in all three 
experimental conditions. 
 56 
 
identified proteins. In mARC1 samples, 38 proteins were identified and 28 proteins 
identified for mARC2. Figure 3.8 represents the number of proteins found in each of the 
different experimental conditions. The proteins identified in the crosslinking experiment 
seemed to demonstrate a higher similarity with proteins identified in both pull-down and 
co-immunoprecipitation. Upon further analysis of the co-immunoprecipitation 
experiments, it was determined that the mARC1 and mARC2 antibodies used were not 
specific and subsequently also purified both mARC proteins. Therefore, we included a 
single circle in the middle of the Venn diagram. In mARC1 samples, 12 proteins were 
found in all three experimental types and mARC2 6 proteins were found in all three types 
 
Figure 3.8: Venn diagram depicting the number of proteins 
identified comparing the experimental conditions. Proteins 
identified in co-immunoprecipitation for mARC1 (*) and mARC2 
(†) 
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(Table 3.4). The proteins in Table 3.5 were identified in two experimental conditions and 
Table 3.6 were identified one experimental condition for mARC1 and mARC2 
respectively.  
Table 3.3: The proteins identified in all three experimental conditions for mARC1 and 
mARC2 proteins.  
UniProt ID Protein Name 
Interacting mARC 
Protein 
Q8N187 Calcium-responsive transcription factor mARC1 
Q8IYX3 Coiled-coil domain-containing protein 116 mARC1 
Q7L0Q8 Rho-related GTP-binding protein RhoU mARC1 
P02768 Serum albumin mARC1 
P31040 
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, 
mitochondrial 
mARC1 
Q15431 Synaptonemal complex protein 1 mARC1 
Q9BZE0 Zinc finger protein GLIS2 mARC1 
Q5VT66 Mitochondrial amidoxime-reducing component 1 mARC1 
R4GMW8 Protein BIVM-ERCC5 (Fragment) mARC1 
Q9P218 Collagen alpha(XX) chain mARC1 
P27816 Microtubule-associated protein 4 mARC1 
Q04726 Transducin-like enhancer protein 3 mARC1 
O75891 Cytosolic 10-formyltetrahydrofolate dehydrogenase mARC2 
O94927 HAUS augmin-like complex subunit 5 mARC2 
O95696 Bromodomain-containing protein 1 mARC2 
Q6UB35 Monofunctional C1-tetrahydrofolate synthase, mitochondrial mARC2 
Q86XP3 ATP-dependent RNA helicase DDX42 mARC2 
Q969Z3 Mitochondrial amidoxime reducing component 2 mARC2 
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 Table 3.4: Proteins identified in at least two experimental conditions interacting partners with 
mARC1 and mARC2 in HEK-293 cell lysate. 
UniProt ID Protein Name 
Interacting mARC 
Protein; Technique 
Q32M45 Anoctamin-4 mARC1; 1, 3 
P06727 Apolipoprotein A-IV mARC1; 1, 3 
Q8IYE1 Coiled-coil domain-containing protein 13 mARC1; 1, 3 
P51160 Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha mARC1; 1, 3 
P78334 Gamma-aminobutyric acid receptor subunit epsilon mARC1; 1, 3 
P04908 Histone H2A type 1-B/E mARC1; 1, 3 
Q6UXK5 Leucine-rich repeat neuronal protein 1 mARC1; 1, 3 
E5KNQ5 Mitochondrial thymidine kinase 2 mARC1; 1, 3 
Q969R2 Oxysterol-binding protein 2 mARC1; 1, 3 
Q8IUH5 Palmitoyltransferase ZDHHC17 mARC1; 1, 3 
Q8NFW9 Rab effector MyRIP mARC1; 1, 3 
Q3MIN7 Ral guanine nucleotide dissociation stimulator-like 3 mARC1; 1, 3 
Q6MZT1 Regulator of G-protein signaling 7-binding protein mARC1; 1, 3 
P21549 Serine--pyruvate aminotransferase mARC1; 1, 3 
Q549N5 Signal recognition particle receptor beta subunit mARC1; 1, 3 
Q8NCR6 Spermatid-specific manchette-related protein 1 mARC1; 1, 3 
Q9BT88 Synaptotagmin1 mARC1; 1, 3 
O95049 Tight junction protein ZO-3 mARC1; 1, 3 
Q8IYS4 Uncharacterized protein C16orf71 mARC1; 1, 3 
Q3SY52 Zinc finger protein interacting with ribonucleoprotein K mARC1; 1, 3 
Q14684 Ribosomal RNA processing protein 1 homolog B mARC1; 1, 2 
P46977 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase mARC1; 1, 2 
Q9NUT2 ATP-binding cassette sub-family B member 8, mitochondrial mARC1; 1, 3 
Q8TCU4 Alstrom syndrome protein 1 mARC1; 1, 3 
Q6P2H3 Centrosomal protein of 85 kDa mARC1; 1, 3 
P62269 40S ribosomal protein S18 mARC2; 1, 3 
P62701 40S ribosomal protein S4, X isoform mARC2; 1, 3 
P46782 40S ribosomal protein S5 mARC2; 1, 3 
Q9C0H9 SRC kinase signaling inhibitor 1 mARC2; 1, 3 
Q71U36 Tubulin alphaA chain mARC2; 1, 3 
Q9UKX5 Integrin alpha1 mARC2; 1, 3 
Q6ZU35 Uncharacterized protein KIAA1211 mARC2; 1, 3 
P54764 Ephrin type-A receptor 4 mARC2; 1, 3 
P00748 Coagulation factor XII mARC2; 1, 3 
Q5T0W9 Protein FAM83B mARC2; 1, 3 
Q6PJ61 F-box only protein 46 mARC2; 1, 3 
Q06787 Fragile X mental retardation protein 1 mARC2; 1, 3 
Technique: 
1. Co-immunoprecipitation 
2. Crosslinking reagent 
3. Pull-down assay 
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Samples were cross-compared searching to see if the other mARC protein was 
present. To this end, co-immunoprecipitation experiments seemed to have both mARC1 
and mARC2 present in the analysis, this data was represented in the center circle of the 
Venn diagram (Figure 3.8) as it could not be distinguished if the proteins identified were 
potentially interacting with mARC1 or mARC2. The chemical crosslinking reagent 
appeared to have the greatest overlap in protein identified when compared to the co-
immunoprecipitation and pull-down assay. There were no proteins identified in mARC1 
and mARC2 samples that were uniquely identified using the LTR-K-BLoC complex, 
suggesting that this method may have a lower false discovery rate. 
To be able to propose a physiological function of mARC proteins, relationships of 
the interacting proteins based on their functions and involvement need to be determined. 
Table 3.5: Proteins identified in one experimental conditions interacting partners with mARC1 
and mARC2 in HEK-293 cell lysate. 
UniProt ID Protein Name 
Interacting mARC 
Protein; Technique 
Q53EZ4 Centrosomal protein of 55 kDa mARC1; 1 
Q9BTM1 Histone H2A.J mARC1; 1 
A2A2F5 Protein TMEPAI mARC1; 1 
J3QRV1 Sodium/hydrogen exchanger 5 mARC1; 1 
Q9H2M3 S-methylmethionine-homocysteine S-methyltransferase BHMT2 mARC1; 3 
Q13496 Myotubularin mARC2; 1 
O76074 cGMP-specific 3',5'-cyclic phosphodiesterase mARC2; 1 
C9JH25 Proline-rich transmembrane protein 4 mARC2; 1 
Q5W0Q7 SUMO-specific isopeptidase USPL1 mARC2; 1 
Q8N7Q3 Zinc finger protein 676 mARC2; 1 
O75128 Protein cordon-bleu mARC2; 1 
O75947 ATP synthase subunit d, mitochondrial mARC2; 1 
Technique: 
1. Co-immunoprecipitation 
2. Crosslinking reagent 
3. Pull-down assay 
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To aid in the analysis two bioinformatics software will be used to help form relationships 
of proteins. 
3.4.2 Bioinformatics Platforms used to Form Relationships for Interacting Protein 
To aid in the analysis of the proteins identified two different bioinformatics 
platforms were used to develop connections of identified proteins (DAVID, Database for 
Annotation, Visualization, and Integrated Discovery), and to help reduce contaminating 
background proteins identified (CRAPome, Contaminant Repository for Affinity 
Purification). DAVID was used by uploading the UniProt Accession numbers and 
proteins were clustered based on similar annotations. CRAPome utilized the proteins 
identified and the spectral counts for each protein within a sample. This software 
platform uses experimental conditions and control conditions and applies a SAINT 
probability score for each protein identified. 
3.4.3 DAVID Bioinformatics Results using the Reduced Protein List 
DAVID bioinformatics software was used to help compare the identified proteins 
by comparing annotations found in several databases. To compare the proteins, GOTerm 
function was used from The European Bioinformatics Institute (http://www.ebi.ac.uk/). 
The initial analysis using DAVID were grouped into functional annotation clustering 
using the parameters similarity term overlap of 3 with a threshold of 0.50, classified with 
at least 3 proteins per group and multiple linkage thresholds of 0.50. The analysis of 
proteins interacting with mARC1 showed 12 clusters with 70 biological process and 
 61 
 
molecular function annotations present. The identified proteins observed in mARC2 
samples had 9 clusters with 76 biological process and molecular function annotations. 
The full GOTerm trees with the cluster number, number of proteins annotated, and 
similar annotation for proteins identified in mARC1 and mARC2 conditions can be found 
in Appendix III, Figure A.2 to A.13. There is evidence that mARC proteins are found 
outside of the mitochondria of cells, but our interest is potential physiological roles of 
mARC proteins. To aid in the narrowing the scope to viable candidates, annotations were 
required to be part of metabolic, and/or cellular function not including cell cycle type 
functions to reduce the complexity and highlight features of interest. A truncated table 
with a few interesting candidate annotations can be found in Table 3.7; the complete table 
can be found in Appendix III, Table A.3, and A.4. A complete table of the identified 
clusters of interacting proteins with mARC1 and mARC2 with their associated GOTerm 
annotations can be found in Appendix III, Table A.8, and A.7. The annotations of interest 
that were found in both mARC1 and mARC2 interacting proteins were several regulatory 
process proteins both cellular and metabolic, and metabolism of various nitrogen-
containing compounds (amine-containing, amino acid, and nucleic acid). The current 
research for both mARC proteins has demonstrated their abilities to reduce several 
amidoxime compounds, mutated base-pairs, and nitrite; which would suggest why 
proteins annotated in nitrogen-containing metabolic processes are being identified as 
well as nucleobase-containing compound metabolic process.[24, 26, 104, 109] More 
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interestingly, however, is the number of proteins with regulatory annotations. With a list 
of proteins that were identified under stringent conditions, using more than one method 
of probing protein-protein interactions, and a potential relationship of proteins based on 
clusters of GOTerm annotations the list of proteins was expanded to include all proteins 
that were identified in the experimental conditions and not in the controls. 
 
 
Table 3.6: Select GOTerm annotations for proteins interacting with mARC1 and mARC2. The 
number of interacting proteins identified for mARC1 and mARC2 are listed under the annotation 
tag with a short description that was found from http://www.ebi.ac.uk/ 
Annotated GOTerm (# of 
Proteins) Description of Term 
Cellular protein 
modification process 
(mARC1 : 0) 
(mARC2 : 3) 
The covalent alteration of one or more amino acids occurring in proteins, peptides 
and nascent polypeptides (co-translational, post-translational modifications) 
occurring at the level of an individual cell. Includes the modification of charged 
tRNAs that are destined to occur in a protein (pre-translation modification). 
Nitrogen compound 
metabolic process 
(mARC1 : 8) 
(mARC2 : 5) 
The chemical reactions and pathways involving organic or inorganic compounds 
that contain nitrogen, including (but not limited to) nitrogen fixation, nitrification, 
denitrification, assimilatory/dissimilatory nitrate reduction and the 
interconversion of nitrogenous organic matter and ammonium. 
Nucleobase-containing 
compound metabolic 
process 
(mARC1 : 4) 
(mARC2 : 3) 
Any cellular metabolic process involving nucleobases, nucleosides, nucleotides 
and nucleic acids. 
Regulation of biological 
process 
(mARC1 : 12) 
(mARC2 : 8) 
Any process that modulates the frequency, rate or extent of a biological process. 
Biological processes are regulated by many means; examples include the control 
of gene expression, protein modification or interaction with a protein or substrate 
molecule. 
Signal transduction 
(mARC1 : 0) 
(mARC2 : 3) 
The cellular process in which a signal is conveyed to trigger a change in the 
activity or state of a cell. Signal transduction begins with reception of a signal (e.g. 
a ligand binding to a receptor or receptor activation by a stimulus such as light), 
or for signal transduction in the absence of ligand, signal-withdrawal or the 
activity of a constitutively active receptor. Signal transduction ends with 
regulation of a downstream cellular process, e.g. regulation of transcription or 
regulation of a metabolic process. Signal transduction covers signaling from 
receptors located on the surface of the cell and signaling via molecules located 
within the cell. For signaling between cells, signal transduction is restricted to 
events at and within the receiving cell. 
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3.4.4 CRAPome Bioinformatics and KEGG Pathway Results for Proteins 
By expanding the list to include all proteins not identified in the controls, there is 
an increased likelihood of identifying false positive results. To help strengthen the results 
a unique bioinformatics software was used. CRAPome utilizes all proteins identified in a 
study (both control and experimental) and compares the spectral count of those proteins 
to generate a SAINT score which is the likelihood of that protein being a positive 
interactor or a background contaminant.[178] The spectral counts for each protein were 
consolidated from the spectral count of each identified peptide in the replicates. By 
expanding the search from the reduced list to the full list, we anticipate expanding the 
list of proteins involved in pathways of interest to aid in the proposition of mARC 
physiological function. Figure 3.9 shows the number of proteins compared to their 
SAINT scores for all the proteins in the study (orange) and the proteins identified in the 
reduced protein list (blue) for mARC1 (Figure 3.9A) and mARC2 (Figure 3.9B). The 
majority of the total proteins had a SAINT score between 0 and 20% meaning the 
likelihood of those proteins interacting with mARC proteins is reduced, and they may be 
background or contaminant. In the reduced protein list the majority of the proteins had 
a SAINT score between 20 and 40% allowing for greater confidence in these interacting 
partners with mARC proteins. As the SAINT score increases the confidence of the 
interacting protein increases. To aid in the analysis of the total proteins, KEGG annotated 
pathways were investigated to see if any relationships could be generated.  
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Figure 3.9: CRAPome SAINT score comparison between the proteins identified in the 
reduced list and the total proteins identified in the study. Blue bars represent the number 
of proteins identified and SAINT scores with the reduced protein list and the orange bars 
represent all the proteins identified in the study. A. SAINT score comparison of identified 
proteins in mARC1 experiments, B.  SAINT score comparison of identified proteins in 
mARC2 experiments 
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The interacting proteins were compared using KEGG pathway annotations to 
elucidate relationships of proteins further. The full list of proteins used in the CRAPome 
analysis was used to compare pathways to attempt to capture a more complete overview 
of interacting partners. To summarize the KEGG annotated proteins, two plots were 
generated with this information for each mARC protein (Figure 3.10, and Figure 3.11).  
When examining the pathway categories for mARC1 (Figure 3.10A), proteins 
annotated in human disease and metabolism have the most identified. The number of 
proteins identified in the category metabolism appears to have many proteins identified, 
but when it is divided into the pathways, the proteins are annotated with “Global and 
overview maps” which is a general pathway annotation. The pathways for human 
disease and organism system categories can be found in Appendix III, Figure A.14A. In 
Figure 3.10B the categories are divided into their pathways and the number of proteins 
identified affiliated with each pathway. A complete list of proteins with their annotated 
KEGG pathways can be found in Appendix III, A.8, and A.9. Interestingly enough, the 
most proteins were identified as part of signal transduction pathways. The signal 
transduction pathways can be further divided into specific pathways of involvement. 
Investigating these pathways may be important in understanding the physiological role 
of mARC1 within the cell. The proteins that were present in the signal transduction 
pathways can be found in Table 3.8 with their specific pathway(s) of involvement. There 
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is not a significant number of proteins identified for one pathway, with MAPK signaling 
pathway having the most, but several of the pathways can be connected to one another
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Figure 3.10: KEGG categories and pathways for proteins interacting with mARC1. A. KEGG 
categories for interacting proteins with mARC1, B. KEGG pathways for interacting proteins with 
mARC1. Human disease, and organismal systems pathways can be found in Appendix III, 
A.14A. Pathways in plot B are color coordinated with the category they are related to. 
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Nitric oxide is an important second messenger molecule in several regulatory 
processes. In fact, it has been reported that some cytokines including tumor necrosis 
factors and interleukins are regulated by nitric oxide.[179, 180] Cytokines are important 
signaling proteins which aid in immune response. The protein identified as an interacting 
partner with mARC1 is tumor necrosis factor superfamily member 11 (O14788) which 
may be involved in the modulation of intracellular concentration of calcium. More 
interesting is that tumor necrosis factor-alpha has been shown to greatly impact the nitric 
oxide synthase mRNA levels inside the endothelium cell.[181] In fact, it was reported that 
the half-life of nitric oxide synthase mRNA was reduced from 48 hours to 3 hours.[181] 
With the declining stability of nitric oxide synthase mRNA, it is possible that mARC1 
may aid in the control of cytokines and promote homeostasis within the cell through the 
production of nitric oxide from nitrite. 
One of the predicted interactions with mARC1 is ubiquitin C which labels proteins 
for degradation, DNA repair, cell cycle regulation, kinase modification, endocytosis, and 
regulation of other cell signaling pathways. Two different E3 ubiquitin protein ligases 
were identified as interacting with mARC1, mitogen-activated protein kinase 1, E3 
ubiquitin protein ligase (Q13233) and E3 ubiquitin-protein ligase parkin (O60260). 
Although there is no exact reason for the ubiquitination, we suggest it may be involved 
in regulating mARC1 involvement in cell signaling. 
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Mammalian signaling pathways aid the cellular response to external changes in 
the cell to elicit a response inside the cell. Some signal responses are activated by receptors 
or secondary messenger molecules resulting in several changes within the cell. It is of 
interest that mARC1 was identified as interacting with several proteins in signaling 
pathways because one of the predicted functions of mARC proteins is the reduction of 
nitrite to nitric oxide under hypoxic conditions. Nitric oxide is known as a very potent 
signaling molecule within cells. In the calcium signaling pathway, an efflux of calcium 
into the cell binds calmodulin protein and subsequently activating the enzyme. Once 
calmodulin is activated it targets proteins downstream within the NOS proteins, MAPK 
and phosphatidylinositol signaling pathways, as well as other pathways. Interestingly, 
the protein that was identified as interacting with mARC1, guanine nucleotide binding 
protein (P30679), is upstream of calmodulin. Through a series of activations promoted by 
Table 3.7: Signal transduction proteins and pathways identified as interacting proteins 
with mARC1. 
Signal Transduction Pathway  Proteins Names (UniProt ID) 
Calcium signaling Guanine nucleotide binding protein (P30679) 
Hippo signaling Par-6 family cell polarity regulator (Q9BYG4) 
MAPK signaling 
Mitogen-activated protein kinase 5 (Q99683) 
Mitogen-activated protein kinase 6 (O95382) 
Mitogen-activated protein kinase 1, ubiquitin protein ligase (Q13233) 
NF-kappa B signaling Tumor necrosis factor 11 (O14788) 
Phosphatidylinositol signaling Phosphatidylinositol-4-phosphate 3-kinase (O00750) 
PI3K-Akt signaling Integrin 6 (P18564) 
Rap1 signaling Par-6 family cell polarity regulator (Q9BYG4) 
Sphingolipid signaling Mitogen-activated protein kinase 5 (Q99683) 
TGF-beta signaling Retinoblastoma-like 1 (P28749) 
TNF signaling Mitogen-activated protein kinase 5 (Q99683) 
Wnt signaling LDL receptor related protein 6 (O75581) 
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guanine nucleotide binding protein, calcium is released from the endoplasmic reticulum. 
The release of calcium then activates calmodulin, promoting downstream processes. The 
MAPK signaling pathway is a highly conserved cascade that is capable of controlling 
several cellular processes. Three different mitogen-activated kinases (Mitogen-activated 
protein kinase 1 (Q13233), Mitogen-activated protein kinase 5 (Q99683), Mitogen-
activated protein kinase 6 (O95382)) were identified as interacting with mARC1. It has 
been reported that the phosphorylation of eNOS occurs through interactions with MAPK 
proteins.[182] Bernier et al. were able to isolate a complex containing eNOS, ERK1/2, Raf1, 
and Akt through co-immunoprecipitation; through a Brandykinin treatment, they were 
able to determine that eNOS is phosphorylated by extracellular signal-regulated kinase 
(ERK) proteins.[182] The MAPK signaling pathway can be divided into three cascades, 
ERK1/2 module, JNK/p38 module, and ERK5 module, each affecting different 
downstream processes. The proteins that were identified as interacting with mARC1 are 
affiliated with the JNK/p38 module of the MAPK signaling cascade. Suggesting that 
mARC1 may be phosphorylated for activation or deactivation within the cell. The MAPK 
signaling pathway has involvement in the phosphorylation of proteins in the Wnt, PI3K-
Akt, and the sphingolipid signaling pathways. Nitric oxide has been determined to 
promote the regulation of the Wnt signaling pathway by inhibiting Dickkopf-1 gene 
expression.[183] The Dickkopf family of proteins negatively inhibits the Wnt pathways 
by binding the same receptor that is used to stimulate the pathway.[184] The PI3K-Akt 
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and the sphingolipid signaling pathways promote the production of nitric oxide through 
the phosphorylation of NOS proteins. It is unclear why mARC1 would interact with 
integrin 6 (P18564), which is a β-subunit in the receptor complex; but Murohara et al. 
report that nitric oxide aids in maintaining the functional expression of integrin αvβ3 in 
endothelial cells.[185] The potential physiological involvement of mARC1 appears to be 
extremely complex, but we propose it is involved in the regulation of signal transduction 
pathways through nitric oxide production.  
Comparing the annotated functions of mARC1 and mARC2 it is clear that fewer 
proteins are annotated in mARC2 as affiliated with different metabolic functions. 
Examining this information more closely, it can be noted that there are no proteins 
annotated as “Global and overview maps” identified as interacting with mARC2 (Figure 
3.11B). The general categories for mARC2 proteins (Figure 3.6A) exhibit a similar 
relationship to mARC1 about “Environmental Information Processing,” and it is under 
this category that the signaling pathways can be identified. The pathways for human 
disease and organism system categories can be found in Appendix III, Figure A.14B. A 
new third pathway list in Figure 3.11B was identified in proteins interacting with mARC2 
(“Membrane transport”) when compared to mARC1 pathways. 
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Figure 3.11: KEGG categories and pathways for proteins interacting with mARC2. A. KEGG 
categories for interacting proteins with mARC1, B. KEGG pathways for interacting proteins with 
mARC2. Human disease, and organismal systems pathways can be found in Appendix III, 
A.14B. Pathways in plot B are color coordinated with the category they are related to. 
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 The annotated “Membrane transport” proteins are of interest to investigating the 
potential physiological role of mARC2 because they can be related to what is currently 
know about the enzyme. A complete list of annotated “Membrane transport” proteins 
can be found in Appendix III, Table A.3. Three different ATP synthase subunits (P36542, 
P48047, and O75947) were identified as being mitochondrial, similar to the known 
location of the mARC2 protein. ATP synthase is a protein complex that utilizes a proton 
gradient to produce ATP from ADP and inorganic phosphate. One cell process, in 
particular, requires ATP to drive the uptake of calcium into the cell and results in muscle 
contractions. Previously reported an increase in nitric oxide levels caused an inhibition 
of ATP synthase in rat muscle cells.[186] Similar to mARC1, mARC2 is capable of 
producing nitric oxide from nitrite.[26] Suggesting that mARC2 may aid in the relaxation 
of muscle cell by generating nitric oxide to inhibit ATP synthase and as a result decreasing 
the calcium uptake allowed through the energy-dependent calcium transport proteins.  
 A sequence analysis of mARC2 protein demonstrates the presence of a 
molybdenum cofactor sulfurase (MOSC) domain, which is a highly conserved region in 
other molybdenum containing enzymes (AO, and xanthine dehydrogenase). The three 
molybdenum cofactor maturation proteins, MOCS1, MOCS2, and GPHN, were also 
identified as interacting partners with mARC2. This would suggest that a complex 
between the four proteins may take place in the maturation of mARC2. 
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 Similar to the mARC1 proteins, interacting proteins with mARC2 were identified 
as being affiliated with several signaling pathways. The pathways and proteins for 
interacting proteins with mARC2 can be found in Table 3.9. Comparable to the pathways 
identified in mARC1 interacting proteins, the calcium, MAPK, phosphatidylinositol, 
PI3K-Akt, Rap1 and Wnt signaling pathways seem to be present. Interestingly the cGMP-
PKG pathway is also present, which has involvement in nitric oxide and natriuretic 
peptides regulation. Nitric oxide binds to soluble guanylate cyclase catalyzing the 
conversion of cGTP to cGMP.[75] The resulting cGMP molecule activates protein kinase 
G, subsequently influencing several downstream pathways including the reduction of 
calcium within the cell causing muscle relaxation. The increase of cGMP within the cell 
prevents the hydrolysis of cAMP by cGMP-inhibited phosphodiesterases.[187-189] The 
cAMP signaling pathway also regulates downstream processes like metabolism, calcium 
Table 3.9: Signal transduction proteins and pathways identified as interacting proteins 
with mARC2. 
Signal Transduction Pathway  Proteins Names (UniProt ID) 
Calcium signaling 
Solute carrier family 25 (P05141) 
Calcium channel, voltage-dependent (Q13698) 
cAMP signaling 
Glutamate receptor, AMPA 2 (P42262) 
Calcium channel, voltage-dependent (Q13698) 
cGMP-PKG signaling 
Phosphodiesterase 5A (O76074) 
Solute carrier family 25 (P05141) 
Calcium channel, voltage-dependent (Q13698) 
MAPK signaling 
Platelet derived growth factor (P01127) 
Calcium channel, voltage-dependent (Q13698) 
Phosphatidylinositol signaling Myotubularin 1 (Q13496) 
Phospholipase D signaling Platelet derived growth factor (P01127) 
PI3K-Akt signaling 
Integrin subunit alpha 11 (Q9UKX5) 
Platelet derived growth factor (P01127) 
Rap1 signaling Platelet derived growth factor (P01127) 
Ras signaling Platelet derived growth factor (P01127) 
Wnt signaling LDL receptor related protein 6 (O75581) 
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homeostasis, and muscle contraction through the direct activation of protein kinase A, 
Rap guanine nucleotide exchange factor, and cyclic nucleotide-gated ion channels. 
Protein kinase A regulates ion channels, transporters, intracellular Ca2+-handling 
proteins, and the contractile machinery, to name a few, through phosphorylation. 
Guanine nucleotide exchange factor, on the other hand, modulates phospholipases and 
Rap signaling downstream. Phospholipase D catalyzes the hydrolysis of 
phosphatidylcholine to phosphatidic acid, which is an invaluable second messenger in 
the activation of MAPK signaling pathway. In fact, nitric oxide has been reported as 
stimulating the activation of phospholipase D and subsequently activating the MAPK 
signaling cascade.[190-194] Nitric oxide is a potent second messenger that has an 
immense impact on several pathways throughout the cells and the data presented 
suggests that mARC2 may be involved as a proximity pathway activator through the 
production of nitric oxide.  
3.5 Protein-protein Interactions Summary for mARC1 and mARC2 
 Three methods of investigating protein-protein interactions were used to 
understand the potential physiological role of mARC1 and mARC2 in mammalian cells. 
The co-immunoprecipitation experiments were carried out using commercially available 
antibodies and were able to identify 194 potential interacting proteins with mARC1 and 
117 with mARC2. The crosslinking reagent experiments utilized a unique method 
involving a substrate (K-BLoC) specifically designed to bind mARC proteins and “lock” 
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into the binding pocket bound to a commercially available non-specific crosslinking 
reagent. There was a total of 104 potential interacting proteins with mARC1 and 38 
proteins with mARC2. The final experiment, pull-down assay, utilized recombinant poly-
his tagged mARC1 and mARC2. There was a total of 192 potential interacting proteins 
with mARC1 and 123 proteins with mARC2. To fortify the data collected from the three 
methods, thresholds were applied to reduce the protein list and increase the validity. The 
reduced protein list resulted in 38 proteins identified as interacting with mARC1 and 28 
proteins with mARC2. There were 11 proteins that were identified in all three 
experiments for mARC1 and 6 proteins for mARC2. The crosslinking reagent 
experiments appeared to have the least number of potential false positive identified 
proteins, as there were no unique proteins identified in the experiment. 
 The bioinformatics software DAVID and CRAPome were used to analysis and 
group proteins together based on their GOTerm and KEGG pathway annotations. The 
proteins identified as interacting with mARC1 and mARC2 proteins were clustered into 
GOTerm biological and molecular function processes. There were 12 clusters of proteins 
with 70 biological and molecular function processes for interacting proteins with mARC1 
and 9 clusters with 76 biological and molecular function processes with mARC2. There 
were 3 processes identified in proteins interacting with mARC1 and mARC2 that are of 
potential importance based on what is currently known about mARC proteins and 2 
processes identified only in mARC2 interacting proteins of interest. Nitrogen compound 
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metabolic, regulation of biological, and nucleobase-containing compound metabolic 
process were three processes had multiple identified interacting proteins with mARC1 
and mARC2. The mARC proteins have been reported previously to reduce nitrogen 
containing compounds, namely nitrite and compounds containing amidoxime 
components as well as reducing mutated nucleobases. Interestingly, the regulation of 
biological process and the other 2 processes identified in mARC2 interacting proteins, 
signal transduction, and cellular proteins modification processes, may be related to 
mARC proteins capabilities to produce nitric oxide from nitrite.  
The bioinformatics software CRAPome was used to statistically compare the 
proteins identified in the control and experimental conditions and scored for the 
likelihood of positive identification. The CRAPome data was then analyzed and 
compared using KEGG pathway annotations. It was found that when the interacting 
proteins were grouped into their subcategories that the majority of the proteins were 
grouped into signal transduction pathways. Upon further investigation of the interacting 
proteins, it was found that mARC1 interacted with a tumor necrosis factor type protein 
(O14788) and 2 ubiquitin-protein ligase (Q13233, O60260). We were unable to confirm a 
connection between the ubiquitination of and the potential role of signaling cascades, but 
we propose that mARC1 may it is possible that mARC1 may aid in the control of 
cytokines and promote homeostasis within the cell through the production of nitric oxide 
from nitrite. The effects of nitric oxide in several of the signaling pathways including 
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calcium, Wnt, PI3K-Akt, and the sphingolipid. There is a chance that mARC1 may be 
phosphorylated through the JNK/p38 module of the MAPK signaling cascade, and 
subsequently affecting its reactivity or activation. We propose that the potential 
physiological involvement of mARC1 appears to be involved in the regulation of signal 
transduction pathways through nitric oxide production and a potential safety net for cells 
if nitric oxide synthase proteins become functionally impaired. A very similar trend was 
able to be followed with mARC2 protein. The signal transduction subcategory had the 
majority of the proteins annotated when compared to the other categories. In addition, 
there was a great deal of membrane transport proteins that were identified as interacting 
with mARC2. Three subunits, in particular, that are part of the ATP synthase protein 
(P36542, P48047, and O75947) may demonstrate the role of mARC2 in inhibiting the 
calcium reuptake by nitric oxide and subsequently allowing muscle relaxation. The three 
molybdenum cofactor maturation proteins, MOCS1, MOCS2, and GPHN, were also 
identified as interacting partners with mARC2. Suggesting that a complex between the 
four proteins may take place in the maturation of mARC2. The signaling pathways 
identified in mARC2 are comparable to the ones identified in mARC1, except for the 
cAMP, and cGMP-PKG signaling pathways that were found in mARC2. Nitric oxide aids 
in the catalysis of cGTP to cGMP in the cGMP-PKG signaling pathways. The generation 
of cGMP has been found to inhibit the hydrolysis of cAMP, promoting that cAMP 
pathway which affects muscle contraction through calcium transport regulation. Nitric 
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oxide is a potent second messenger that has an immense impact on several pathways 
throughout the cells and the data presented suggest that mARC2 may be involved as a 
proximity pathway activator through the production of nitric oxide.  
3.6 Reverse Co-immunoprecipitation of mARC Proteins in HEK-293 Cells 
Using the data derived from DAVID, and CRAPome analysis two proteins for 
mARC1 and mARC2 were selected for reverse co-immunoprecipitation to support 
evidence of the interactions. Reverse co-immunoprecipitation uses the same principles as 
co-immunoprecipitation, except the intended target. The prey protein from the original 
co-immunoprecipitation becomes the target of the antibody with the goal of precipitating 
the proteins of interest. The objective of this reverse co-immunoprecipitation is to select 
interacting proteins with mARC1 and mARC2, and using their antibodies to 
immunoprecipitate the interacting protein with mARC proteins. The proteins selected 
were of interest to signaling pathways and were identified in multiple experiments. This 
was used as a confirmatory method to see if the mARC proteins interacted with the 
proteins selected.  
Reverse co-immunoprecipitation has been used previously by researchers to help 
support their data from co-immunoprecipitation experiments. Denuc et al. used this 
method to support evidence of connexin 43, a gap junction related protein found in 
cardiomyocyte mitochondria, interacting with two new proteins that were identified 
through co-immunoprecipitation.[195] A total of 80 candidate proteins were identified in 
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three co-immunoprecipitation experiments using connexin 43 antibody.[195] Of those 
proteins identified two proteins were selected for reverse co-immunoprecipitation 
experiments to support evidence of protein-protein interactions, apoptosis-inducing 
factor, and electron-transfer flavoprotein subunit beta.[195] They were able to determine 
that connexin 43 preferentially interacts with apoptosis-inducing factor and electron-
transfer flavoprotein subunit beta.[195] Using a similar strategy, Vandermoere et al.  used 
co-immunoprecipitation of serine/threonine kinase Akt and identified ten interacting 
partners.[196] They were able to identify a 14-fold increase in the interaction of activated-
Akt with cytoskeleton protein actin when compared to the non-activated form.[196] They 
confirmed the interaction of Akt and cytoskeleton protein actin using reverse co-
immunoprecipitation and confocal microscopy, in which they used the cytoskeleton 
protein actin antibody to isolate Akt.[196] Reverse co-immunoprecipitation helps to 
support evidence of protein-protein interactions when coupled with previous methods 
(i.e., co-immunoprecipitation, crosslinking reagents, and pull-down assays). 
The reverse co-immunoprecipitation followed the same method as co-
immunoprecipitation except different antibodies were used (Table 2.1), and no purified 
mARC1 and mARC2 protein were added to the sample, meaning all analysis was carried 
out under native protein concentrations. The control antibody for the reverse co-
immunoprecipitation experiments was an antibody for Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH). GAPDH was not identified in any of the mARC experiments 
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and the commercially available antibodies are specific. During the LC-MS/MS analysis, a 
preferential auto MS/MS method was established in which specific mARC1 and mARC2 
peptides that were previously identified consistently were scanned for and fragmented 
using the parameters present in Table 3.10 and Table 3.11. Utilizing the preferred 
function in auto MS/MS allows for the selected precursor ions to search for, while also 
performing MS/MS on other peptides.
Table 3.9: Selected ions for preferential MS/MS for 
analysis of mARC1 protein. 
Sequence 
(Amino Acid Location) 
Precursor 
m/z 
Z 
Retention 
Time (min) 
DLLLPIK 
(133-139) 
811.52 1 17 
GVPVSEAECTAMGLR 
(78-85) 
788.87 2 15.3 
KEPLETLK 
(288-295) 
479.46 2 5.7 
KEPLETLKSYR 
(288-298) 
682.38 2 9.6 
RPHQIADLFRPK 
(191-202) 
493.28 3 11.1 
VGDPVYLLGQ 
(328-337) 
530.78 2 18.3 
VHGLEIEGR 
(151-159) 
505.46 2 7.2 
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Agilent MassHunter Qualitative Analysis with BioConfirm software was used to 
identify peptides in the spectrum data for each condition. In the control condition using 
GAPDH antibody, no mARC1 or mARC2 peptides were identified, establishing it as a 
viable negative control. For mARC1, mitogen-activated protein kinase 5 (Q99683) and 
phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta (O00750) 
were the target bait proteins. Table 3.12 is the number of unique mARC1 peptides and 
the number of spectral counts for peptides using reverse co-immunoprecipitation in 
Table 3.10: Selected ions for preferential MS/MS for 
analysis of mARC2 protein 
Sequence 
(Amino Acid Location) 
Precursor 
m/z 
Z 
Retention 
Time (min) 
DRFWLVIK 
(90-97) 
538.81 2 18.5 
GVPVSEAECTAMGLRSGNLR 
(70-89) 
788.87 2 15.3 
IFGLDIK 
(150-156) 
805.48 1 18.2 
IFGLDIKGR 
(150-158) 
509.8 2 15 
IGSLRVGDPVYR 
(322-333) 
444.58 3 11.6 
KQPLDTLK 
(287-294) 
471.96 2 5.1 
LCDPSERELYK 
(298-308) 
705.33 2 8.3 
LSPLFGIYYSVEK 
(309-321) 
758.4 2 23.4 
LVQFETNMK 
(179-187) 
555.28 2 11.1 
LVQFETNMKGR 
(179-189) 
661.84 2 9.5 
LWIYPVK 
(60-66) 
459.95 2 16.3 
LWIYPVKSCK 
(60-69) 
647.35 2 13.6 
SGNLRDRFWLVIK 
(85-97) 
802.87 2 19.6 
VGDPVYR 
(327-333) 
403.21 2 4.7 
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HEK-293 cells. In both replicates, mARC1 peptides were identified supporting the 
evidence that the interactions of mARC1 with mitogen-activated protein kinase 5 and 
phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta may exist. 
It should be noted that in the LC-MS/MS method seven peptides were scanned for but in 
the second replicate using mitogen-activated protein kinase 5 there were 8 unique 
peptides identified, this is the benefits of using preferential auto MS/MS.  
 For mARC2 ADP/ATP translocase 1 (P12235) and myotubularin (Q13496) were the 
target bait proteins. Table 3.13 is the number of unique mARC2 peptides and the number 
of spectral counts for peptides using reverse co-immunoprecipitation in HEK-293 cells. 
In both replicates, mARC2 peptides were identified supporting the evidence that the 
interactions of mARC2 with ADP/ATP translocase 1 and myotubularin may exist. 
 It needs to be reiterated that all proteins were at natural abundances within the 
experiments. In proteomic studies, it is accepted that proteins identified with 2 or more 
Table 3.11: The number of unique peptides and spectral counts for mARC1 in HEK-
293 cells lysate using reverse co-immunoprecipitation of selected proteins.  
UniProt ID Protein Name 
Unique Peptides (Spectral Counts) 
Replicate 1 Replicate 2 
Q99683 Mitogen-activated protein kinase 5 5 (8) 8 (17) 
O00750 
Phosphatidylinositol 4-phosphate 3-kinase 
C2 domain-containing subunit beta 
3 (6) 4 (7) 
P04406 
Glyceraldehyde-3-phosphate 
dehydrogenase 
0 (0) 0 (0) 
 
Table 3.12: The number of unique peptides and spectral counts for mARC2 in HEK-
293 cells lysate using reverse co-immunoprecipitation of selected proteins.  
UniProt ID Protein Name 
Unique Peptides (Spectral Counts) 
Replicate 1 Replicate 2 
P12235 ADP/ATP translocase 1 3 (3) 7 (8) 
Q13496 Myotubularin 5 (5) 4 (4) 
P04406 
Glyceraldehyde-3-phosphate 
dehydrogenase 
0 (0) 0 (0) 
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unique peptides with multiple spectral counts for the identified proteins to suggest a high 
probability that the identified protein was confirmed. In mARC1 and mARC2 reverse co-
immunoprecipitation experiments, more than 2 unique peptides were identified in each 
experimental condition, and no mARC protein was identified in the GAPDH control 
condition. This information helps to support that mARC1 and mARC2 interact with the 
selected proteins.  
3.7 Reverse Co-immunoprecipitation Results in Tissue Samples 
 The study was expanded further to include pig liver mitochondrial fraction and 
rat liver tissue. The pig liver mitochondrial fractions were supplied by Dr. Antje 
Havemeyer of the Institute of Pharmaceutical Chemistry, Christian-Albrechts University 
of Kiel, Kiel and rat liver tissue was supplied by Dr. Courtney Sparacino-Watkins 
University of Pittsburgh, Pittsburgh, PA. Sample preparation and further information can 
be found in Chapter 2.1. The reverse co-immunoprecipitation of tissue cell lysate 
followed the same method and antibodies as previously described in Chapter 3.6. The 
protein sequences for mARC1 and mARC2 are not well annotated in pig and rat, a protein 
BLAST using human mARC1 and mARC2 sequences was used to identify proteins in 
both organisms. In rat mARC1 (UniProt ID: G3V6I4) had a 77.4% sequence identity to 
human mARC1 and mARC2 (UniProt ID: O88994) had a 74.2% sequence identity to 
human mARC2. After performing the protein sequence BLAST on the pig proteome, 
mARC1 could not be identified but mARC2 (UniProt ID: F1S9I9) with a 74.1% sequence 
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identity to human mARC2. Even though mARC1 was not identified in pig, a sequence 
alignment using human mARC1 and pig mARC2 showed a sequence similarity of 70.0%. 
Mass spectrometric analysis was performed using the method described in Chapter 2.3.1 
and not the preferential auto MS/MS as employed in the previous reverse co-
immunoprecipitation method.  
Agilent MassHunter Qualitative Analysis with BioConfirm was again used to 
identify peptides in the spectrum data for each condition using the mARC1 and mARC2 
protein sequences for each species. Since mARC1 was not identified in pig, but there was 
a high sequence similarity to human mARC1 and pig mARC2, it was in both mARC1 and 
mARC2 analysis. Again, GAPDH antibody was used as a control as no mARC1 or 
mARC2 peptides were not identified.  
In rat liver samples mARC1was identified in both reverse co-immunoprecipitation 
experiments involving mitogen-activated protein kinase 5 and phosphatidylinositol 4-
phosphate 3-kinase C2 domain-containing subunit beta proteins. However, the number 
of unique peptides and spectral counts for rat mARC2 was much lower. Only 1 unique 
peptide for ADP/ATP translocase 1 and 2 unique peptides for myotubularin, potentially 
questioning if rat mARC2 interacts with these two proteins. It also may be caused to a 
low reactivity between the antibody and rat proteins. In Table 3.14 and Table 3.15, the 
number of unique peptides can be seen for mARC1 and mARC2 analysis of rat liver cell 
lysate.  
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In pig liver, mitochondrial fractions samples were analyzed for the presence of pig 
mARC2. Interestingly, the experiments involving mitogen-activated protein kinase 5 and 
phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta proteins 
that were intended to immunoprecipitate mARC1 had unique peptides and spectral 
count in all experiments. Pig mARC2 was also identified in proteins predicted to interact 
with mARC2, ADP/ATP translocase, and myotubularin. In Table 3.14 and Table 3.15, the 
number of unique peptides can be seen for mARC1 and mARC2 analysis of pig liver 
mitochondrial fractions. 
In the rat liver cell lysate samples mARC1 samples demonstrated a high 
relationship with the interactions seen in human mARC1 and HEK-293 cell lysate 
experiments. However, the mARC2 information was less supportive. This could be due 
to a low reactivity of antibody to selected proteins or a low abundance of rat mARC2 
Table 3.13: The number of unique peptides and spectral counts for mARC1 in pig 
liver mitochondria fractions and rat liver cell lysate using reverse co-
immunoprecipitation of selected proteins.  
UniProt ID Protein Name 
Unique Peptides (Spectral Counts) 
Pig Liver Rat Liver 
Q99683 Mitogen-activated protein kinase 5 14 (20) 7 (16) 
O00750 
Phosphatidylinositol 4-phosphate 3-kinase 
C2 domain-containing subunit beta 
11 (15) 5 (10) 
P04406 
Glyceraldehyde-3-phosphate 
dehydrogenase 
0 (0) 0 (0) 
 
Table 3.14: The number of unique peptides and spectral counts for mARC2 in pig 
liver mitochondria fractions and rat liver cell lysate using reverse co-
immunoprecipitation of selected proteins.  
UniProt ID Protein Name 
Unique Peptides (Spectral Counts) 
Pig Liver Rat Liver 
P12235 ADP/ATP translocase 1 8 (8) 1 (2) 
Q13496 Myotubularin 8 (11) 2 (3) 
P04406 
Glyceraldehyde-3-phosphate 
dehydrogenase 
0 (0) 0 (0) 
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protein. Although there was no pig mARC1 identified from BLAST searches, pig mARC2 
was identified in all four reverse co-immunoprecipitation experiments and thus 
supporting the evidence of mARC proteins interacting with the four selected proteins. 
The data collected from reverse co-immunoprecipitation experiments is not conclusive 
because only single replicates were prepared for all conditions. 
3.8 Protein-protein interactions of mARC1 and mARC2 summary and potential 
opportunities for future work 
 The human mARC1 and mARC2 enzymes are pterin-based molybdenum 
enzymes part of the SO family of molybdenum enzymes. Although the physiological 
function of mARC proteins inside the cell remains elusive, studies have shown their 
potential in the activation of pro-drugs, metabolism of mutated base pairs, and producing 
nitric oxide from nitrite under hypoxic conditions. The latter is of interest to many 
researchers as it provides another pathway for production of nitric oxide under oxygen 
limiting conditions. The goal of these experiments was to investigate the protein-protein 
interactions of mARC1 and mARC2 proteins in HEK-293 cell lysate that can corroborate 
with the information obtained previously from co-immunoprecipitation. For this purpose 
reverse co-immunoprecipitation experiments using HEK-293 cell lysate, pig liver 
mitochondrial fractions, and rat liver cells were performed. Three methods were used to 
investigate protein-protein interactions; co-immunoprecipitation, crosslinking reagents, 
and pull-down assays.  
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The crosslinking reagent experiments involved a novel approach of using a 
commercially available non-specific crosslinking reagent (Sulfo-SBED) and creating a 
compound (K-BLoC) that could bind crosslinking reagent and lock into the active site of 
mARC proteins. Mass spectrometric analysis demonstrated that the crosslinking reagent 
and compound were able to bind forming the complex referred to as LTR-K-BLoC. Using 
intact protein mass spectrometry we were able to confirm that mARC1 is about to bind 
the LTR-K-BLoC complex. This demonstrates not only a new way to transform non-
specific crosslinking reagents into site-specific complexes but also potentials a novel 
method for the purification of mARC proteins from lysate samples.  
Three methods were used to investigate protein-protein interactions and were 
performed in triplicate with appropriate controls; co-immunoprecipitation, crosslinking 
reagents, and pull-down assays. Using Agilent MassHunter Qualitative Analysis with 
BioConfirm software a total of 176 proteins were identified in mARC1 co-
immunoprecipitation experiments, 124 proteins in mARC1 crosslinking reagent 
experiments, 181 protein in mARC1 pull-down assays, 83 proteins were identified in 
mARC2 co-immunoprecipitation experiments, 25 proteins in mARC2 crosslinking 
reagent experiments, and 112 protein in mARC2 pull-down assays. To aid in the 
reduction of false positive identification, the original list of peptides needed to meet 
certain criteria to be considered positive potential interacting partners with mARC 
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proteins. There were 38 proteins identified as interacting with mARC1 and 28 proteins 
identified as interacting with mARC2. 
To aid in the formation of relationships in the identified proteins bioinformatics 
software was used. The proteins from the reduced list of interacting partners were 
clustered using GOTerm biological process and molecular function. Five GOTerm 
annotations were interesting to proteins identified as interacting with mARC proteins; 
cellular protein modification process, nitrogen compound metabolic process nucleobase-
containing metabolic process, regulation of biological process, and signal transduction.  
The identified proteins were then compared using KEGG annotated pathways to 
investigate relationships. Interestingly, both mARC1 and mARC2 had several interacting 
partners that were identified as part of signaling pathways. There were 11 signaling 
pathways that were affiliated with proteins identified as interacting with mARC1 and 10 
signaling pathways for mARC2. In both cases, relationships were able to be connected 
based on effects of nitric oxide production, and nitric oxide synthase involvement. Based 
on the analysis of the data we suggest that mARC1 and mARC2 proteins may potentially 
be involved in the production of nitric oxide under oxygen limiting conditions to aid in 
maintaining cell homeostasis through signaling pathways. 
Reverse co-immunoprecipitation was used to support the evidence of interactions 
between mARC1 and mARC2 and selected proteins. This included probing interactions 
in HEK-293 cell lysate, pig liver mitochondrial fractions, and rat liver cell lysate. 
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Interestingly mARC1 and mARC2 proteins were identified in all experimental 
conditions. The information gathered from the reverse co-immunoprecipitation 
experiments supported the evidence of mARC proteins interacting with mitogen-
activated protein kinase 5, phosphatidylinositol 4-phosphate 3-kinase C2 domain-
containing subunit beta, ADP/ATP translocase, and myotubularin. 
The experiments that were compiled together in this study were not driven by a 
common hypothesis but were used to help propel the mARC system research by 
generating new testable hypotheses. A few testable hypotheses we were able to generate 
from this study include: 
1. Post-translational modification of mARC1 occurs through JNK/p38 signaling 
cascade, modulating downstream processes of mARC1. 
2. The mARC1 and mARC2 proteins aid in the regulation of the calcium signaling 
pathway in mammalian systems through the production of nitric oxide from 
nitrite under hypoxic conditions. 
3. The maturation of mARC2 involves the formation of a complex consisting of 
MOCS1, MOCS2, and GPHN. 
4. Through the production of nitric oxide from nitrite under hypoxic conditions, 
mARC2 is involved in the activity of phosphodiesterase 5A, subsequently 
affecting the conversion cGMP to 5’GMP.  
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The hypotheses that preceded are only examples of future direction for research into 
mARC1 and mARC2 systems. We anticipate the information provided by this 
investigation stimulates further research into mARC proteins and their potential 
physiological roles in mammalian cells.  
Although there were relationships that could be formed from the interacting 
proteins with mARC1 and mARC2 through this study, the exact physiological function 
of mARC1 and mARC2 can only be inferred from the data collected. There is still a great 
deal of work that needs to be accomplished to determine their roles in the mammalian 
system. The identified interacting partners with mARC proteins must be confirmed 
through other methods to establish their requirements in the signaling pathways. After 
the interactions have been confirmed, under what conditions is mARC proteins most 
active, potentially under oxygen limiting or nitric oxide synthase inhibited conditions. 
The protein-protein interactions identified in this study have not only raised questions 
but have also allowed for the study of mARC proteins to be expanded outside the realm 
of normal metabolic functions.  
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Appendix I: Reagents, Kits, Materials and Buffers 
Buffers 
IP Lysis/Wash Buffer 
 25 mM tris hydrochloride 
 150 mM sodium chloride 
 1 mM EDTA (Edetic Acid) 
 1% NP-40 (4-Nonylphenyl poly(ethylene glycol)) 
 5% glycerol 
 pH 7.4 
Coupling Buffer (20X) 
 0.01 M sodium phosphate 
 0.15 M sodium chloride 
 pH 7.2 
Quenching Buffer 
 1 M tris hydrochloride 
 pH 7.4 
Wash Solution 
 1 M sodium chloride  
Table A1: Reagents, kits, materials, companies, and catalog numbers for chemicals 
used. 
Reagent/Kit Company Catalog Number 
Pierce™ His Protein Interaction Pull-Down Kit Thermo Fisher Scientific 21277 
Sulfo-SBED Biotin Label Transfer Reagent Thermo Fisher Scientific 33033 
Pierce™ Biotinylated Protein Interaction Pull-
Down Kit 
Thermo Fisher Scientific 21115 
Pierce™ Co-Immunoprecipitation Kit Thermo Fisher Scientific 26149 
Pierce™ Trypsin Protease, MS Grade, Frozen Thermo Fisher Scientific 90305 
Zeba™ Micro Spin Desalting Columns, 7K 
MWCO, 75 µL 
Thermo Fisher Scientific 89877 
Ammonium Bicarbonate Sigma Aldrich A6141 
Dithiothreitol Acros 16568 
2,2,2-trifluoroethanol Oakwood Chemical 001273 
Pierce™ Dimethylsulfoxide (DMSO), LC-MS 
Grade 
Thermo Fisher Scientific 85190 
Formic Acid, Optima™ LC/MS Grade, Fisher 
Chemical 
Fischer Scientific A117 
Iodoacetamide Amresco M216 
Triethylammonium acetate buffer Fluka 90357 
Acetonitrile (Optima™), Fisher Chemical Fischer Scientific A996-4 
Water-0.1% Formic Acid JT Baker 9834-03 
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Figure A.1: Reagents and chemical structures of the compounds used in 
chemical crosslinking. A. Sulfo-SBED Label Transfer Reagent (MW: 
879.97, MW-Na: 856.98), B. K-BLoC compounds (MW: 215.68, MW-HCl: 
179.22), C. LTR-K-BLoC complex (MW: 841.06) 
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Appendix II: Protein Lists for Interacting Proteins with mARC1 and mARC2 
Table A.2: Protein identified as interacting with mARC1 proteins in HEK-293 cell lysate. The 
technique in which proteins were identified in are; 1–co-immunoprecipitation, 2–crosslinking 
reagent, 3–pull-down assay. The condition in which the proteins were identified in are; C–control 
condition, E–experimental condition, CE–control and experimental condition. 
UniProt ID Protein Name 
Technique and 
Condition 
A0A075B6Z2 Protein TRAJ56 1C, 2CE, 3CE 
A2A2F5 Protein TMEPAI 1E, 2E, 3C 
A8K761 
NADH dehydrogenase (Ubiquinone) 1 beta subcomplex, 10, 22kDa, 
isoform CRA_b 
3C 
A8MPX8 Protein phosphatase 2C-like domain-containing protein 1 1E, 3CE 
C9J069 Uncharacterized protein C9orf172 1CE, 2E, 3CE 
E5KNQ5 Mitochondrial thymidine kinase 2 1E, 3CE 
E7EMC7 Sequestosome-1 2E, 3CE 
F5H2Z5 Complement C1r subcomponent-like protein 3C 
F8W1A0 Serine/threonine-protein phosphatase PP1-gamma catalytic subunit 3C 
F8W1K5 Protein canopy homolog 2 1E 
F8W6H6 Unconventional myosin-Va 1CE, 2E, 3CE 
H0Y8F3 Folliculin-interacting protein 2 3E 
H0YE05 Retinoblastoma-like protein 1 1E, 3CE 
H3BP21 Nuclear factor of-activated T-cells 5 1E, 2E 
H3BP40 Mitochondrial Rho GTPase 2 1E, 3E 
H7C2G6 Probable 28S rRNA (cytosine-C(5))-methyltransferase 1E, 3E 
J3KNJ8 DnaJ homolog subfamily C member 4 1CE, 2E, 3C 
J3QRV1 Sodium/hydrogen exchanger 5 1E 
O00267 Transcription elongation factor SPT5 1E, 2E, 3CE 
O00330 Pyruvate dehydrogenase protein X component, mitochondrial 1E, 3CE 
O00425 Insulin-like growth factor 2 mRNA-binding protein 3 1CE, 2E, 3C 
O00750 
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit 
beta 
1CE, 2E, 3CE 
O14730 Serine/threonine-protein kinase RIO3 1E, 2E, 3CE 
O14788 Tumor necrosis factor ligand superfamily member 11 2E, 3CE 
O15079 Syntaphilin 1CE, 2CE, 3C 
O15240 Neurosecretory protein VGF 1E, 2E, 3C 
O43181 NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial 1E, 2E, 3C 
O43312 Metastasis suppressor protein 1 1CE 
O43314 
Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate 
kinase 2 
1CE, 2E, 3CE 
O60260 E3 ubiquitin-protein ligase parkin 1E, 3CE 
O60518 Ran-binding protein 6 3CE 
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Table A.2: Continued 
UniProt ID Protein Name 
Technique and 
Condition 
O60683 Peroxisome biogenesis factor 10 1E, 2E 
O75061 Putative tyrosine-protein phosphatase auxilin 1CE, 2E, 3CE 
O75128 Protein cordon-bleu 1E, 2E, 3CE 
O75530 Polycomb protein EED 1E, 3CE 
O75581 Low-density lipoprotein receptor-related protein 6 1CE, 2E, 3CE 
O75891 Cytosolic 10-formyltetrahydrofolate dehydrogenase 1E, 2E, 3CE 
O94761 ATP-dependent DNA helicase Q4 1CE, 2E, 3CE 
O94806 Serine/threonine-protein kinase D3 1CE, 2E, 3C 
O94983 Calmodulin-binding transcription activator 2 1CE, 2E, 3CE 
O95049 Tight junction protein ZO-3 1CE, 2C, 3E 
O95199 RCC1 and BTB domain-containing protein 2 1E, 2E, 3CE 
O95382 Mitogen-activated protein kinase kinase kinase 6 1CE, 2E, 3CE 
O95447 Lebercilin-like protein 1CE, 2E, 3C 
O95602 DNA-directed RNA polymerase I subunit RPA1 1CE, 2E, 3CE 
O95954 Formimidoyltransferase-cyclodeaminase 3C 
P00734 Prothrombin 1E, 2E, 3CE 
P01036 Cystatin-S 1E, 3C 
P02768 Serum albumin 1E, 2E, 3E 
P04406 Glyceraldehyde-3-phosphate dehydrogenase 1E, 3E 
P04818 Thymidylate synthase 1C, 2E 
P04908 Histone H2A type 1-B/E 1E, 3E 
P06727 Apolipoprotein A-IV 1CE, 3C 
P0C870 JmjC domain-containing protein 7 1E, 2E, 3C 
P11216 Glycogen phosphorylase, brain form 1CE, 2E, 3CE 
P12273 Prolactin-inducible protein 3C 
P15313 V-type proton ATPase subunit B, kidney isoform 1E, 3CE 
P18564 Integrin beta-6 1CE, 2E, 3CE 
P20810 Calpastatin 1E, 3CE 
P21549 Serine-pyruvate aminotransferase 1E, 3CE 
P22059 Oxysterol-binding protein 1 1CE, 2CE, 3CE 
P23396 40S ribosomal protein S3 1CE, 2CE, 3CE 
P23467 Receptor-type tyrosine-protein phosphatase beta 1CE, 3CE 
P25705 ATP synthase subunit alpha, mitochondrial 2E, 3E 
P27816 Microtubule-associated protein 4 1E, 2E, 3CE 
P30050 60S ribosomal protein L12 1CE, 2E, 3CE 
P30679 Guanine nucleotide-binding protein subunit alpha-15 3E 
P31040 
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, 
mitochondrial 
1CE, 2E, 3CE 
P31937 3-hydroxyisobutyrate dehydrogenase, mitochondrial 1CE, 2E, 3CE 
P43355 Melanoma-associated antigen 1 1C, 3CE 
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Table A.2: Continued 
UniProt ID Protein Name 
Technique and 
Condition 
P46977 
Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 
STT3A 
1E, 2E, 3C 
P49862 Kallikrein-7 1E, 2E, 3C 
P50479 PDZ and LIM domain protein 4 1C, 3CE 
P51160 Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha 1E, 2E, 3CE 
P52788 Spermine synthase 1CE, 2CE, 3C 
P55056 Apolipoprotein C-IV 2E, 3E 
P62330 ADP-ribosylation factor 6 1E 
P62701 40S ribosomal protein S4, X isoform 1CE, 2E, 3C 
P78334 Gamma-aminobutyric acid receptor subunit epsilon 1E, 3CE 
P85037 Forkhead box protein K1 1CE, 2E, 3CE 
P98088 Mucin-5AC 1CE, 2CE, 3CE 
Q01970 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 1CE, 2E, 3CE 
Q02383 Semenogelin-2 1CE, 2E, 3E 
Q03113 Guanine nucleotide-binding protein subunit alpha-12 1C, 2E 
Q04726 Transducin-like enhancer protein 3 1E, 2E, 3CE 
Q07021 
Complement component 1 Q subcomponent-binding protein, 
mitochondrial 
1E, 3C 
Q12879 Glutamate receptor ionotropic, NMDA 2A 1CE, 2E, 3CE 
Q13112 Chromatin assembly factor 1 subunit B 1CE, 2E, 3C 
Q13233 Mitogen-activated protein kinase kinase kinase 1 1CE, 2E, 3CE 
Q13884 Beta-1-syntrophin 1E 
Q14103 Heterogeneous nuclear ribonucleoprotein D0 1CE, 2E, 3CE 
Q14141 Septin-6 1E, 2E, 3CE 
Q14684 Ribosomal RNA processing protein 1 homolog B 1E, 2E, 3C 
Q14789 Golgin subfamily B member 1 1CE, 2E, 3CE 
Q15431 Synaptonemal complex protein 1 1CE, 2E, 3CE 
Q155Q3 Dixin 1E, 2E, 3CE 
Q15637 Splicing factor 1 1E, 3E 
Q16555 Dihydropyrimidinase-related protein 2 1E, 2E, 3C 
Q17R98 Zinc finger protein 827 1E, 3CE 
Q2TAC6 Kinesin-like protein KIF19 1CE, 2E, 3CE 
Q32M45 Anoctamin-4 1E, 3E 
Q3MIN7 Ral guanine nucleotide dissociation stimulator-like 3 1CE, 3E 
Q3SY52 Zinc finger protein interacting with ribonucleoprotein K 1E, 3C 
Q49A26 Putative oxidoreductase GLYR1 1E, 2E, 3CE 
Q53EZ4 Centrosomal protein of 55 kDa 1CE 
Q53RY4 Keratinocyte-associated protein 3 3E 
Q549N5 Signal recognition particle receptor beta subunit 3E 
Q5JQC9 A-kinase anchor protein 4 1CE, 2E, 3CE 
Q5T749 Keratinocyte proline-rich protein 1E, 2E, 3CE 
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Table A.2: Continued 
UniProt ID Protein Name 
Technique and 
Condition 
Q5TEU4 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 
5 
1E, 3E 
Q5VVJ2 Histone H2A deubiquitinase MYSM1 1CE, 2CE, 3CE 
Q66K64 DDB1- and CUL4-associated factor 15 2E, 3C 
Q66K74 Microtubule-associated protein 1S 1CE, 2CE, 3CE 
Q6BAA4 Fc receptor-like B 1E, 2E, 3CE 
Q6IQ32 ADNP homeobox protein 2 1CE, 2E, 3CE 
Q6MZT1 Regulator of G-protein signaling 7-binding protein 1CE, 3CE 
Q6P1R4 tRNA-dihydrouridine(16/17) synthase [NAD(P)(+)]-like 1E, 2E, 3CE 
Q6P3S6 F-box only protein 42 1CE, 2E, 3C 
Q6P996 Pyridoxal-dependent decarboxylase domain-containing protein 1 3CE 
Q6PF15 Kelch-like protein 35 1E, 2E, 3CE 
Q6Q0C0 E3 ubiquitin-protein ligase TRAF7 1E, 2E, 3CE 
Q6SJ96 TATA box-binding protein-like protein 2 1E, 3C 
Q6TGC4 Protein-arginine deiminase type-6 1E, 3C 
Q6UXK5 Leucine-rich repeat neuronal protein 1 1E, 2E, 3E 
Q6UXU4 Germ cell-specific gene 1-like protein 1E 
Q6ZNA1 Zinc finger protein 836 1CE, 2E, 3CE 
Q6ZS94 Putative uncharacterized protein C1orf229 1C, 2E 
Q7L0Q8 Rho-related GTP-binding protein RhoU 1E, 2E 
Q7L590 Protein MCM10 homolog 1CE, 2E, 3C 
Q7L8A9 Vasohibin-1 1CE 
Q7Z4P5 Growth/differentiation factor 7 2E 
Q7Z5M5 Transmembrane channel-like protein 3 1CE, 2E, 3E 
Q7Z7G8 Vacuolar protein sorting-associated protein 13B 1CE, 2E, 3CE 
Q86WI1 Fibrocystin-L 1E, 2E, 3CE 
Q86YV0 RAS protein activator like-3 2E, 3CE 
Q8IUH5 Palmitoyltransferase ZDHHC17 1CE, 3CE 
Q8IWV8 E3 ubiquitin-protein ligase UBR2 1CE, 2E, 3CE 
Q8IXY8 Peptidyl-prolyl cis-trans isomerase-like 6 1E, 3CE 
Q8IYE1 Coiled-coil domain-containing protein 13 1CE, 2E, 3CE 
Q8IYS4 Uncharacterized protein C16orf71 3E 
Q8IYX3 Coiled-coil domain-containing protein 116 1CE, 2CE, 3CE 
Q8IZ73 RNA pseudouridylate synthase domain-containing protein 2 1CE, 3CE 
Q8N0U4 Protein FAM185A 1E 
Q8N187 Calcium-responsive transcription factor 1CE, 2E 
Q8N4H5 Mitochondrial import receptor subunit TOM5 homolog 3C 
Q8N7S6 Uncharacterized protein ARIH2OS 1E 
Q8N7X4 Melanoma-associated antigen B6 2C, 3CE 
Q8NCR6 Spermatid-specific manchette-related protein 1 1E, 3CE 
Q8ND04 Protein SMG8 1E, 2E, 3CE 
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Table A.2: Continued 
UniProt ID Protein Name 
Technique and 
Condition 
Q8NDV3 Structural maintenance of chromosomes protein 1B 1CE, 2E, 3CE 
Q8NEE6 F-box/LRR-repeat protein 13 1CE, 2E, 3CE 
Q8NFW9 Rab effector MyRIP 1CE, 3CE 
Q92616 eIF-2-alpha kinase activator GCN1 1E, 2CE, 3CE 
Q92945 Far upstream element-binding protein 2 1CE, 2CE, 3CE 
Q969R2 Oxysterol-binding protein 2 1CE, 3CE 
Q96AG3 Solute carrier family 25 member 46 1E 
Q96B01 RAD51-associated protein 1 1CE, 3CE 
Q96BH3 Epididymal sperm-binding protein 1 3E 
Q96F45 Zinc finger protein 503 1CE, 3CE 
Q96FV2 Secernin-2 1E, 3CE 
Q96GN5 Cell division cycle-associated 7-like protein 1E, 2E 
Q96N96 Spermatogenesis-associated protein 13 1CE, 2E, 3CE 
Q96QB1 Rho GTPase-activating protein 7 1CE, 2E, 3CE 
Q99489 D-aspartate oxidase 3E 
Q99683 Mitogen-activated protein kinase kinase kinase 5 1CE, 2E, 3CE 
Q9BPX6 Calcium uptake protein 1, mitochondrial 1E, 3E 
Q9BT88 Synaptotagmin-11 1E, 3E 
Q9BTM1 Histone H2A.J 1E 
Q9BYG4 Partitioning defective 6 homolog gamma 3E 
Q9BZE0 Zinc finger protein GLIS2 1E, 2E, 3CE 
Q9C0F0 Putative Polycomb group protein ASXL3 1CE, 2E, 3CE 
Q9H0N0 Ras-related protein Rab-6C 1E, 2E, 3C 
Q9H2D6 TRIO and F-actin-binding protein 1CE, 2E, 3CE 
Q9H2M3 S-methylmethionine-homocysteine S-methyltransferase BHMT2 3E 
Q9H490 Phosphatidylinositol glycan anchor biosynthesis class U protein 3C 
Q9H5N1 Rab GTPase-binding effector protein 2 1E, 2E, 3CE 
Q9H9Z2 Protein lin-28 homolog A 1E, 3CE 
Q9HD20 Manganese-transporting ATPase 13A1 1E, 2E, 3CE 
Q9NQW6 Actin-binding protein anillin 1CE, 2E, 3E 
Q9NU02 Ankyrin repeat and EF-hand domain-containing protein 1 1E, 2E, 3CE 
Q9NUQ3 Gamma-taxilin 1E, 3CE 
Q9NY59 Sphingomyelin phosphodiesterase 3 1CE, 3CE 
Q9NYK5 39S ribosomal protein L39, mitochondrial 1CE, 2CE, 3C 
Q9P015 39S ribosomal protein L15, mitochondrial 1CE, 2E, 3CE 
Q9P218 Collagen alpha-1(XX) chain 1E, 2E, 3CE 
Q9P266 Junctional protein associated with coronary artery disease 1E, 2E, 3CE 
Q9P2J5 Leucine--tRNA ligase, cytoplasmic 1CE, 3CE 
Q9P2N5 RNA-binding protein 27 1CE, 2E, 3CE 
Q9UBW7 Zinc finger MYM-type protein 2 1CE, 2CE, 3CE 
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Table A.2: Continued 
UniProt ID Protein Name 
Technique and 
Condition 
Q9UHN6 Transmembrane protein 2 1E, 2E, 3CE 
Q9UHV7 Mediator of RNA polymerase II transcription subunit 13 1CE, 3CE 
Q9UKS7 Zinc finger protein Helios 1CE, 2CE, 3CE 
Q9UPT8 Zinc finger CCCH domain-containing protein 4 1CE, 2E, 3CE 
Q9UPU5 Ubiquitin carboxyl-terminal hydrolase 24 1E, 2E, 3CE 
Q9UQ10 Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase 1CE, 3C 
Q9UQ84 Exonuclease 1 1CE, 2E, 3CE 
Q9Y2P5 Bile acyl-CoA synthetase 1E, 3CE 
Q9Y2X0 Mediator of RNA polymerase II transcription subunit 16 1CE, 2CE, 3CE 
Q9Y426 C2 domain-containing protein 2 1C, 2E, 3CE 
Q9Y466 Nuclear receptor subfamily 2 group E member 1 1CE, 2CE, 3CE 
Q9Y6X6 Unconventional myosin-XVI 1E, 2E, 3CE 
R4GMW8 Protein BIVM-ERCC5 1E, 2E, 3CE 
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Table A.3: Protein identified as interacting with mARC2 proteins in HEK-293 cell lysate. The 
technique in which proteins were identified in are; 1–co-immunoprecipitation, 2–crosslinking 
reagent, 3–pull-down assay. The condition in which the proteins were identified in are; C–control 
condition, E–experimental condition, CE–control and experimental condition. 
UniProt ID Protein Name 
Technique and 
Condition 
A0A075B6Z2 Protein TRAJ56 1CE, 2CE, 3CE 
A5YKK6 CCR4-NOT transcription complex subunit 1 1E, 2E, 3CE 
A6NE02 BTB/POZ domain-containing protein 17 1C, 3CE 
B1AL46 NUT family member 2E 3CE 
B1ANS9 WD repeat-containing protein 64 1C, 3CE 
C9IYN7 Elongator complex protein 6 1C 
C9JH25 Proline-rich transmembrane protein 4 1C, 3CE 
E9PIH7 Solute carrier family 26 member 10 3E 
E9PKF4 Four and a half LIM domains protein 2 3E 
G8JLL9 MYH14 protein 1CE, 2CE, 3CE 
O14730 Serine/threonine-protein kinase RIO3 1CE, 3CE 
O15020 Spectrin beta chain, non-erythrocytic 2 1CE, 2CE, 3CE 
O43312 Metastasis suppressor protein 1 1CE, 3CE 
O43708 Maleylacetoacetate isomerase 3E 
O75061 Putative tyrosine-protein phosphatase auxilin 1CE, 3CE 
O75128 Protein cordon-bleu 3CE 
O75581 Low-density lipoprotein receptor-related protein 6 1CE, 3CE 
O75695 Protein XRP2 3CE 
O75891 Cytosolic 10-formyltetrahydrofolate dehydrogenase 1E, 3CE 
O75947 ATP synthase subunit d, mitochondrial 3CE 
O76074 cGMP-specific 3',5'-cyclic phosphodiesterase 3CE 
O94927 HAUS augmin-like complex subunit 5 1CE, 2E, 3CE 
O95696 Bromodomain-containing protein 1 1CE, 2E, 3CE 
O95870 Protein ABHD16A 3CE 
O96007 Molybdopterin synthase catalytic subunit 3E 
P00748 Coagulation factor XII 1E, 3CE 
P01127 Platelet-derived growth factor subunit B 3E 
P05141 ADP/ATP translocase 2 1E, 2CE, 3CE 
P06727 Apolipoprotein A-IV 1CE 
P0C870 JmjC domain-containing protein 7 3E 
P14410 Sucrase-isomaltase, intestinal 1E, 3CE 
P14678 Small nuclear ribonucleoprotein-associated proteins B and B' 1CE, 2E, 3CE 
P23396 40S ribosomal protein S3 1E, 2CE, 3CE 
P27694 Replication protein A 70 kDa DNA-binding subunit 1C, 3C 
P36542 ATP synthase subunit gamma, mitochondrial 1CE, 3CE 
P39019 40S ribosomal protein S19 1E 
P40855 Peroxisomal biogenesis factor 19 1E, 3C 
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Table A.3: Continued 
UniProt ID Protein Name 
Technique and 
Condition 
P42262 Glutamate receptor 2 3CE 
P42285 Superkiller viralicidic activity 2-like 2 1CE, 3CE 
P46782 40S ribosomal protein S5 1C, 2C, 3CE 
P48047 ATP synthase subunit O, mitochondrial 2E, 3C 
P50454 Serpin H1 3CE 
P54259 Atrophin-1 1C 
P54764 Ephrin type-A receptor 4 3E 
P62249 40S ribosomal protein S16 1E, 3CE 
P62269 40S ribosomal protein S18 3CE 
P62273 40S ribosomal protein S29 3CE 
P62701 40S ribosomal protein S4, X isoform 1CE, 3CE 
P62750 60S ribosomal protein L23a 1E, 3CE 
P85037 Forkhead box protein K1 1CE, 2E, 3CE 
Q02952 A-kinase anchor protein 12 1CE, 3CE 
Q06787 Synaptic functional regulator FMR1 1CE, 3CE 
Q07021 
Complement component 1 Q subcomponent-binding protein, 
mitochondrial 
1C 
Q13404 Ubiquitin-conjugating enzyme E2 variant 1 1E 
Q13496 Myotubularin 3CE 
Q13698 Voltage-dependent L-type calcium channel subunit alpha-1S 1E, 2CE, 3CE 
Q15185 Prostaglandin E synthase 3 1C, 3E 
Q15390 Mitochondrial fission regulator 1 1C, 2E, 3CE 
Q2M2I8 AP2-associated protein kinase 1 1CE, 3CE 
Q32P51 Heterogeneous nuclear ribonucleoprotein A1-like 2 1C, 2CE, 3CE 
Q5BKY1 Leucine-rich repeat-containing protein 10 1CE 
Q5S007 Leucine-rich repeat serine/threonine-protein kinase 2 1CE, 2E, 3CE 
Q5T0W9 Protein FAM83B 3CE 
Q5U651 Ras-interacting protein 1 1CE, 3E 
Q5W0Q7 SUMO-specific isopeptidase USPL1 3CE 
Q6EEV4 DNA-directed RNA polymerase II subunit GRINL1A, isoforms 4/5 1C 
Q6NUQ1 RAD50-interacting protein 1 1C, 3E 
Q6P2H3 Centrosomal protein of 85 kDa 3CE 
Q6PD62 RNA polymerase-associated protein CTR9 homolog 1CE, 2CE, 3CE 
Q6PI77 Protein BHLHb9 3CE 
Q6PJ61 F-box only protein 46 3CE 
Q6UB35 Monofunctional C1-tetrahydrofolate synthase, mitochondrial 1C, 2CE, 3CE 
Q6ZU35 Uncharacterized protein KIAA1211 1CE, 3E 
Q71U36 Tubulin alpha-1A chain 1E, 3CE 
Q7Z2K8 G protein-regulated inducer of neurite outgrowth 1 1E, 3CE 
Q7Z388 Probable C-mannosyltransferase DPY19L4 1C, 2E, 3CE 
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Table A.3: Continued 
UniProt ID Protein Name 
Technique and 
Condition 
Q7Z7M0 Multiple epidermal growth factor-like domains protein 8 1CE, 3CE 
Q86WI3 Protein NLRC5 1CE, 3CE 
Q86XP3 ATP-dependent RNA helicase DDX42 1E, 2C, 3E 
Q8IUR0 Trafficking protein particle complex subunit 5 3C 
Q8IY51 Tigger transposable element-derived protein 4 1CE, 3CE 
Q8IYE1 Coiled-coil domain-containing protein 13 1C, 3C 
Q8N0U4 Protein FAM185A 3CE 
Q8N187 Calcium-responsive transcription factor 3C 
Q8N4Q0 Zinc-binding alcohol dehydrogenase domain-containing protein 2 1C, 3C 
Q8N7Q3 Zinc finger protein 676 3E 
Q8NBS9 Thioredoxin domain-containing protein 5 1CE, 2E, 3CE 
Q8NBU5 ATPase family AAA domain-containing protein 1 1C, 3E 
Q8NEM8 Cytosolic carboxypeptidase 3 1CE, 2E, 3CE 
Q8TBB5 Kelch domain-containing protein 4 1CE, 3E 
Q8TCU4 Alstrom syndrome protein 1 1E, 3CE 
Q8TD16 Protein bicaudal D homolog 2 1CE, 3CE 
Q8TD57 Dynein heavy chain 3, axonemal 1CE, 3CE 
Q8WUY1 Protein THEM6 3CE 
Q8WWN9 Interactor protein for cytohesin exchange factors 1 1E, 3C 
Q8WXS8 A disintegrin and metalloproteinase with thrombospondin motifs 14 1CE, 3CE 
Q96AE7 Tetratricopeptide repeat protein 17 1CE, 3CE 
Q96F45 Zinc finger protein 503 1CE, 3C 
Q96JH8 Ras-associating and dilute domain-containing protein 1C, 3C 
Q96RP9 Elongation factor G, mitochondrial 1E, 3CE 
Q96RS0 Trimethylguanosine synthase 3E 
Q9BRT2 Ubiquinol-cytochrome-c reductase complex assembly factor 2 1E, 3CE 
Q9BT88 Synaptotagmin-11 1E, 2E, 3C 
Q9C0D5 Protein TANC1 1C, 3CE 
Q9C0H9 SRC kinase signaling inhibitor 1 3CE 
Q9HCE9 Anoctamin-8 1CE, 3CE 
Q9NQW6 Actin-binding protein anillin 1CE, 3E 
Q9NQX3 Gephyrin [Includes: Molybdopterin adenylyltransferase 3CE 
Q9NUE0 Palmitoyltransferase ZDHHC18 1E, 3C 
Q9NUT2 ATP-binding cassette sub-family B member 8, mitochondrial 1E, 3CE 
Q9NY43 BarH-like 2 homeobox protein 3CE 
Q9NZB8 Molybdenum cofactor biosynthesis protein 1 3E 
Q9P2P1 Protein NYNRIN 1CE, 3CE 
Q9P2Y5 UV radiation resistance-associated gene protein 3C 
Q9UHD8 Septin-9 1E, 3C 
Q9UKX5 Integrin alpha-11 3CE 
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Table A.3: Continued 
UniProt ID Protein Name 
Technique and 
Condition 
Q9UPA5 Protein bassoon 1CE, 2E, 3CE 
Q9Y285 Phenylalanine-tRNA ligase alpha subunit  1CE, 3CE 
Q9Y2G9 Protein strawberry notch homolog 2 3CE 
R4GMW8 Protein BIVM-ERCC5 1C, 2CE, 3C 
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Appendix III: GOTerm and KEGG Pathway Annotations   
 
Figure A.2: Biological processes GOTerm annotations for proteins that were identified as interacting partners with mARC1 and 
mARC2. Green boxes depict annotations found in proteins identified in both mARC1 and mARC2, blue boxes depict annotations 
found in proteins identified in both mARC1, and orange boxes depict annotations found in proteins identified in both mARC2. The 
DAVID cluster number is in the top right corner of each box (mARC1:mARC2). The number of proteins with that annotation are found 
in the top left of each box (mARC1:mARC2). Figures A.3 through Figure A.8 are expanded portions of the individual sections. 
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Figure A.3: Expanded Section I of the GOTerm annotations tree for proteins that were identified 
as interacting partners with mARC1 and mARC2. 
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Figure A.4: Expanded Section II of the GOTerm annotations tree for proteins that were identified as 
interacting partners with mARC1 and mARC2. 
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Figure A.5: Expanded Section III of the GOTerm annotations tree for proteins that were identified as interacting partners with 
mARC1 and mARC2. 
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Figure A.6: Expanded Section IV of the GOTerm annotations tree for proteins that were identified as interacting partners 
with mARC1 and mARC2. 
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Figure A.7: Expanded Section V of the GOTerm annotations tree for proteins that were identified as interacting partners 
with mARC1 and mARC2. 
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Figure A.8: Expanded Section VI of the GOTerm annotations tree for proteins that were identified as interacting partners 
with mARC1 and mARC2. 
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Figure A.9: Molecular functions GOTerm annotations for proteins that 
were identified as interacting partners with mARC1 and mARC2. Green 
boxes depict annotations found in proteins identified in both mARC1 and 
mARC2, blue boxes depict annotations found in proteins identified in 
both mARC1, and orange boxes depict annotations found in proteins 
identified in both mARC2. The DAVID cluster number is in the top right 
corner of each box (mARC1:mARC2). The number of proteins with that 
annotation are found in the top left of each box (mARC1:mARC2). Figures 
A.10 through Figure A.13 are expanded portions of the individual 
quadrants. 
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Figure A.10: Expanded Quadrant I of the GOTerm annotations 
tree for proteins that were identified as interacting partners 
with mARC1 and mARC2. 
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Figure A.11: Expanded Quadrant II of the GOTerm annotations 
tree for proteins that were identified as interacting partners 
with mARC1 and mARC2. 
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Figure A.12: Expanded Quadrant III of the GOTerm annotations tree for proteins 
that were identified as interacting partners with mARC1 and mARC2. 
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Figure A.13: Expanded Quadrant IV of the GOTerm 
annotations tree for proteins that were identified as interacting 
partners with mARC1 and mARC2. 
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Table A.4: GOTerm biological and molecular process annotations for proteins interacting with 
mARC1 and mARC2. The number of interacting proteins identified for mARC1 and mARC2 are 
listed under the annotation tag with a short description that was found from 
http://www.ebi.ac.uk/ 
Annotated GOTerm (# of 
Proteins) 
Description of Term 
Amine metabolic process 
(mARC1 : 3) 
(mARC2 : 0) 
The chemical reactions and pathways involving any organic compound that is 
weakly basic in character and contains an amino or a substituted amino group, as 
carried out by individual cells. Amines are called primary, secondary, or tertiary 
according to whether one, two, or three carbon atoms are attached to the nitrogen 
atom. 
Biosynthetic process 
(mARC1 : 7) 
(mARC2 : 7) 
The chemical reactions and pathways resulting in the formation of substances; 
typically the energy-requiring part of metabolism in which simpler substances are 
transformed into more complex ones. 
Carboxylic acid metabolic 
process 
(mARC1 : 3) 
(mARC2 : 0) 
The chemical reactions and pathways involving carboxylic acids, any organic acid 
containing one or more carboxyl (COOH) groups or anions (COO-). 
Cellular amino acid 
metabolic process 
(mARC1 : 3) 
(mARC2 : 0) 
The chemical reactions and pathways involving amino acids, carboxylic acids 
containing one or more amino groups, as carried out by individual cells. 
Cellular biosynthetic 
process 
(mARC1 : 7) 
(mARC2 : 6) 
The chemical reactions and pathways resulting in the formation of substances, 
carried out by individual cells. 
Cellular ketone metabolic 
process 
(mARC1 : 3) 
(mARC2 : 0) 
The chemical reactions and pathways involving any of a class of organic 
compounds that contain the carbonyl group, CO, and in which the carbonyl 
group is bonded only to carbon atoms, as carried out by individual cells. The 
general formula for a ketone is RCOR, where R and R are alkyl or aryl groups. 
Cellular macromolecule 
biosynthetic process 
(mARC1 : 5) 
(mARC2 : 4) 
The chemical reactions and pathways resulting in the formation of a 
macromolecule, any molecule of high relative molecular mass, the structure of 
which essentially comprises the multiple repetition of units derived, actually or 
conceptually, from molecules of low relative molecular mass, carried out by 
individual cells. 
Cellular macromolecule 
metabolic process 
(mARC1 : 8) 
(mARC2 : 9) 
The chemical reactions and pathways involving macromolecules, any molecule of 
high relative molecular mass, the structure of which essentially comprises the 
multiple repetition of units derived, actually or conceptually, from molecules of 
low relative molecular mass, as carried out by individual cells. 
Cellular metabolic process 
(mARC1 : 11) 
(mARC2 : 8) 
The chemical reactions and pathways by which individual cells transform 
chemical substances. 
Cellular nitrogen 
compound metabolic 
process 
(mARC1 : 8) 
(mARC2 : 4) 
The chemical reactions and pathways involving various organic and inorganic 
nitrogenous compounds, as carried out by individual cells. 
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Table A.4: Continued 
Annotated GOTerm (# of 
Proteins) 
Description of Term 
Cellular process 
(mARC1 : 0) 
(mARC2 : 19) 
Any process that is carried out at the cellular level, but not necessarily restricted 
to a single cell. For example, cell communication occurs among more than one 
cell, but occurs at the cellular level. 
Cellular protein metabolic 
process 
(mARC1 : 0) 
(mARC2 : 8) 
The chemical reactions and pathways involving a specific protein, rather than of 
proteins in general, occurring at the level of an individual cell. Includes cellular 
protein modification. 
Cellular protein 
modification process 
(mARC1 : 0) 
(mARC2 : 3) 
The covalent alteration of one or more amino acids occurring in proteins, peptides 
and nascent polypeptides (co-translational, post-translational modifications) 
occurring at the level of an individual cell. Includes the modification of charged 
tRNAs that are destined to occur in a protein (pre-translation modification). 
Heterocycle metabolic 
process 
(mARC1 : 0) 
(mARC2 : 4) 
The chemical reactions and pathways involving heterocyclic compounds, those 
with a cyclic molecular structure and at least two different atoms in the ring (or 
rings). 
Macromolecule 
biosynthetic process 
(mARC1 : 5) 
(mARC2 : 3) 
The chemical reactions and pathways resulting in the formation of a 
macromolecule, any molecule of high relative molecular mass, the structure of 
which essentially comprises the multiple repetition of units derived, actually or 
conceptually, from molecules of low relative molecular mass. 
Macromolecule metabolic 
process 
(mARC1 : 8) 
(mARC2 : 10) 
The chemical reactions and pathways involving macromolecules, any molecule of 
high relative molecular mass, the structure of which essentially comprises the 
multiple repetition of units derived, actually or conceptually, from molecules of 
low relative molecular mass. 
Macromolecule 
modification 
(mARC1 : 0) 
(mARC2 : 3) 
The covalent alteration of one or more monomeric units in a polypeptide, 
polynucleotide, polysaccharide, or other biological macromolecule, resulting in a 
change in its properties. 
Metabolic process 
(mARC1 : 12) 
(mARC2 : 15) 
The chemical reactions and pathways, including anabolism and catabolism, by 
which living organisms transform chemical substances. Metabolic processes 
typically transform small molecules, but also include macromolecular processes 
such as DNA repair and replication, and protein synthesis and degradation. 
Nitrogen compound 
metabolic process 
(mARC1 : 8) 
(mARC2 : 5) 
The chemical reactions and pathways involving organic or inorganic compounds 
that contain nitrogen, including (but not limited to) nitrogen fixation, nitrification, 
denitrification, assimilatory/dissimilatory nitrate reduction and the 
interconversion of nitrogenous organic matter and ammonium. 
Nucleobase-containing 
compound metabolic 
process 
(mARC1 : 4) 
(mARC2 : 3) 
Any cellular metabolic process involving nucleobases, nucleosides, nucleotides 
and nucleic acids. 
Organic acid metabolic 
process 
(mARC1 : 3) 
(mARC2 : 0) 
The chemical reactions and pathways involving organic acids, any acidic 
compound containing carbon in covalent linkage. 
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Table A.4: Continued 
Annotated GOTerm (# of 
Proteins) 
Description of Term 
Oxoacid metabolic process 
(mARC1 : 3) 
(mARC2 : 0) 
The chemical reactions and pathways involving any oxoacid; an oxoacid is a 
compound which contains oxygen, at least one other element, and at least one 
hydrogen bound to oxygen, and which produces a conjugate base by loss of 
positive hydrogen ion(s) (hydrons). 
Primary metabolic process 
(mARC1 : 11) 
(mARC2 : 13) 
The chemical reactions and pathways involving those compounds which are 
formed as a part of the normal anabolic and catabolic processes. These processes 
take place in most, if not all, cells of the organism. 
Post-translational protein 
modification 
(mARC1 : 0) 
(mARC2 : 3) 
The process of covalently altering one or more amino acids in a protein after the 
protein has been completely translated and released from the ribosome. 
Protein metabolic process 
(mARC1 : 0) 
(mARC2 : 9) 
The chemical reactions and pathways involving a specific protein, rather than of 
proteins in general. Includes protein modification. 
Signal transduction 
(mARC1 : 0) 
(mARC2 : 3) 
The cellular process in which a signal is conveyed to trigger a change in the 
activity or state of a cell. Signal transduction begins with reception of a signal (e.g. 
a ligand binding to a receptor or receptor activation by a stimulus such as light), 
or for signal transduction in the absence of ligand, signal-withdrawal or the 
activity of a constitutively active receptor. Signal transduction ends with 
regulation of a downstream cellular process, e.g. regulation of transcription or 
regulation of a metabolic process. Signal transduction covers signaling from 
receptors located on the surface of the cell and signaling via molecules located 
within the cell. For signaling between cells, signal transduction is restricted to 
events at and within the receiving cell. 
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Table A.5: GOTerm regulation process annotations for proteins interacting with mARC1 and 
mARC2. The number of interacting proteins identified for mARC1 and mARC2 are listed under 
the annotation tag with a short description that was found from http://www.ebi.ac.uk/ 
Annotated GOTerm (# of 
Proteins) 
Description of Term 
Regulation of cellular 
metabolic process 
(mARC1 : 5) 
(mARC2 : 4) 
Any process that modulates the frequency, rate or extent of the chemical reactions 
and pathways by which individual cells transform chemical substances. 
Biological regulation 
(mARC1 : 13) 
(mARC2 : 9) 
Any process that modulates a measurable attribute of any biological process, 
quality or function. 
Positive regulation of 
biological process 
(mARC1 : 3) 
(mARC2 : 0) 
Any process that activates or increases the frequency, rate or extent of a biological 
process. Biological processes are regulated by many means; examples include the 
control of gene expression, protein modification or interaction with a protein or 
substrate molecule. 
Positive regulation of 
cellular process 
(mARC1 : 3) 
(mARC2 : 0) 
Any process that activates or increases the frequency, rate or extent of a cellular 
process, any of those that are carried out at the cellular level, but are not 
necessarily restricted to a single cell. For example, cell communication occurs 
among more than one cell, but occurs at the cellular level. 
Regulation of biological 
process 
(mARC1 : 12) 
(mARC2 : 8) 
Any process that modulates the frequency, rate or extent of a biological process. 
Biological processes are regulated by many means; examples include the control 
of gene expression, protein modification or interaction with a protein or substrate 
molecule. 
Regulation of Biological 
Quality 
(mARC1 : 0) 
(mARC2 : 5) 
Any process that modulates a qualitative or quantitative trait of a biological 
quality. A biological quality is a measurable attribute of an organism or part of an 
organism, such as size, mass, shape, color, etc. 
Regulation of biosynthetic 
process 
(mARC1 : 5) 
(mARC2 : 3) 
Any process that modulates the frequency, rate or extent of the chemical reactions 
and pathways resulting in the formation of substances. 
Regulation of cellular 
biosynthetic process 
(mARC1 : 5) 
(mARC2 : 3) 
Any process that modulates the frequency, rate or extent of the chemical reactions 
and pathways resulting in the formation of substances, carried out by individual 
cells. 
Regulation of cellular 
protein metabolic process 
(mARC1 : 0) 
(mARC2 : 3) 
Any process that modulates the frequency, rate or extent of the chemical reactions 
and pathways involving a protein, occurring at the level of an individual cell. 
Regulation of cellular 
process 
(mARC1 : 12) 
(mARC2 : 8) 
Any process that modulates the frequency, rate or extent of a cellular process, any 
of those that are carried out at the cellular level, but are not necessarily restricted 
to a single cell. For example, cell communication occurs among more than one 
cell, but occurs at the cellular level. 
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Table A.5: Continued 
Annotated GOTerm (# of 
Proteins) 
Description of Term 
Regulation of 
macromolecule 
biosynthetic process 
(mARC1 : 4) 
(mARC2 : 3) 
Any process that modulates the frequency, rate or extent of the chemical reactions 
and pathways involving macromolecules, any molecule of high relative molecular 
mass, the structure of which essentially comprises the multiple repetition of units 
derived, actually or conceptually, from molecules of low relative molecular mass. 
Regulation of 
macromolecule metabolic 
process 
(mARC1 : 5) 
(mARC2 : 4) 
Any process that modulates the frequency, rate or extent of the chemical reactions 
and pathways involving macromolecules, any molecule of high relative molecular 
mass, the structure of which essentially comprises the multiple repetition of units 
derived, actually or conceptually, from molecules of low relative molecular mass. 
Regulation of metabolic 
process 
(mARC1 : 5) 
(mARC2 : 4) 
Any process that modulates the frequency, rate or extent of the chemical reactions 
and pathways within a cell or an organism. 
Regulation of nitrogen 
compound metabolic 
Process 
(mARC1 : 4) 
(mARC2 : 0) 
Any process that modulates the frequency, rate or extent of the chemical reactions 
and pathways involving nitrogen or nitrogenous compounds. 
Regulation of nucleobase-
containing metabolic 
process 
(mARC1 : 4) 
(mARC2 : 0) 
Any cellular process that modulates the frequency, rate or extent of the chemical 
reactions and pathways involving nucleobases, nucleosides, nucleotides and 
nucleic acids. 
Regulation of primary 
metabolic process 
(mARC1 : 5) 
(mARC2 : 4) 
Any process that modulates the frequency, rate or extent of the chemical reactions 
and pathways within a cell or an organism involving those compounds formed as 
a part of the normal anabolic and catabolic processes. These processes take place 
in most, if not all, cells of the organism. 
Regulation of protein 
metabolic process 
(mARC1 : 0) 
(mARC2 : 3) 
Any process that modulates the frequency, rate or extent of the chemical reactions 
and pathways involving a protein. 
Regulation of RNA 
metabolic process 
(mARC1 : 3) 
(mARC2 : 0) 
Any process that modulates the frequency, rate or extent of the chemical reactions 
and pathways involving RNA. 
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Figure A.14: KEGG pathways for proteins interacting with mARC proteins for human diseases 
and organismal system categories. A. KEGG human diseases and organismal system categories 
for proteins interacting with mARC1, B. KEGG human diseases and organismal system 
categories for proteins interacting with mARC2. 
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Table A.6: Annotated membrane transport proteins for proteins identified 
as interacting with mARC2. 
UniProt ID Proteins Names 
Q9NUT2 ATP binding cassette subfamily B member 8 
P36542 
ATP synthase, H+ transporting, mitochondrial F1 complex, gamma 
polypeptide 1 
P48047 ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit 
O75947 ATP synthase, H+ transporting, mitochondrial Fo complex subunit D 
O43708 Glutathione S-transferase zeta 1 
Q6UB35 
Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-
like 
Q9NZB8 Molybdenum cofactor synthesis 1 
O96007 Molybdenum cofactor synthesis 2 
Q13496 Myotubularin 1 
Q15185 Prostaglandin E synthase 3 
P14410 Sucrase-isomaltase 
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Table A.7: GOTerm annotations and clusters for proteins identified as interacting with mARC1.  
Cluster UniProt ID Protein Name GOTerm Annotations 
1 
P02768 albumin establishment of localization, ion binding, localization, transport 
P06727 apolipoprotein A-IV 
establishment of localization, ion binding, localization, macromolecule 
localization, transport 
P21549 alanine-glyoxylate aminotransferase 
establishment of localization, localization, macromolecule localization, 
transport 
P31040 
succinate dehydrogenase complex, subunit A, 
flavoprotein (Fp) 
establishment of localization, localization, transport 
P78334 gamma-aminobutyric acid (GABA) A receptor, epsilon establishment of localization, ion binding, localization, transport 
Q32M45 anoctamin 4 establishment of localization, ion binding, localization, transport 
Q3SY52 zinc finger protein interacting with K protein 1 homolog ion binding 
Q7L0Q8 ras homolog gene family, member U ion binding 
Q8IUH5 zinc finger, DHHC-type containing 17 
establishment of localization, ion binding, localization, macromolecule 
localization, transport 
Q8NFW9 myosin VIIA and Rab interacting protein 
establishment of localization, ion binding, localization, macromolecule 
localization, transport 
Q969R2 oxysterol binding protein 2 
establishment of localization, localization, macromolecule localization, 
transport 
Q9BT88 synaptotagmin XI establishment of localization, ion binding, localization, transport 
Q9BZE0 GLIS family zinc finger 2 ion binding 
Q9H2M3 betaine-homocysteine methyltransferase 2 ion binding 
2 
P04908 histone cluster 1, H2ae; histone cluster 1, H2ab 
cellular component assembly, cellular component biogenesis, cellular 
component organization, cellular macromolecular complex assembly, 
cellular macromolecular complex subunit organization, macromolecular 
complex assembly, macromolecular complex subunit organization 
P06727 apolipoprotein A-IV 
cellular component assembly, cellular component biogenesis, cellular 
component organization, macromolecular complex assembly, 
macromolecular complex subunit organization 
P21549 alanine-glyoxylate aminotransferase cellular component organization 
Q14684 ribosomal RNA processing 1 homolog B cellular component biogenesis 
Q15431 synaptonemal complex protein 1 
cellular component assembly, cellular component biogenesis, cellular 
component organization 
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Table A.7: Continued  
Cluster UniProt ID Protein Name GOTerm Annotations 
2 
Q53EZ4 centrosomal protein 55kDa cellular component organization 
Q7L0Q8 ras homolog gene family, member U cellular component organization 
Q8NCR6 chromosome 9 open reading frame 24 
cellular component assembly, cellular component biogenesis, cellular 
component organization, cellular macromolecular complex assembly, 
cellular macromolecular complex subunit organization, macromolecular 
complex assembly, macromolecular complex subunit organization 
Q9BTM1 H2A histone family, member J 
cellular component assembly, cellular component biogenesis, cellular 
component organization, cellular macromolecular complex assembly, 
cellular macromolecular complex subunit organization, macromolecular 
complex assembly, macromolecular complex subunit organization 
P04908 histone cluster 1, H2ae; histone cluster 1, H2ab 
cellular component assembly, cellular component biogenesis, cellular 
component organization, cellular macromolecular complex assembly, 
cellular macromolecular complex subunit organization, macromolecular 
complex assembly, macromolecular complex subunit organization 
P06727 apolipoprotein A-IV 
cellular component assembly, cellular component biogenesis, cellular 
component organization, macromolecular complex assembly, 
macromolecular complex subunit organization 
P21549 alanine-glyoxylate aminotransferase cellular component organization 
Q14684 ribosomal RNA processing 1 homolog B cellular component biogenesis 
Q15431 synaptonemal complex protein 1 
cellular component assembly, cellular component biogenesis, cellular 
component organization 
3 
P06727 apolipoprotein A-IV 
amine metabolic process, cellular amine metabolic process, cellular 
amino acid and derivative metabolic process 
P21549 alanine-glyoxylate aminotransferase 
amine metabolic process, cellular amine metabolic process, cellular 
amino acid and derivative metabolic process 
Q9H2M3 betaine-homocysteine methyltransferase 2 
amine metabolic process, cellular amine metabolic process, cellular 
amino acid and derivative metabolic process 
4 
P04908 histone cluster 1, H2ae; histone cluster 1, H2ab organelle organization 
P21549 alanine-glyoxylate aminotransferase organelle organization 
Q15431 synaptonemal complex protein 1 cell cycle, cell cycle phase, cell cycle process, organelle organization 
Q53EZ4 centrosomal protein 55kDa cell cycle, cell cycle phase, cell cycle process, organelle organization 
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Table A.7: Continued  
Cluster UniProt ID Protein Name GOTerm Annotations 
4 
Q7L0Q8 ras homolog gene family, member U cell cycle, cell cycle phase, cell cycle process, organelle organization 
Q9BTM1 H2A histone family, member J organelle organization 
5 
P02768 albumin DNA binding, nucleic acid binding 
P04908 histone cluster 1, H2ae; histone cluster 1, H2ab chromosome organization, DNA binding, nucleic acid binding 
Q15431 synaptonemal complex protein 1 chromosome organization, DNA binding, nucleic acid binding 
Q3SY52 zinc finger protein interacting with K protein 1 DNA binding, nucleic acid binding 
Q8N187 
amyotrophic lateral sclerosis 2 (juvenile) chromosome 
region, candidate 8 
DNA binding, nucleic acid binding 
Q9BTM1 H2A histone family, member J chromosome organization, DNA binding, nucleic acid binding 
Q9BZE0 GLIS family zinc finger 2 DNA binding, nucleic acid binding 
6 
P06727 apolipoprotein A-IV macromolecule localization 
P21549 alanine-glyoxylate aminotransferase 
establishment of protein localization, macromolecule localization, 
protein localization, protein transport 
Q8IUH5 zinc finger, DHHC-type containing 17 
establishment of protein localization, macromolecule localization, 
protein localization, protein transport 
Q8NFW9 myosin VIIA and Rab interacting protein 
establishment of protein localization, macromolecule localization, 
protein localization, protein transport 
Q969R2 oxysterol binding protein 2 macromolecule localization 
7 
P21549 alanine-glyoxylate aminotransferase 
carboxylic acid metabolic process, catalytic activity, cellular ketone 
metabolic process, organic acid metabolic process, oxoacid metabolic 
process 
P31040 
succinate dehydrogenase complex, subunit A, 
flavoprotein (Fp) 
carboxylic acid metabolic process, catalytic activity, cellular ketone 
metabolic process, organic acid metabolic process, oxoacid metabolic 
process 
P46977 
STT3, subunit of the oligosaccharyltransferase complex, 
homolog A 
catalytic activity 
P51160 phosphodiesterase 6C, cGMP-specific, cone, alpha prime catalytic activity 
Q7L0Q8 ras homolog gene family, member U catalytic activity 
Q8IUH5 zinc finger, DHHC-type containing 17 catalytic activity 
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Table A.7: Continued  
Cluster UniProt ID Protein Name GOTerm Annotations 
7 Q9H2M3 betaine-homocysteine methyltransferase 2 
carboxylic acid metabolic process, catalytic activity, cellular ketone 
metabolic process, organic acid metabolic process, oxoacid metabolic 
process 
8 
P02768 albumin 
cation binding, ion binding, metal ion binding, transition metal ion 
binding 
P06727 apolipoprotein A-IV 
cation binding, ion binding, metal ion binding, transition metal ion 
binding 
P78334 gamma-aminobutyric acid (GABA) A receptor, epsilon ion binding 
Q32M45 anoctamin 4 cation binding, ion binding, metal ion binding 
Q3SY52 zinc finger protein interacting with K protein 1 
cation binding, ion binding, metal ion binding, transition metal ion 
binding, zinc ion binding 
Q7L0Q8 ras homolog gene family, member U cation binding, ion binding, metal ion binding 
Q8IUH5 zinc finger, DHHC-type containing 17 
cation binding, ion binding, metal ion binding, transition metal ion 
binding, zinc ion binding 
Q8NFW9 myosin VIIA and Rab interacting protein 
cation binding, ion binding, metal ion binding, transition metal ion 
binding, zinc ion binding 
Q9BT88 synaptotagmin XI cation binding, ion binding, metal ion binding 
Q9BZE0 GLIS family zinc finger 2 
cation binding, ion binding, metal ion binding, transition metal ion 
binding, zinc ion binding 
Q9H2M3 betaine-homocysteine methyltransferase 2 
cation binding, ion binding, metal ion binding, transition metal ion 
binding, zinc ion binding 
9 
P02768 albumin transition metal ion binding 
P06727 apolipoprotein A-IV 
positive regulation of biological process, positive regulation of cellular 
process, transition metal ion binding 
Q3SY52 zinc finger protein interacting with K protein 1 homolog transition metal ion binding 
Q8IUH5 zinc finger, DHHC-type containing 17 
positive regulation of biological process, positive regulation of cellular 
process, transition metal ion binding 
Q8NFW9 myosin VIIA and Rab interacting protein transition metal ion binding 
Q9BZE0 GLIS family zinc finger 2 
positive regulation of biological process, positive regulation of cellular 
process, transition metal ion binding 
Q9H2M3 betaine-homocysteine methyltransferase 2 transition metal ion binding 
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Table A.7: Continued  
Cluster UniProt ID Protein Name GOTerm Annotations 
10 
P02768 albumin 
biological regulation, regulation of biological process, regulation of 
cellular process 
P06727 apolipoprotein A-IV 
biological regulation, regulation of biological process, regulation of 
cellular process 
P27816 microtubule-associated protein 4 
biological regulation, regulation of biological process, regulation of 
cellular process 
P51160 phosphodiesterase 6C, cGMP-specific, cone, alpha prime 
biological regulation, regulation of biological process, regulation of 
cellular process 
Q04726 transducin-like enhancer of split 3 
biological regulation, regulation of biological process, regulation of 
cellular process 
Q15431 synaptonemal complex protein 1 biological regulation, regulation of biological process 
Q3MIN7 ral guanine nucleotide dissociation stimulator-like 3 
biological regulation, regulation of biological process, regulation of 
cellular process 
Q3SY52 zinc finger protein interacting with K protein 1 homolog 
biological regulation, regulation of biological process, regulation of 
cellular process 
Q6MZT1 regulator of G-protein signaling 7 binding protein 
biological regulation, regulation of biological process, regulation of 
cellular process 
Q7L0Q8 ras homolog gene family, member U 
biological regulation, regulation of biological process, regulation of 
cellular process 
Q8IUH5 zinc finger, DHHC-type containing 17 
biological regulation, regulation of biological process, regulation of 
cellular process 
Q8N187 
amyotrophic lateral sclerosis 2 (juvenile) chromosome 
region, candidate 8 
biological regulation, regulation of biological process, regulation of 
cellular process 
Q9BZE0 GLIS family zinc finger 2 
biological regulation, regulation of biological process, regulation of 
cellular process 
11 P06727 apolipoprotein A-IV 
cellular macromolecule metabolic process, cellular metabolic process, 
cellular nitrogen compound metabolic process, macromolecule metabolic 
process, metabolic process, nitrogen compound metabolic process, 
nucleobase, nucleoside, nucleotide and nucleic acid metabolic process, 
primary metabolic process, regulation of biosynthetic process, regulation 
of cellular biosynthetic process, regulation of cellular metabolic process, 
regulation of macromolecule metabolic process, regulation of metabolic 
process 
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Table A.7: Continued  
Cluster UniProt ID Protein Name GOTerm Annotations 
11 
P21549 alanine-glyoxylate aminotransferase 
biosynthetic process, cellular biosynthetic process, cellular metabolic 
process, cellular nitrogen compound metabolic process, metabolic 
process, nitrogen compound metabolic process, primary metabolic 
process, transferase activity 
P31040 
succinate dehydrogenase complex, subunit A, 
flavoprotein (Fp) 
cellular metabolic process, metabolic process 
P46977 STT3, subunit of the oligosaccharyltransferase complex 
biosynthetic process, cellular biosynthetic process, cellular 
macromolecule biosynthetic process, cellular metabolic process, 
macromolecule biosynthetic process, macromolecule metabolic process, 
metabolic process, primary metabolic process, regulation of 
macromolecule metabolic process, transferase activity 
Q04726 transducin-like enhancer of split 3 
biosynthetic process, cellular biosynthetic process, cellular 
macromolecule biosynthetic process, cellular macromolecule metabolic 
process, cellular metabolic process, cellular nitrogen compound 
metabolic process, gene expression, macromolecule biosynthetic process, 
macromolecule metabolic process, metabolic process, nitrogen 
compound metabolic process, nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process, primary metabolic process, regulation of 
biosynthetic process, regulation of cellular biosynthetic process, 
regulation of cellular metabolic process, regulation of gene expression, 
regulation of macromolecule biosynthetic process, regulation of 
macromolecule metabolic process, regulation of metabolic process, 
regulation of nitrogen compound metabolic process, regulation of 
nucleobase, nucleoside, nucleotide and nucleic acid metabolic process, 
regulation of primary metabolic process, regulation of RNA metabolic 
process, regulation of transcription, regulation of transcription, DNA-
dependent, transcription 
Q14684 ribosomal RNA processing 1 homolog B 
cellular metabolic process, cellular nitrogen compound metabolic 
process, gene expression, macromolecule metabolic process, metabolic 
process, nitrogen compound metabolic process, primary metabolic 
process, regulation of macromolecule metabolic process, regulation of 
primary metabolic process 
Q15431 synaptonemal complex protein 1 
cellular metabolic process, cellular nitrogen compound metabolic 
process, macromolecule metabolic process, metabolic process, nitrogen 
compound metabolic process, primary metabolic process, regulation of 
macromolecule metabolic process, regulation of primary metabolic 
process 
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Table A.7: Continued  
Cluster UniProt ID Protein Name GOTerm Annotations 
11 
Q3SY52 zinc finger protein interacting with K protein 1 
biosynthetic process, cellular biosynthetic process, cellular 
macromolecule biosynthetic process, cellular macromolecule metabolic 
process, cellular metabolic process, cellular nitrogen compound 
metabolic process, gene expression, macromolecule biosynthetic process, 
macromolecule metabolic process, metabolic process, nitrogen 
compound metabolic process, nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process, primary metabolic process, regulation of 
biosynthetic process, regulation of cellular biosynthetic process, 
regulation of cellular metabolic process, regulation of gene expression, 
regulation of macromolecule biosynthetic process, regulation of 
macromolecule metabolic process, regulation of metabolic process, 
regulation of nitrogen compound metabolic process, regulation of 
nucleobase, nucleoside, nucleotide and nucleic acid metabolic process, 
regulation of primary metabolic process, regulation of RNA metabolic 
process, regulation of transcription, regulation of transcription, DNA-
dependent, transcription 
Q8IUH5 zinc finger, DHHC-type containing 17 
biosynthetic process, cellular biosynthetic process, cellular 
macromolecule biosynthetic process, cellular metabolic process, 
macromolecule biosynthetic process, macromolecule metabolic process, 
metabolic process, primary metabolic process, regulation of 
macromolecule metabolic process, transferase activity 
Q8N187 
amyotrophic lateral sclerosis 2 (juvenile) chromosome 
region, candidate 8 
cellular macromolecule metabolic process, nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic process, regulation of biosynthetic 
process, regulation of cellular biosynthetic process, regulation of cellular 
metabolic process, regulation of gene expression, regulation of 
macromolecule biosynthetic process, regulation of metabolic process, 
regulation of nitrogen compound metabolic process, regulation of 
nucleobase, nucleoside, nucleotide and nucleic acid metabolic process, 
regulation of RNA metabolic process, regulation of transcription, 
regulation of transcription, DNA-dependent 
Q969R2 oxysterol binding protein 2 metabolic process, primary metabolic process 
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Table A.7: Continued  
Cluster UniProt ID Protein Name GOTerm Annotations 
11 
Q9BZE0 GLIS family zinc finger 2 
biosynthetic process, cellular biosynthetic process, cellular 
macromolecule biosynthetic process, cellular macromolecule metabolic 
process, cellular metabolic process, cellular nitrogen compound 
metabolic process, gene expression, macromolecule biosynthetic process, 
macromolecule metabolic process, metabolic process, nitrogen 
compound metabolic process, nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process, primary metabolic process, regulation of 
biosynthetic process, regulation of cellular biosynthetic process, 
regulation of cellular metabolic process, regulation of gene expression, 
regulation of macromolecule biosynthetic process, regulation of 
macromolecule metabolic process, regulation of metabolic process, 
regulation of nitrogen compound metabolic process, regulation of 
nucleobase, nucleoside, nucleotide and nucleic acid metabolic process, 
regulation of primary metabolic process, regulation of transcription, 
transcription 
Q9H2M3 betaine-homocysteine methyltransferase 2 
biosynthetic process, cellular biosynthetic process, cellular metabolic 
process, cellular nitrogen compound metabolic process, metabolic 
process, nitrogen compound metabolic process, primary metabolic 
process, transferase activity 
12 
P06727 apolipoprotein A-IV multicellular organismal process 
P31040 
succinate dehydrogenase complex, subunit A, 
flavoprotein (Fp) 
anatomical structure development, developmental process, multicellular 
organismal development, multicellular organismal process, system 
development 
P51160 phosphodiesterase 6C, cGMP-specific, cone, alpha prime multicellular organismal process 
Q04726 transducin-like enhancer of split 3 
anatomical structure development, developmental process, multicellular 
organismal development, multicellular organismal process, system 
development 
Q15431 synaptonemal complex protein 1 multicellular organismal process 
Q9BZE0 GLIS family zinc finger 2 
anatomical structure development, developmental process, multicellular 
organismal development, multicellular organismal process, system 
development 
 
  
 
131 
Table A.8: GOTerm annotations and clusters for proteins identified as interacting with mARC2.  
Cluster UniProt ID Protein Name GOTerm Annotations 
1 
O75891 aldehyde dehydrogenase 1 family, member L1 catalytic activity 
O75947 
ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit d 
ATPase activity, catalytic activity, hydrolase activity, hydrolase activity, 
acting on acid anhydrides, hydrolase activity, acting on acid anhydrides, 
in phosphorus-containing anhydrides, nucleoside-triphosphatase 
activity, pyrophosphatase activity 
O76074 phosphodiesterase 5A, cGMP-specific 
catalytic activity, hydrolase activity, nucleoside binding, nucleotide 
binding, purine nucleoside binding, purine nucleotide binding, purine 
ribonucleotide binding, ribonucleotide binding 
P00748 coagulation factor XII catalytic activity, hydrolase activity 
P54764 EPH receptor A4 
adenyl nucleotide binding, adenyl ribonucleotide binding, ATP binding, 
catalytic activity, nucleoside binding, nucleotide binding, purine 
nucleoside binding, purine nucleotide binding, purine ribonucleotide 
binding, ribonucleotide binding 
Q13496 myotubularin 1 catalytic activity, hydrolase activity 
Q5W0Q7 ubiquitin specific peptidase like 1 catalytic activity, hydrolase activity 
Q6UB35 
methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1-like 
adenyl nucleotide binding, adenyl ribonucleotide binding, ATP binding, 
catalytic activity, nucleoside binding, nucleotide binding, purine 
nucleoside binding, purine nucleotide binding, purine ribonucleotide 
binding, ribonucleotide binding 
Q71U36 tubulin, alpha 1a 
catalytic activity, hydrolase activity, hydrolase activity, acting on acid 
anhydrides, hydrolase activity, acting on acid anhydrides, in 
phosphorus-containing anhydrides, nucleoside-triphosphatase activity, 
nucleotide binding, purine nucleotide binding, purine ribonucleotide 
binding, pyrophosphatase activity, ribonucleotide binding 
Q86XP3 DEAD (Asp-Glu-Ala-Asp) box polypeptide 42 
adenyl nucleotide binding, adenyl ribonucleotide binding, ATP binding, 
ATPase activity, catalytic activity, hydrolase activity, hydrolase activity, 
acting on acid anhydrides, hydrolase activity, acting on acid anhydrides, 
in phosphorus-containing anhydrides, nucleoside binding, nucleoside-
triphosphatase activity, nucleotide binding, purine nucleoside binding, 
purine nucleotide binding, purine ribonucleotide binding, 
pyrophosphatase activity, ribonucleotide binding 
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Table A.8: Continued  
Cluster UniProt ID Protein Name GOTerm Annotations 
1 Q9NUT2 
ATP-binding cassette, sub-family B (MDR/TAP), member 
8 
adenyl nucleotide binding, adenyl ribonucleotide binding, ATP binding, 
ATPase activity, catalytic activity, hydrolase activity, hydrolase activity, 
acting on acid anhydrides, hydrolase activity, acting on acid anhydrides, 
in phosphorus-containing anhydrides, nucleoside binding, nucleoside-
triphosphatase activity, nucleotide binding, purine nucleoside binding, 
purine nucleotide binding, purine ribonucleotide binding, 
pyrophosphatase activity, ribonucleotide binding 
2 
O75891 aldehyde dehydrogenase 1 family, member L1 cellular metabolic process, cellular process, metabolic process 
O75947 
ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit d 
cellular metabolic process, cellular process, metabolic process, primary 
metabolic process 
O76074 phosphodiesterase 5A, cGMP-specific 
cellular metabolic process, cellular process, metabolic process, primary 
metabolic process 
O94927 HAUS augmin-like complex, subunit 5 cellular process 
O95696 bromodomain containing 1 
cellular macromolecule metabolic process, cellular metabolic process, 
cellular process, cellular protein metabolic process, macromolecule 
metabolic process, metabolic process, primary metabolic process, protein 
metabolic process 
P00748 coagulation factor XII 
macromolecule metabolic process, metabolic process, primary metabolic 
process, protein metabolic process 
P46782 ribosomal protein S5 
cellular macromolecule metabolic process, cellular metabolic process, 
cellular process, cellular protein metabolic process, macromolecule 
metabolic process, metabolic process, primary metabolic process, protein 
metabolic process 
P54764 EPH receptor A4 
cellular macromolecule metabolic process, cellular metabolic process, 
cellular process, cellular protein metabolic process, macromolecule 
metabolic process, metabolic process, primary metabolic process, protein 
metabolic process 
P62269 
ribosomal protein S18 pseudogene 12; ribosomal protein 
S18 pseudogene 5; ribosomal protein S18 
cellular macromolecule metabolic process, cellular metabolic process, 
cellular process, cellular protein metabolic process, macromolecule 
metabolic process, metabolic process, primary metabolic process, protein 
metabolic process  
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Table A.8: Continued  
Cluster UniProt ID Protein Name GOTerm Annotations 
2 
P62701 
ribosomal protein S4X pseudogene 6; ribosomal protein 
S4X pseudogene 13; ribosomal protein S4, X-linked 
cellular macromolecule metabolic process, cellular metabolic process, 
cellular process, cellular protein metabolic process, macromolecule 
metabolic process, metabolic process, primary metabolic process, protein 
metabolic process 
Q13496 myotubularin 1 
cellular macromolecule metabolic process, cellular metabolic process, 
cellular process, cellular protein metabolic process, macromolecule 
metabolic process, metabolic process, primary metabolic process, protein 
metabolic process 
Q5W0Q7 ubiquitin specific peptidase like 1 
cellular macromolecule metabolic process, cellular metabolic process, 
cellular process, cellular protein metabolic process, macromolecule 
metabolic process, metabolic process, primary metabolic process, protein 
metabolic process 
Q6PJ61 F-box protein 46 
cellular macromolecule metabolic process, cellular metabolic process, 
cellular process, cellular protein metabolic process, macromolecule 
metabolic process, metabolic process, primary metabolic process, protein 
metabolic process 
Q6UB35 
methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1-like 
cellular metabolic process, cellular process, metabolic process 
Q71U36 tubulin, alpha 1a cellular process 
Q8N7Q3 zinc finger protein 676 
cellular macromolecule metabolic process, cellular metabolic process, 
cellular process, macromolecule metabolic process, metabolic process, 
primary metabolic process 
Q8TCU4 Alstrom syndrome 1 
cellular metabolic process, cellular process, metabolic process, primary 
metabolic process 
Q9C0H9 
hypothetical LOC100132856; hypothetical LOC100128100; 
hypothetical LOC100133017; SNAP25-interacting protein 
cellular process 
Q9NUT2 
ATP-binding cassette, sub-family B (MDR/TAP), member 
8 
cellular process 
Q9UKX5 integrin, alpha 11 cellular process 
3 
O75891 aldehyde dehydrogenase 1 family, member L1 biosynthetic process 
O75947 
ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit d 
biosynthetic process, cellular biosynthetic process 
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Table A.8: Continued  
Cluster UniProt ID Protein Name GOTerm Annotations 
3 
O76074 phosphodiesterase 5A, cGMP-specific 
biological regulation, multicellular organismal process, regulation of 
biological process, regulation of biological quality, regulation of cellular 
process, response to stimulus 
Q6UB35 
methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1-like 
heterocycle metabolic process, nitrogen compound metabolic process 
Q8N7Q3 zinc finger protein 676 
cellular nitrogen compound metabolic process, nitrogen compound 
metabolic process, nucleobase, nucleoside, nucleotide and nucleic acid 
metabolic process 
4 
O75891 aldehyde dehydrogenase 1 family, member L1 biosynthetic process 
O75947 
ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit d 
biosynthetic process, cellular biosynthetic process 
O76074 phosphodiesterase 5A, cGMP-specific 
biological regulation, multicellular organismal process, regulation of 
biological process, regulation of biological quality, regulation of cellular 
process, response to stimulus 
P00748 coagulation factor XII 
biological regulation, gene expression, multicellular organismal process, 
regulation of biological process, regulation of biological quality, 
regulation of cellular metabolic process, regulation of cellular process, 
regulation of cellular protein metabolic process, regulation of gene 
expression, regulation of macromolecule metabolic process, regulation of 
metabolic process, regulation of primary metabolic process, regulation of 
protein metabolic process, response to stimulus 
P46782 ribosomal protein S5 
biological regulation, biosynthetic process, cellular biosynthetic process, 
cellular macromolecule biosynthetic process, gene expression, 
macromolecule biosynthetic process, nucleic acid binding, regulation of 
biological process, regulation of biological quality, regulation of 
biosynthetic process, regulation of cellular biosynthetic process, 
regulation of cellular metabolic process, regulation of cellular process, 
regulation of cellular protein metabolic process, regulation of gene 
expression, regulation of macromolecule biosynthetic process, regulation 
of macromolecule metabolic process, regulation of metabolic process, 
regulation of primary metabolic process, regulation of protein metabolic 
process, RNA binding, structural constituent of ribosome, structural 
molecule activity, translation, translational elongation 
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Table A.8: Continued  
Cluster UniProt ID Protein Name GOTerm Annotations 
4 
P54764 EPH receptor A4 
biological regulation, multicellular organismal process, regulation of 
biological process, regulation of cellular process, response to stimulus 
P62269 
ribosomal protein S18 pseudogene 12; ribosomal protein 
S18 pseudogene 5; ribosomal protein S18 
biosynthetic process, cellular biosynthetic process, cellular 
macromolecule biosynthetic process, gene expression, macromolecule 
biosynthetic process, nucleic acid binding, RNA binding, structural 
constituent of ribosome, structural molecule activity, translation, 
translational elongation 
P62701 
ribosomal protein S4X pseudogene 6; ribosomal protein 
S4X pseudogene 13; ribosomal protein S4, X-linked 
biological regulation, biosynthetic process, cellular biosynthetic process, 
cellular macromolecule biosynthetic process, gene expression, 
macromolecule biosynthetic process, nucleic acid binding, regulation of 
biological process, regulation of biological quality, regulation of 
biosynthetic process, regulation of cellular biosynthetic process, 
regulation of cellular metabolic process, regulation of cellular process, 
regulation of cellular protein metabolic process, regulation of gene 
expression, regulation of macromolecule biosynthetic process, regulation 
of macromolecule metabolic process, regulation of metabolic process, 
regulation of primary metabolic process, regulation of protein metabolic 
process, RNA binding, structural constituent of ribosome, structural 
molecule activity, translation, translational elongation 
Q06787 fragile X mental retardation 1 multicellular organismal process, nucleic acid binding, RNA binding 
Q13496 myotubularin 1 
biological regulation, multicellular organismal process, regulation of 
biological quality 
Q6UB35 
methylenetetrahydrofolate dehydrogenase (NADP+ 
dependent) 1-like 
biosynthetic process, cellular biosynthetic process 
Q71U36 tubulin, alpha 1a structural molecule activity 
Q86XP3 DEAD (Asp-Glu-Ala-Asp) box polypeptide 42 nucleic acid binding, RNA binding 
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Table A.8: Continued  
Cluster UniProt ID Protein Name GOTerm Annotations 
4 
Q8N7Q3 zinc finger protein 676 
biological regulation, biosynthetic process, cellular biosynthetic process, 
cellular macromolecule biosynthetic process, gene expression, 
macromolecule biosynthetic process, nucleic acid binding, regulation of 
biological process, regulation of biosynthetic process, regulation of 
cellular biosynthetic process, regulation of cellular metabolic process, 
regulation of cellular process, regulation of gene expression, regulation 
of macromolecule biosynthetic process, regulation of macromolecule 
metabolic process, regulation of metabolic process, regulation of primary 
metabolic process 
Q8TCU4 Alstrom syndrome 1 
biological regulation, multicellular organismal process, regulation of 
biological process, regulation of biological quality, regulation of cellular 
process, response to stimulus 
Q9C0H9 
hypothetical LOC100132856; hypothetical LOC100128100; 
hypothetical LOC100133017; SNAP25-interacting protein 
biological regulation, regulation of biological process, regulation of 
cellular process 
Q9UKX5 integrin, alpha 11 multicellular organismal process 
5 
O76074 phosphodiesterase 5A, cGMP-specific 
anatomical structure development, biological regulation, developmental 
process, multicellular organismal development, multicellular organismal 
process, nervous system development, regulation of biological quality, 
response to stimulus, signal transduction, system development 
P00748 coagulation factor XII 
biological regulation, multicellular organismal process, regulation of 
biological quality, response to stimulus 
P46782 ribosomal protein S5 biological regulation, regulation of biological quality 
P54764 EPH receptor A4 
anatomical structure development, biological regulation, developmental 
process, multicellular organismal development, multicellular organismal 
process, nervous system development, response to stimulus, signal 
transduction, system development 
P62701 
ribosomal protein S4X pseudogene 6; ribosomal protein 
S4X pseudogene 13; ribosomal protein S4, X-linked 
biological regulation, developmental process, multicellular organismal 
development, multicellular organismal process 
Q06787 fragile X mental retardation 1 
anatomical structure development, developmental process, multicellular 
organismal development, multicellular organismal process, nervous 
system development, system development 
Q13496 myotubularin 1 
anatomical structure development, biological regulation, developmental 
process, multicellular organismal development, multicellular organismal 
process, organ development, regulation of biological quality, system 
development 
 
  
 
137 
Table A.8: Continued  
Cluster UniProt ID Protein Name GOTerm Annotations 
5 
Q8N7Q3 zinc finger protein 676 biological regulation 
Q8TCU4 Alstrom syndrome 1 
anatomical structure development, biological regulation, developmental 
process, multicellular organismal development, multicellular organismal 
process, nervous system development, organ development, regulation of 
biological quality, response to stimulus, signal transduction, system 
development 
Q9C0H9 
hypothetical LOC100132856; hypothetical LOC100128100; 
hypothetical LOC100133017; SNAP25-interacting protein 
biological regulation 
Q9UKX5 integrin, alpha 11 
anatomical structure development, developmental process, multicellular 
organismal development, multicellular organismal process, organ 
development, system development 
6 
O94927 HAUS augmin-like complex, subunit 5 
cellular component assembly, cellular component biogenesis, cellular 
component organization 
O95696 bromodomain containing 1 cellular component organization 
P54764 EPH receptor A4 cellular component organization 
Q71U36 tubulin, alpha 1a 
cellular component assembly, cellular component biogenesis, cellular 
component organization 
Q8TCU4 Alstrom syndrome 1 
cellular component assembly, cellular component biogenesis, cellular 
component organization 
7 
O95696 bromodomain containing 1 
biopolymer modification, post-translational protein modification, 
protein modification process 
P54764 EPH receptor A4 
biopolymer modification, post-translational protein modification, 
protein modification process 
Q13496 myotubularin 1 
biopolymer modification, post-translational protein modification, 
protein modification process 
8 
O75947 
ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit d 
establishment of localization, localization, transport 
Q06787 fragile X mental retardation 1 establishment of localization, localization, transport 
Q9C0H9 
hypothetical LOC100132856; hypothetical LOC100128100; 
hypothetical LOC100133017; SNAP25-interacting protein 
establishment of localization, localization, transport 
Q9NUT2 
ATP-binding cassette, sub-family B (MDR/TAP), member 
8 
establishment of localization, localization, transport 
Q9UKX5 integrin, alpha 11 localization 
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Table A.8: Continued  
Cluster UniProt ID Protein Name GOTerm Annotations 
9 
O76074 phosphodiesterase 5A, cGMP-specific 
cation binding, ion binding, metal ion binding, transition metal ion 
binding, zinc ion binding 
O95696 bromodomain containing 1 
cation binding, ion binding, metal ion binding, transition metal ion 
binding, zinc ion binding 
Q8N7Q3 zinc finger protein 676 
cation binding, ion binding, metal ion binding, transition metal ion 
binding, zinc ion binding 
Q9UKX5 integrin, alpha 11 cation binding, ion binding, metal ion binding 
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Table A.9: KEGG pathways for proteins identified as interacting with mARC1 in HEK-293 cell 
lysate.  
UniProt ID Protein Name KEGG Category, Pathway Class, and Pathway SAINT Score 
O00330 
pyruvate dehydrogenase 
complex component X 
Metabolism 
Global and overview maps 
-Metabolic pathways 
0.39 
O00750 
phosphatidylinositol-4-
phosphate 3-kinase catalytic 
subunit type 2 beta 
Environmental Information Processing 
Signal transduction 
-Phosphatidylinositol signaling system 
Metabolism 
Carbohydrate metabolism 
-Inositol phosphate metabolism 
Global and overview maps 
-Metabolic pathways 
0.26 
O14788 
tumor necrosis factor 
superfamily member 11 
Environmental Information Processing 
Signal transduction 
-NF-kappa B signaling pathway 
Signaling molecules and interaction 
-Cytokine-cytokine receptor interaction 
Human Diseases 
Immune diseases 
-Rheumatoid arthritis 
Organismal Systems 
Development 
-Osteoclast differentiation 
Endocrine system 
-Prolactin signaling pathway 
0.37 
O43181 
NADH:ubiquinone 
oxidoreductase subunit S4 
Human Diseases 
Endocrine and metabolic diseases 
-Non-alcoholic fatty liver disease (NAFLD) 
Neurodegenerative diseases 
-Alzheimer's disease 
-Huntington's disease 
-Parkinson's disease 
Metabolism 
Energy metabolism 
-Oxidative phosphorylation 
Global and overview maps 
-Metabolic pathways 
0.2 
O60260 
parkin RBR E3 ubiquitin 
protein ligase 
Genetic Information Processing 
Folding, sorting and degradation 
-Protein processing in endoplasmic reticulum 
-Ubiquitin mediated proteolysis 
Human Diseases 
Neurodegenerative diseases 
-Parkinson's disease 
0.17 
O60683 
peroxisomal biogenesis factor 
10 
Cellular Processes 
Transport and catabolism 
-Peroxisome 
0.28 
O75581 
LDL receptor related protein 
6 
Environmental Information Processing 
Signal transduction 
-Wnt signaling pathway 
0.18 
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Table A.9: Continued 
UniProt ID Protein Name KEGG Category, Pathway Class, and Pathway SAINT Score 
O95049 tight junction protein 3 
Cellular Processes 
Cellular community 
-Tight junction 
0.33 
O95382 
mitogen-activated protein 
kinase 6 
Environmental Information Processing 
Signal transduction 
-MAPK signaling pathway 
0.22 
O95602 
polymerase (RNA) I 
polypeptide A 
Genetic Information Processing 
Transcription 
-RNA polymerase 
Metabolism 
Global and overview maps 
-Metabolic pathways 
Nucleotide metabolism 
-Purine metabolism 
-Pyrimidine metabolism 
0.51 
P00734 
coagulation factor II, 
thrombin 
Cellular Processes 
Cell motility 
-Regulation of actin cytoskeleton 
Environmental Information Processing 
Signaling molecules and interaction 
-Neuroactive ligand-receptor interaction 
Organismal Systems 
Immune system 
-Complement and coagulation cascades 
0.51 
P11216 phosphorylase, glycogen 
Human Diseases 
Endocrine and metabolic diseases 
-Insulin resistance 
Metabolism 
Carbohydrate metabolism 
-Starch and sucrose metabolism 
Global and overview maps 
-Metabolic pathways 
Organismal Systems 
Endocrine system 
-Glucagon signaling pathway 
-Insulin signaling pathway 
0.32 
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Table A.9: Continued 
UniProt ID Protein Name KEGG Category, Pathway Class, and Pathway SAINT Score 
P15313 
ATPase, H+ transporting, 
lysosomal 56/58kDa, V1 
subunit B1 
Cellular Processes 
Transport and catabolism 
-Phagosome 
Human Diseases 
Immune diseases 
-Rheumatoid arthritis 
Infectious diseases: Bacterial 
-Epithelial cell signaling in Helicobacter pylori 
infection 
-Vibrio cholerae infection 
Metabolism 
Energy metabolism 
-Oxidative phosphorylation 
Global and overview maps 
-Metabolic pathways 
Organismal Systems 
Excretory system 
-Collecting duct acid secretion 
Nervous system 
-Synaptic vesicle cycle 
0.16 
P18564 integrin subunit beta 6 
Cellular Processes 
Cell motility 
-Regulation of actin cytoskeleton 
Cellular community 
-Focal adhesion 
Environmental Information Processing 
Signal transduction 
-PI3K-Akt signaling pathway 
Signaling molecules and interaction 
-ECM-receptor interaction 
Human Diseases 
Cardiovascular diseases 
-Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
-Dilated cardiomyopathy 
-Hypertrophic cardiomyopathy (HCM) 
0.37 
P21549 
alanine-glyoxylate 
aminotransferase 
Cellular Processes 
Transport and catabolism 
-Peroxisome 
Metabolism 
Amino acid metabolism 
-Alanine, aspartate and glutamate metabolism 
-Glycine, serine and threonine metabolism 
Carbohydrate metabolism 
-Glyoxylate and dicarboxylate metabolism 
Global and overview maps 
-Carbon metabolism 
-Metabolic pathways 
0.35 
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Table A.9: Continued 
UniProt ID Protein Name KEGG Category, Pathway Class, and Pathway SAINT Score 
P28749 retinoblastoma-like 1 
Cellular Processes 
Cell growth and death 
-Cell cycle 
Environmental Information Processing 
Signal transduction 
-TGF-beta signaling pathway 
Human Diseases 
Cancers: Overview 
-Viral carcinogenesis 
0.11 
P30679 
guanine nucleotide binding 
protein (G protein), alpha 15 
Environmental Information Processing 
Signal transduction 
-Calcium signaling pathway 
Human Diseases 
Infectious diseases: Parasitic 
-Amoebiasis 
-Chagas disease (American trypanosomiasis) 
0.17 
P31040 
succinate dehydrogenase 
complex subunit A, 
flavoprotein (Fp) 
Human Diseases 
Endocrine and metabolic diseases 
-Non-alcoholic fatty liver disease (NAFLD) 
Neurodegenerative diseases 
-Alzheimer's disease 
-Huntington's disease 
-Parkinson's disease 
Metabolism 
Carbohydrate metabolism 
-Citrate cycle (TCA cycle) 
Energy metabolism 
-Oxidative phosphorylation 
Global and overview maps 
-Carbon metabolism 
-Metabolic pathways 
0 
P46977 
STT3A, subunit of the 
oligosaccharyltransferase 
complex 
Genetic Information Processing 
Folding, sorting and degradation 
-Protein processing in endoplasmic reticulum 
Metabolism 
Global and overview maps 
-Metabolic pathways 
Glycan biosynthesis and metabolism 
-N-Glycan biosynthesis 
0.18 
P51160 phosphodiesterase 6C 
Metabolism 
Nucleotide metabolism 
-Purine metabolism 
0.3 
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Table A.9: Continued 
UniProt ID Protein Name KEGG Category, Pathway Class, and Pathway SAINT Score 
P52788 spermine synthase 
Metabolism 
Amino acid metabolism 
-Arginine and proline metabolism 
-Cysteine and methionine metabolism 
Global and overview maps 
-Metabolic pathways 
Metabolism of other amino acids 
-beta-Alanine metabolism 
-Glutathione metabolism 
0.29 
P78334 
gamma-aminobutyric acid 
(GABA) A receptor, epsilon 
Environmental Information Processing 
Signaling molecules and interaction 
-Neuroactive ligand-receptor interaction 
Human Diseases 
Substance dependence 
-Morphine addiction 
-Nicotine addiction 
Organismal Systems 
Nervous system 
-GABAergic synapse 
-Retrograde endocannabinoid signaling 
0.3 
Q13233 
mitogen-activated protein 
kinase 1, E3 ubiquitin protein 
ligase 
Environmental Information Processing 
Signal transduction 
-MAPK signaling pathway 
Genetic Information Processing 
Folding, sorting and degradation 
-Ubiquitin mediated proteolysis 
Human Diseases 
Infectious diseases: Viral 
-Hepatitis B 
-HTLV-I infection 
Organismal Systems 
Endocrine system 
-GnRH signaling pathway 
Immune system 
-RIG-I-like receptor signaling pathway 
Nervous system 
-Neurotrophin signaling pathway 
0.16 
Q16555 dihydropyrimidinase like 2 
Organismal Systems 
Development 
-Axon guidance 
0.17 
Q549N5 SRP receptor beta subunit 
Genetic Information Processing 
Folding, sorting and degradation 
-Protein export 
0.51 
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Table A.9: Continued 
UniProt ID Protein Name KEGG Category, Pathway Class, and Pathway SAINT Score 
Q6SJ96 
TATA-box binding protein 
like 2 
Genetic Information Processing 
Transcription 
-Basal transcription factors 
Human Diseases 
Cancers: Overview 
-Viral carcinogenesis 
Infectious diseases: Viral 
-Epstein-Barr virus infection 
-Herpes simplex infection 
-HTLV-I infection 
0.14 
Q8WZ42 titin 
Human Diseases 
Cardiovascular diseases 
-Dilated cardiomyopathy 
-Hypertrophic cardiomyopathy (HCM) 
0.47 
Q99683 
mitogen-activated protein 
kinase 5 
Cellular Processes 
Cell growth and death 
-Apoptosis 
Environmental Information Processing 
Signal transduction 
-MAPK signaling pathway 
-Sphingolipid signaling pathway 
-TNF signaling pathway 
Genetic Information Processing 
Folding, sorting and degradation 
-Protein processing in endoplasmic reticulum 
Human Diseases 
Endocrine and metabolic diseases 
-Non-alcoholic fatty liver disease (NAFLD) 
Neurodegenerative diseases 
-Amyotrophic lateral sclerosis (ALS) 
Organismal Systems 
Nervous system 
-Neurotrophin signaling pathway 
0.47 
Q9BYG4 
par-6 family cell polarity 
regulator gamma 
Cellular Processes 
Cellular community 
-Tight junction 
Transport and catabolism 
-Endocytosis 
Environmental Information Processing 
Signal transduction 
-Hippo signaling pathway 
-Rap1 signaling pathway 
Organismal Systems 
Development 
-Axon guidance 
0.34 
Q9H2M3 
betaine--homocysteine S-
methyltransferase 2 
Metabolism 
Amino acid metabolism 
-Cysteine and methionine metabolism 
Global and overview maps 
-Metabolic pathways 
0.33 
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Table A.9: Continued 
UniProt ID Protein Name KEGG Category, Pathway Class, and Pathway SAINT Score 
Q9P2J5 leucyl-tRNA synthetase 
Genetic Information Processing 
Translation 
-Aminoacyl-tRNA biosynthesis 
0.15 
Q9UHV7 mediator complex subunit 13 
Organismal Systems 
Endocrine system 
-Thyroid hormone signaling pathway 
0.19 
Q9UQ84 exonuclease 1 
Genetic Information Processing 
Replication and repair 
-Mismatch repair 
0.13 
Q9Y2P5 
solute carrier family 27 (fatty 
acid transporter), member 5 
Human Diseases 
Endocrine and metabolic diseases 
-Insulin resistance 
Metabolism 
Global and overview maps 
-Metabolic pathways 
Lipid metabolism 
-Primary bile acid biosynthesis 
Organismal Systems 
Digestive system 
-Bile secretion 
Endocrine system 
-PPAR signaling pathway 
0.15 
Q9Y2X0 mediator complex subunit 16 
Organismal Systems 
Endocrine system 
-Thyroid hormone signaling pathway 
0.13 
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Table A.10: KEGG pathways for proteins identified as interacting with mARC2 in HEK-293 cell 
lysate.  
UniProt ID Protein Name KEGG Category, Pathway Class, and Pathway SAINT Score 
A5YKK6 
CCR4-NOT transcription 
complex subunit 1 
Genetic Information Processing 
Folding, sorting and degradation 
-RNA degradation 
0.35 
O43708 
hsa:2954 GSTZ1; glutathione 
S-transferase zeta 1 
Environmental Information Processing 
Membrane transport 
-Metabolic pathways 
Metabolism 
Amino acid metabolism 
-Tyrosine metabolism 
0.08 
O75061 
DnaJ heat shock protein 
family (Hsp40) member C6 
Cellular Processes 
Transport and catabolism 
-Endocytosis 
0.05 
O75581 
LDL receptor related protein 
6 
Environmental Information Processing 
Signal transduction 
-Wnt signaling pathway 
0.4 
O75891 
aldehyde dehydrogenase 1 
family member L1 
Metabolism 
Metabolism of cofactors and vitamins 
-One carbon pool by folate 
0.23 
O75947 
ATP synthase, H+ 
transporting, mitochondrial 
Fo complex subunit D 
Environmental Information Processing 
Membrane transport 
-Metabolic pathways 
Human Diseases 
Neurodegenerative diseases 
-Alzheimer's disease 
-Huntington's disease 
Metabolism 
Energy metabolism 
-Oxidative phosphorylation 
0.28 
O76074 phosphodiesterase 5A 
Environmental Information Processing 
Signal transduction 
-cGMP-PKG signaling pathway 
Metabolism 
Nucleotide metabolism 
-Purine metabolism 
0.11 
O95685 
protein phosphatase 1 
regulatory subunit 3D 
Human Diseases 
Endocrine and metabolic diseases 
-Insulin resistance 
Organismal Systems 
Endocrine system 
-Insulin signaling pathway 
0 
O96007 
molybdenum cofactor 
synthesis 2 
Environmental Information Processing 
Membrane transport 
-Metabolic pathways 
Genetic Information Processing 
Folding, sorting and degradation 
-Sulfur relay system 
Metabolism 
Metabolism of cofactors and vitamins 
-Folate biosynthesis 
0.25 
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Table A.10: Continued 
UniProt ID Protein Name KEGG Category, Pathway Class, and Pathway SAINT Score 
P00748 coagulation factor XII 
Organismal Systems 
Immune system 
-Complement and coagulation cascades 
0.18 
P01127 
platelet derived growth 
factor subunit B 
Cellular Processes 
Cellular community 
-Focal adhesion 
-Gap junction 
Cell motility 
-Regulation of actin cytoskeleton 
Environmental Information Processing 
Signal transduction 
-MAPK signaling pathway 
-Phospholipase D signaling pathway 
-PI3K-Akt signaling pathway 
-Rap1 signaling pathway 
-Ras signaling pathway 
Signaling molecules and interaction 
-Cytokine-cytokine receptor interaction 
Human Diseases 
Cancers 
-Choline metabolism in cancer 
-Glioma 
-Melanoma 
-MicroRNAs in cancer 
-Pathways in cancer 
-Prostate cancer 
-Renal cell carcinoma 
Infectious diseases 
-HTLV-I infection 
0.17 
P05141 
solute carrier family 25 
(mitochondrial carrier; 
adenine nucleotide 
translocator), member 5 
Environmental Information Processing 
Signal transduction 
-Calcium signaling pathway 
-cGMP-PKG signaling pathway 
Human Diseases 
Infectious diseases 
-HTLV-I infection 
Neurodegenerative diseases 
-Huntington's disease 
-Parkinson's disease 
0.03 
P14410 
sucrase-isomaltase (alpha-
glucosidase) 
Environmental Information Processing 
Membrane transport 
-Metabolic pathways 
Metabolism 
Carbohydrate metabolism 
-Galactose metabolism 
-Starch and sucrose metabolism 
Organismal Systems 
Digestive system 
-Carbohydrate digestion and absorption 
0.08 
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Table A.10: Continued 
UniProt ID Protein Name KEGG Category, Pathway Class, and Pathway SAINT Score 
P14678 
small nuclear 
ribonucleoprotein 
polypeptides B and B1 
Genetic Information Processing 
Transcription 
-Spliceosome 
Human Diseases 
Immune diseases 
-Systemic lupus erythematosus 
0.04 
P23396 ribosomal protein S3 
Genetic Information Processing 
Translation 
-Ribosome 
0 
P27694 replication protein A1 
Genetic Information Processing 
Replication and repair 
-DNA replication 
-Fanconi anemia pathway 
-Homologous recombination 
-Mismatch repair 
-Nucleotide excision repair 
0 
P36542 
ATP synthase, H+ 
transporting, mitochondrial 
F1 complex, gamma 
polypeptide 1  
Environmental Information Processing 
Membrane transport 
-Metabolic pathways 
Human Diseases 
Neurodegenerative diseases 
-Alzheimer's disease 
-Huntington's disease 
-Parkinson's disease 
Metabolism 
Energy metabolism 
-Oxidative phosphorylation 
0.12 
P39019 ribosomal protein S19 
Genetic Information Processing 
Translation 
-Ribosome 
0 
P40855 
peroxisomal biogenesis factor 
19 
Cellular Processes 
Transport and catabolism 
-Peroxisome 
0.1 
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Table A.10: Continued 
UniProt ID Protein Name KEGG Category, Pathway Class, and Pathway SAINT Score 
P42262 
glutamate receptor, 
ionotropic, AMPA 2 
Environmental Information Processing 
Signal transduction 
-cAMP signaling pathway 
Signaling molecules and interaction 
-Neuroactive ligand-receptor interaction 
Human Diseases 
Neurodegenerative diseases 
-Amyotrophic lateral sclerosis (ALS) 
Substance dependence 
-Amphetamine addiction 
-Cocaine addiction 
Organismal Systems 
Environmental adaptation 
-Circadian entrainment 
Nervous system 
-Dopaminergic synapse 
-Glutamatergic synapse 
-Long-term depression 
-Long-term potentiation 
-Retrograde endocannabinoid signaling 
0.01 
P42285 Ski2 like RNA helicase 2 
Genetic Information Processing 
Folding, sorting and degradation 
-RNA degradation 
0.08 
P46782 ribosomal protein S5 
Genetic Information Processing 
Translation 
-Ribosome 
0.07 
P48047 
ATP synthase, H+ 
transporting, mitochondrial 
F1 complex, O subunit 
Environmental Information Processing 
Membrane transport 
-Metabolic pathways 
Human Diseases 
Neurodegenerative diseases 
-Alzheimer's disease 
-Huntington's disease 
-Parkinson's disease 
Metabolism 
Energy metabolism 
-Oxidative phosphorylation 
0.01 
P54764 EPH receptor A4 
Organismal Systems 
Development 
-Axon guidance 
0.26 
P62249 ribosomal protein S16 
Genetic Information Processing 
Translation 
-Ribosome 
0.01 
P62269 ribosomal protein S18 
Genetic Information Processing 
Translation 
-Ribosome 
0 
P62273 ribosomal protein S29 
Genetic Information Processing 
Translation 
-Ribosome 
0.04 
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Table A.10: Continued 
UniProt ID Protein Name KEGG Category, Pathway Class, and Pathway SAINT Score 
P62701 
ribosomal protein S4, X-
linked 
Genetic Information Processing 
Translation 
-Ribosome 
0 
P62750 ribosomal protein L23a 
Genetic Information Processing 
Translation 
-Ribosome 
0.01 
P62979 ribosomal protein S27a 
Genetic Information Processing 
Translation 
-Ribosome 
0 
Q06787 fragile X mental retardation 1 
Genetic Information Processing 
Translation 
- RNA transport 
0.29 
Q07021 
complement component 1, q 
subcomponent binding 
protein 
Human Diseases 
Infectious diseases 
-Herpes simplex infection 
0 
Q13496 myotubularin 1 
Environmental Information Processing 
Membrane transport 
-Metabolic pathways 
Signal transduction 
-Phosphatidylinositol signaling system 
Metabolism 
Carbohydrate metabolism 
-Inositol phosphate metabolism 
0.29 
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Table A.10: Continued 
UniProt ID Protein Name KEGG Category, Pathway Class, and Pathway SAINT Score 
Q13698 
calcium channel, voltage-
dependent, L type, alpha 1S 
subunit 
Environmental Information Processing 
Signal transduction 
-Calcium signaling pathway 
-cAMP signaling pathway 
-cGMP-PKG signaling pathway 
-MAPK signaling pathway 
Human Diseases 
Cardiovascular diseases 
-Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
-Dilated cardiomyopathy 
-Hypertrophic cardiomyopathy (HCM) 
Neurodegenerative diseases 
-Alzheimer's disease 
Organismal Systems 
Circulatory system 
-Adrenergic signaling in cardiomyocytes 
-Cardiac muscle contraction 
-Vascular smooth muscle contraction 
Endocrine system 
-Aldosterone synthesis and secretion 
-GnRH signaling pathway 
-Insulin secretion 
-Oxytocin signaling pathway 
-Renin secretion 
Nervous system 
-Cholinergic synapse 
-GABAergic synapse 
-Retrograde endocannabinoid signaling 
-Serotonergic synapse 
0.24 
Q15185 prostaglandin E synthase 3 
Environmental Information Processing 
Membrane transport 
-Metabolic pathways 
Metabolism 
Lipid metabolism 
-Arachidonic acid metabolism 
0.05 
Q32P51 
heterogeneous nuclear 
ribonucleoprotein A1-like 2 
Genetic Information Processing 
Transcription 
-Spliceosome 
0 
Q5S007 leucine-rich repeat kinase 2 
Human Diseases 
Neurodegenerative diseases 
-Parkinson's disease 
0.27 
Q6UB35 
methylenetetrahydrofolate 
dehydrogenase (NADP+ 
dependent) 1-like 
Environmental Information Processing 
Membrane transport 
-Metabolic pathways 
Metabolism 
Metabolism of cofactors and vitamins 
-One carbon pool by folate 
0.14 
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Table A.10: Continued 
UniProt ID Protein Name KEGG Category, Pathway Class, and Pathway SAINT Score 
Q71U36 tubulin alpha 1a 
Cellular Processes 
Cell growth and death 
-Apoptosis 
Cellular community 
-Gap junction 
Transport and catabolism 
-Phagosome 
Human Diseases 
Infectious diseases 
-Pathogenic Escherichia coli infection 
0 
Q86XP3 DEAD-box helicase 42 
Genetic Information Processing 
Transcription 
-Spliceosome 
0.54 
Q8NBS9 
thioredoxin domain 
containing 5 
Genetic Information Processing 
Folding, sorting and degradation 
-Protein processing in endoplasmic reticulum 
0.08 
Q8TD57 
dynein, axonemal, heavy 
chain 3 
Human Diseases 
Neurodegenerative diseases 
-Huntington's disease 
0.19 
Q96RS0 
trimethylguanosine synthase 
1 
Genetic Information Processing 
Translation 
-RNA transport 
0.41 
Q9BTM1 H2A histone family member J 
Human Diseases 
Immune diseases 
-Systemic lupus erythematosus 
Substance dependence 
-Alcoholism 
0 
Q9NQX3 gephyrin 
Organismal Systems 
Nervous system 
-GABAergic synapse 
0.3 
Q9NUT2 
ATP binding cassette 
subfamily B member 8 
Environmental Information Processing 
Membrane transport 
-ABC transporters 
0.43 
Q9NZB8 
molybdenum cofactor 
synthesis 1 
Environmental Information Processing 
Membrane transport 
-Metabolic pathways 
Genetic Information Processing 
Folding, sorting and degradation 
-Sulfur relay system 
Metabolism 
Metabolism of cofactors and vitamins 
-Folate biosynthesis 
0.1 
Q9UHD8 septin 9 
Human Diseases 
Infectious diseases 
-Bacterial invasion of epithelial cells 
0.02 
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Table A.10: Continued 
UniProt ID Protein Name KEGG Category, Pathway Class, and Pathway SAINT Score 
Q9UKX5 integrin subunit alpha 11 
Cellular Processes 
Cell motility 
-Regulation of actin cytoskeleton 
Cellular community 
-Focal adhesion 
Environmental Information Processing 
Signal transduction 
-PI3K-Akt signaling pathway 
Signaling molecules and interaction 
-ECM-receptor interaction 
Human Diseases 
Cardiovascular diseases 
-Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
-Dilated cardiomyopathy 
-Hypertrophic cardiomyopathy (HCM 
0.3 
Q9Y285 
phenylalanyl-tRNA 
synthetase alpha subunit 
Genetic Information Processing 
Translation 
-Aminoacyl-tRNA biosynthesis 
0 
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Appendix IV: Protein sequence comparison for mARC1 and mARC2 in human, rat, 
and pig 
 
Figure A.15: Protein sequence comparison for mARC1 and mARC2 in 
human and rat. A. mARC1 (Q5VT66) in human compared to mARC1 
(G3V6I4) in rat, B. mARC2 (Q969Z3) in human compared to mARC2 
(O88994) in rat. 
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Figure A.16: Protein sequence comparison for mARC1 and mARC2 in 
human and pig. A. mARC1 (Q5VT66) in human compared to mARC2 
(F1S9I9) in pig, B. mARC2 (Q969Z3) in human compared to mARC2 
(F1S9I9) in pig. 
A
B
 156 
 
WORKS CITED 
[1] Sardesai VM. Molybdenum: an essential trace element. Nutr Clin Pract. 1993;8:277-81. 
 
[2] Hille R, Hall J, Basu P. The Mononuclear Molybdenum Enzymes. Chem Rev 
(Washington, DC, U S). 2014;114:3963-4038. 
 
[3] Moberg C, Catalano RD, Charnock-Jones DS, Olovsson M. VEGF-A and serum 
withdrawal induced changes in the transcript profile in human endometrial endothelial 
cells. Reprod Sci. 2010;17:590-611. 
 
[4] Wagner SA, Beli P, Weinert BT, Nielsen ML, Cox J, Mann M, et al. A proteome-wide, 
quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. 
Mol Cell Proteomics. 2011;10:M111.013284, 13 pp. 
 
[5] Schwarz G, Mendel RR, Ribbe MW. Molybdenum cofactors, enzymes and pathways. 
Nature (London, U K). 2009;460:839-47. 
 
[6] Emanuele MJ, Elia AEH, Xu Q, Thoma CR, Izhar L, Leng Y, et al. Global Identification 
of Modular Cullin-RING Ligase Substrates. Cell (Cambridge, MA, U S). 2011;147:459-74. 
 
[7] Sitras V, Paulssen R, Leirvik J, Vaartun A, Acharya G. Placental gene expression 
profile in intrauterine growth restriction due to placental insufficiency. Reprod Sci. 
2009;16:701-11. 
 
[8] Schwarz G. Molybdenum cofactor and human disease. Curr Opin Chem Biol. 
2016;31:179-87. 
 
[9] Matsumoto M, Hatakeyama S, Oyamada K, Oda Y, Nishimura T, Nakayama KI. 
Large-scale analysis of the human ubiquitin-related proteome. Proteomics. 2005;5:4145-
51. 
 
[10] Lee KA, Hammerle LP, Andrews PS, Stokes MP, Mustelin T, Silva JC, et al. Ubiquitin 
Ligase Substrate Identification through Quantitative Proteomics at Both the Protein and 
Peptide Levels. J Biol Chem. 2011;286:41530-8, S/1-S/21. 
 
[11] Johnson JS, Laegreid WS, Basaraba RJ, Baker DC. Truncated gamma-glutamyl 
carboxylase in Rambouillet sheep. Vet Pathol. 2006;43:430-7. 
 
 157 
 
[12] Hu Y, Ribbe MW. Nitrogenases - A tale of carbon atom(s). Angew Chem, Int Ed. 
2016;55:8216-26. 
 
[13] Schwarz G, Belaidi AA. Molybdenum in human health and disease. Met Ions Life 
Sci. 2013;13:415-50. 
 
[14] Boll M, Schink B, Messerschmidt A, Kroneck PMH. Novel bacterial molybdenum 
and tungsten enzymes: Three-dimensional structure, spectroscopy, and reaction 
mechanism. Biol Chem. 2005;386:999-1006. 
 
[15] Mendel RR. Biology of the molybdenum cofactor. J Exp Bot. 2007;58:2289-96. 
 
[16] Moura JJG, Brondino CD, Trincao J, Romao MJ. Mo and W bis-MGD enzymes: nitrate 
reductases and formate dehydrogenases. JBIC, J Biol Inorg Chem. 2004;9:791-9. 
 
[17] Rothery RA, Workun GJ, Weiner JH. The prokaryotic complex iron-sulfur 
molybdoenzyme family. Biochim Biophys Acta, Biomembr. 2008;1778:1897-929. 
 
[18] Hille R. The Mononuclear Molybdenum Enzymes. Chem Rev (Washington, D C). 
1996;96:2757-816. 
 
[19] Wahl B, Reichmann D, Niks D, Krompholz N, Havemeyer A, Clement B, et al. 
Biochemical and Spectroscopic Characterization of the Human Mitochondrial 
Amidoxime Reducing Components hmARC-1 and hmARC-2 Suggests the Existence of a 
New Molybdenum Enzyme Family in Eukaryotes. J Biol Chem. 2010;285:37847-59. 
 
[20] Havugimana PC, Hart GT, Nepusz T, Yang H, Turinsky AL, Li Z, et al. A Census of 
Human Soluble Protein Complexes. Cell (Cambridge, MA, U S). 2012;150:1068-81. 
 
[21] Coelho C, Mahro M, Trincao J, Carvalho ATP, Ramos MJ, Terao M, et al. The First 
Mammalian Aldehyde Oxidase Crystal Structure. J Biol Chem. 2012;287:40690-702. 
 
[22] Ott G, Havemeyer A, Clement B. The mammalian molybdenum enzymes of mARC. 
JBIC, J Biol Inorg Chem. 2015;20:265-75. 
 
[23] Garattini E, Terao M. Aldehyde oxidase and its importance in novel drug discovery: 
present and future challenges. Expert Opin Drug Discovery. 2013;8:641-54. 
 
[24] Havemeyer A, Lang J, Clement B. The fourth mammalian molybdenum enzyme 
mARC: current state of research. Drug Metab Rev. 2011;43:524-39. 
 158 
 
 
[25] Plitzko B, Ott G, Reichmann D, Henderson CJ, Wolf CR, Mendel R, et al. The 
involvement of mitochondrial amidoxime reducing components 1 and 2 and 
mitochondrial cytochrome b5 in N-reductive metabolism in human cells. J Biol Chem. 
2013;288:20228-37. 
 
[26] Sparacino-Watkins CE, Tejero J, Sun B, Gauthier MC, Thomas J, Ragireddy V, et al. 
Nitrite reductase and nitric-oxide synthase activity of the mitochondrial molybdopterin 
enzymes mARC1 and mARC2. J Biol Chem. 2014;289:10345-58. 
 
[27] Shiva S. Nitrite: A physiological store of nitric oxide and modulator of mitochondrial 
function. Redox Biol. 2013;1:40-4. 
 
[28] Moncada S, Higgs EA. The L-arginine-nitric oxide pathway. Curr. Sci.; 1993. p. 12.1-
.8. 
 
[29] Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric 
oxide from L-arginine. Nature (London). 1988;333:664-6. 
 
[30] Sakuma I, Stuehr DJ, Gross SS, Nathan C, Levi R. Identification of arginine as a 
precursor of endothelium-derived relaxing factor. Proc Natl Acad Sci U S A. 1988;85:8664-
7. 
 
[31] Schmidt HHHW, Klein MM, Niroomand F, Boehme E. Is arginine a physiological 
precursor of endothelium-derived nitric oxide? Eur J Pharmacol. 1988;148:293-5. 
 
[32] Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function 
and inhibition. Biochem J. 2001;357:593-615. 
 
[33] Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res. 
1999;43:521-31. 
 
[34] Foerstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur 
Heart J. 2012;33:829-37. 
 
[35] Tsutsui M, Tanimoto A, Tamura M, Mukae H, Yanagihara N, Shimokawa H, et al. 
Significance of nitric oxide synthases: Lessons from triple nitric oxide synthases null mice. 
J Pharmacol Sci (Amsterdam, Neth). 2015;127:42-52. 
 
 159 
 
[36] Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from 
marvel to menace. Circulation. 2006;113:1708-14. 
 
[37] Rafikov R, Fonseca FV, Kumar S, Pardo D, Darragh C, Elms S, et al. eNOS activation 
and NO function: Structural motifs responsible for the posttranslational control of 
endothelial nitric oxide synthase activity. J Endocrinol. 2011;210:271-84. 
 
[38] Chen K, Pittman RN, Popel AS. Nitric Oxide in the Vasculature: Where Does It Come 
From and Where Does It Go? A Quantitative Perspective. Antioxid Redox Signaling. 
2008;10:1185-98. 
 
[39] Yang Y, Loscalzo J. S-nitrosoprotein formation and localization in endothelial cells. 
Proc Natl Acad Sci U S A. 2005;102:117-22. 
 
[40] Daaka Y. S-Nitrosylation-regulated GPCR signaling. Biochim Biophys Acta, Gen 
Subj. 2012;1820:743-51. 
 
[41] Al-Ani B, Hewett PW, Ahmed S, Cudmore M, Fujisawa T, Ahmad S, et al. The release 
of nitric oxide from S-nitrosothiols promotes angiogenesis. PLoS One. 2006;1:No pp. 
given. 
 
[42] Askew SC, Barnett DJ, McAninly J, Williams DLH. Catalysis by Cu2+ of nitric oxide 
release from S-nitrosothiols (RSNO). J Chem Soc, Perkin Trans 2. 1995:741-5. 
 
[43] Rotta JCG, Lunardi CN, Tedesco AC. Nitric oxide release from the S-nitrosothiol zinc 
phthalocyanine complex by flash photolysis. Braz J Med Biol Res. 2003;36:587-94. 
 
[44] Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in 
physiology and therapeutics. Nat Rev Drug Discovery. 2008;7:156-67. 
 
[45] Jansson EA, Huang L, Malkey R, Govoni M, Nihlen C, Olsson A, et al. A mammalian 
functional nitrate reductase that regulates nitrite and nitric oxide homeostasis. Nat Chem 
Biol. 2008;4:411-7. 
 
[46] Sparacino-Watkins C, Stolz JF, Basu P. Nitrate and periplasmic nitrate reductases. 
Chem Soc Rev. 2014;43:676-706. 
 
[47] Stolz JF, Basu P. Evolution of nitrate reductase: molecular and structural variations 
on a common function. chembiochem. 2002;3:198-206. 
 
 160 
 
[48] Maia LB, Pereira V, Mira L, Moura JJG. Nitrite reductase activity of rat and human 
xanthine oxidase, xanthine dehydrogenase, and aldehyde oxidase: Evaluation of their 
contribution to NO formation in vivo. Biochemistry. 2015;54:685-710. 
 
[49] Tabach Y, Golan T, Hernandez-Hernandez A, Messer AR, Fukuda T, Kouznetsova 
A, et al. Human disease locus discovery and mapping to molecular pathways through 
phylogenetic profiling. Mol Syst Biol. 2013;9:692. 
 
[50] Wang J, Krizowski S, Fischer-Schrader K, Niks D, Tejero J, Sparacino-Watkins C, et 
al. Sulfite Oxidase Catalyzes Single-Electron Transfer at Molybdenum Domain to Reduce 
Nitrite to Nitric Oxide. Antioxid Redox Signaling. 2015;23:283-94. 
 
[51] Weed RI, Reed CF, Berg G. Is hemoglobin an essential structural component of 
human erythrocyte membranes? J Clin Invest. 1963;42:581-8. 
 
[52] Doster W, Longeville S. Microscopic diffusion and hydrodynamic interactions of 
hemoglobin in red blood cells. Biophys J. 2007;93:1360-8. 
 
[53] Huang Z, Shiva S, Kim-Shapiro DB, Patel RP, Ringwood LA, Irby CE, et al. Enzymatic 
function of hemoglobin as a nitrite reductase that produces NO under allosteric control. 
J Clin Invest. 2005;115:2099-107. 
 
[54] Shiva S, Huang Z, Grubina R, Sun J, Ringwood LA, MacArthur PH, et al. 
Deoxymyoglobin is a nitrite reductase that generates nitric oxide and regulates 
mitochondrial respiration. Circ Res. 2007;100:654-61. 
 
[55] Umbrello M, Dyson A, Feelisch M, Singer M. The Key Role of Nitric Oxide in 
Hypoxia: Hypoxic Vasodilation and Energy Supply-Demand Matching. Antioxid Redox 
Signaling. 2013;19:1690-710. 
 
[56] Allen BW, Stamler JS, Piantadosi CA. Hemoglobin, nitric oxide and molecular 
mechanisms of hypoxic vasodilation. Trends Mol Med. 2009;15:452-60. 
 
[57] Floegel U, Fago A, Rassaf T. Keeping the heart in balance: the functional interactions 
of myoglobin with nitrogen oxides. J Exp Biol. 2010;213:2726-33. 
 
[58] Li H, Samouilov A, Liu X, Zweier JL. Characterization of the Magnitude and Kinetics 
of Xanthine Oxidase-Catalyzed Nitrate Reduction: Evaluation of its Role in Nitrite and 
Nitric Oxide Generation in Anoxic Tissues. Biochemistry. 2003;42:1150-9. 
 161 
 
[59] Lu P, Liu F, Yao Z, Wang C-Y, Chen D-D, Tian Y, et al. Nitrite-derived nitric oxide 
by xanthine oxidoreductase protects the liver against ischemia-reperfusion injury. 
Hepatobiliary Pancreatic Dis Int. 2005;4:350-5. 
 
[60] Castello PR, David PS, McClure T, Crook Z, Poyton RO. Mitochondrial cytochrome 
oxidase produces nitric oxide under hypoxic conditions: implications for oxygen sensing 
and hypoxic signaling in eukaryotes. Cell Metab. 2006;3:277-87. 
 
[61] Zhang Z, Naughton D, Winyard PG, Benjamin N, Blake DR, Symons MCR. 
Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential 
pathway for nitric oxide formation in the absence of nitric oxide synthase activity. 
Biochem Biophys Res Commun. 1998;249:767-72. 
 
[62] Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of 
nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2002;99:8306-11. 
 
[63] Beretta M, Woelkart G, Schernthaner M, Griesberger M, Neubauer R, Schmidt K, et 
al. Vascular Bioactivation of Nitroglycerin Is Catalyzed by Cytosolic Aldehyde 
Dehydrogenase-2. Circ Res. 2012;110:385-93. 
 
[64] Wolkart G, Beretta M, Wenzl MV, Stessel H, Schmidt K, Maeda N, et al. Tolerance to 
nitroglycerin through proteasomal down-regulation of aldehyde dehydrogenase-2 in a 
genetic mouse model of ascorbate deficiency. Br J Pharmacol. 2013;168:1868-77. 
 
[65] Sydow K, Daiber A, Oelze M, Chen Z, August M, Wendt M, et al. Central role of 
mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin 
tolerance and cross-tolerance. J Clin Invest. 2004;113:482-9. 
 
[66] Li H, Liu X, Cui H, Chen Y-R, Cardounel AJ, Zweier JL. Characterization of the 
Mechanism of Cytochrome P450 Reductase-Cytochrome P450-mediated Nitric Oxide and 
Nitrosothiol Generation from Organic Nitrates. J Biol Chem. 2006;281:12546-54. 
 
[67] Bogdan C. Nitric oxide and the immune response. Nat Immunol. 2001;2:907-16. 
 
[68] Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a 
neural role for nitric oxide. Nature. 1990;347:768-70. 
 
[69] Bredt DS, Snyder SH. Nitric oxide, a novel neuronal messenger. Neuron. 1992;8:3-11. 
 
 162 
 
[70] Hibbs JB, Jr., Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated 
macrophage effector molecule. Biochem Biophys Res Commun. 1988;157:87-94. 
 
[71] Napoli C, Ignarro LJ. Nitric Oxide and Atherosclerosis. Nitric Oxide. 2001;5:88-97. 
 
[72] Toda N, Ayajiki K, Okamura T. Neurogenic and Endothelial Nitric Oxide Regulates 
Blood Circulation in Lingual and Other Oral Tissues. J Cardiovasc Pharmacol. 
2012;60:100-8. 
 
[73] Toda N, Nakanishi-Toda M. How mental stress affects endothelial function. 
Pfluegers Arch. 2011;462:779-94. 
 
[74] Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase 
and increases guanosine 3',5'-cyclic monophosphate levels in various tissue preparations. 
Proc Natl Acad Sci U S A. 1977;74:3203-7. 
 
[75] Denninger JW, Marletta MA. Guanylate cyclase and the .bul.NO/cGMP signaling 
pathway. Biochim Biophys Acta, Bioenerg. 1999;1411:334-50. 
 
[76] Derbyshire ER, Marletta MA. Structure and regulation of soluble guanylate cyclase. 
Annu Rev Biochem. 2012;81:533-59. 
 
[77] Hussain MB, Hobbs AJ, MacAllister RJ. Autoregulation of nitric oxide-soluble 
guanylate cyclase-cyclic GMP signaling in mouse thoracic aorta. Br J Pharmacol. 
1999;128:1082-8. 
 
[78] Furchgott RF, Vanhoutte PM. Endothelium-derived relaxing and contracting factors. 
FASEB J. 1989;3:2007-18. 
 
[79] Carvajal JA, Germain AM, Huidobro-Toro JP, Weiner CP. Molecular mechanism of 
cGMP-mediated smooth muscle relaxation. J Cell Physiol. 2000;184:409-20. 
 
[80] Cohen RA, Weisbrod RM, Gericke M, Yaghoubi M, Bierl C, Bolotina VM. Mechanism 
of nitric oxide-induced vasodilatation: refilling of intracellular stores by sarcoplasmic 
reticulum Ca2+ ATPase and inhibition of store-operated Ca2+ influx. Circ Res. 
1999;84:210-9. 
 
[81] Ignarro LJ, Kadowitz PJ. The pharmacological and physiological role of cyclic GMP 
in vascular smooth muscle relaxation. Annu Rev Pharmacol Toxicol. 1985;25:171-91. 
 163 
 
[82] Ledoux J, Werner ME, Brayden JE, Nelson MT. Calcium-activated potassium 
channels and the regulation of vascular tone. Physiology. 2006;21:69-78. 
 
[83] Weisbrod RM, Griswold MC, Yaghoubi M, Komalavilas P, Lincoln TM, Cohen RA. 
Evidence that additional mechanisms to cyclic GMP mediate the decrease in intracellular 
calcium and relaxation of rabbit aortic smooth muscle to nitric oxide. Br J Pharmacol. 
1998;125:1695-707. 
 
[84] Lee MR, Li L, Kitazawa T. Cyclic GMP causes Ca2+ desensitization in vascular 
smooth muscle by activating the myosin light chain phosphatase. J Biol Chem. 
1997;272:5063-8. 
 
[85] Lindpaintner K, Ganten D, Editors. Molecular Reviews in Cardiovascular Medicine: 
Chapman & Hall; 1996. 
 
[86] Mizuno Y, Isotani E, Huang J, Ding H, Stull JT, Kamm KE. Myosin light chain kinase 
activation and calcium sensitization in smooth muscle in vivo. Am J Physiol. 
2008;295:C358-C64. 
 
[87] Webb RC. Smooth muscle contraction and relaxation. Adv Physiol Educ. 2003;27:201-
6. 
 
[88] Word RA, Tang D-C, Kamm KE. Activation properties of myosin light chain kinase 
during contraction/relaxation cycles of tonic and phasic smooth muscles. J Biol Chem. 
1994;269:21596-602. 
 
[89] Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, et al. 
Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, 
nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active 
intermediates. J Pharmacol Exp Ther. 1981;218:739-49. 
 
[90] Whalen EJ, Foster MW, Matsumoto A, Ozawa K, Violin JD, Que LG, et al. Regulation 
of β-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor 
kinase 2. Cell (Cambridge, MA, U S). 2007;129:511-22. 
 
[91] Whalen EJ, Johnson AK, Lewis SJ. β-Adrenoceptor dysfunction after inhibition of NO 
synthesis. Hypertension. 2000;36:376-82. 
 
[92] Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation. 
2000;101:558-69. 
 164 
 
 
[93] Brodde OE. Beta-adrenoceptors in cardiac disease. Pharmacol Ther. 1993;60:405-30. 
 
[94] Chruscinski A, Brede ME, Meinel L, Lohse MJ, Kobilka BK, Hein L. Differential 
distribution of β-adrenergic receptor subtypes in blood vessels of knockout mice lacking 
β1- or β2-adrenergic receptors. Mol Pharmacol. 2001;60:955-62. 
 
[95] Guimaraes S, Moura D. Vascular adrenoceptors: An update. Pharmacol Rev. 
2001;53:319-56. 
 
[96] Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac β-adrenergic 
receptors, and heart failure. Circulation. 2000;101:1634-7. 
 
[97] Motomura S, Reinhard-Zerkowski H, Daul A, Brodde OE. On the physiologic role of 
beta-2 adrenoceptors in the human heart: in vitro and in vivo studies. Am Heart J. 
1990;119:608-19. 
 
[98] Vatner DE, Knight DR, Homcy CJ, Vatner SF, Young MA. Subtypes of β-adrenergic 
receptors in bovine coronary arteries. Circ Res. 1986;59:463-73. 
 
[99] Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Boehm M, et al. Soluble 
guanylate cyclase: a potential therapeutic target for heart failure. Heart Failure Rev. 
2013;18:123-34. 
 
[100] Chamizo-Ampudia A, Galvan A, Fernandez E, Llamas A. The Chlamydomonas 
reinhardtii molybdenum cofactor enzyme crARC has a Zn-dependent activity and 
protein partners similar to those of its human homologue. Eukaryotic Cell. 2011;10:1270-
82. 
 
[101] Anantharaman V, Aravind L. MOSC domains: ancient, predicted sulfur-carrier 
domains, present in diverse metal-sulfur cluster biosynthesis proteins including 
Molybdenum cofactor sulfurases. FEMS Microbiol Lett. 2002;207:55-61. 
 
[102] Klein JM, Busch JD, Potting C, Baker MJ, Langer T, Schwarz G. The Mitochondrial 
Amidoxime-reducing Component (mARC1) Is a Novel Signal-anchored Protein of the 
Outer Mitochondrial Membrane. J Biol Chem. 2012;287:42795-803. 
 
[103] Uhlen M, Fagerberg L, Hallstroem BM, Lindskog C, Oksvold P, Mardinoglu A, et 
al. Tissue-based map of the human proteome. Science (Washington, DC, U S). 
2015;347:394. 
 165 
 
 
[104] Havemeyer A, Bittner F, Wollers S, Mendel R, Kunze T, Clement B. Identification of 
the Missing Component in the Mitochondrial Benzamidoxime Prodrug-converting 
System as a Novel Molybdenum Enzyme. J Biol Chem. 2006;281:34796-802. 
 
[105] Neve EPA, Nordling A, Andersson TB, Hellman U, Diczfalusy U, Johansson I, et al. 
Amidoxime reductase system containing cytochrome b5 type B (CYB5B) and MOSC2 is 
of importance for lipid synthesis in adipocyte mitochondria. J Biol Chem. 2012;287:6307-
17. 
 
[106] Sparacino-Watkins CE, Lai Y-C, Gladwin MT. Nitrate-nitrite-nitric oxide pathway 
in pulmonary arterial hypertension therapeutics. Circulation. 2012;125:2824-6. 
 
[107] Froriep D, Clement B, Bittner F, Mendel RR, Reichmann D, Schmalix W, et al. 
Activation of the anti-cancer agent upamostat by the mARC enzyme system. Xenobiotica. 
2013;43:780-4. 
 
[108] Gruenewald S, Wahl B, Bittner F, Hungeling H, Kanzow S, Kotthaus J, et al. The 
Fourth Molybdenum Containing Enzyme mARC: Cloning and Involvement in the 
Activation of N-Hydroxylated Prodrugs. J Med Chem. 2008;51:8173-7. 
 
[109] Havemeyer A, Grunewald S, Wahl B, Bittner F, Mendel R, Erdelyi P, et al. Reduction 
of N-hydroxy-sulfonamides, including N-hydroxy-valdecoxib, by the molybdenum-
containing enzyme mARC. Drug Metab Dispos. 2010;38:1917-21. 
 
[110] Krompholz N, Krischkowski C, Reichmann D, Garbe-Schoenberg D, Mendel R-R, 
Bittner F, et al. The Mitochondrial Amidoxime Reducing Component (mARC) Is Involved 
in Detoxification of N-Hydroxylated Base Analogues. Chem Res Toxicol. 2012;25:2443-
50. 
 
[111] Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global 
quantification of mammalian gene expression control. Nature. 2011;473:337-42. 
 
[112] Wilhelm M, Schlegl J, Hahne H, Gholami AM, Lieberenz M, Savitski MM, et al. 
Mass-spectrometry-based draft of the human proteome. Nature (London, U K). 
2014;509:582-7. 
 
[113] Kotthaus J, Wahl B, Havemeyer A, Kotthaus J, Schade D, Garbe-Schoenberg D, et 
al. Reduction of Nω-hydroxy-L-arginine by the mitochondrial amidoxime reducing 
component (mARC). Biochem J. 2011;433:383-91. 
 166 
 
 
[114] Borgese N, D'Arrigo A, De Silvestris M, Pietrini G. NADH-cytochrome b5 reductase 
and cytochrome b5 isoforms as models for the study of post-translational targeting to the 
endoplasmic reticulum. FEBS Lett. 1993;325:70-5. 
 
[115] Slaughter SR, Williams CH, Jr., Hultquist DE. Demonstration that bovine 
erythrocyte cytochrome b5 is the hydrophilic segment of liver microsomal cytochrome 
b5. Biochim Biophys Acta, Protein Struct Mol Enzymol. 1982;705:228-37. 
 
[116] Jakobs HH, Mikula M, Havemeyer A, Strzalkowska A, Borowa-Chmielak M, 
Dzwonek A, et al. The N-reductive system composed of mitochondrial amidoxime 
reducing component (mARC), cytochrome b5 (CYB5B) and cytochrome b5 reductase 
(CYB5R) is regulated by fasting and high fat diet in mice. PLoS One. 2014;9:e105371/1-
e/11, 11 pp. 
 
[117] D'Arrigo A, Manera E, Longhi R, Borgese N. The specific subcellular localization of 
two isoforms of cytochrome b5 suggests novel targeting pathways. J Biol Chem. 
1993;268:2802-8. 
 
[118] Ito A. Cytochrome b5-like hemoprotein of outer mitochondrial membrane; OM 
cytochrome b. I. Purification of OM cytochrome b from rat liver mitochondria and 
comparison of its molecular properties with those of cytochrome b5. J Biochem. 
1980;87:63-71. 
 
[119] Borgese N, Gazzoni I, Barberi M, Colombo S, Pedrazzini E. Targeting of a tail-
anchored protein to endoplasmic reticulum and mitochondrial outer membrane by 
independent but competing pathways. Mol Biol Cell. 2001;12:2482-96. 
 
[120] Kurian JR, Bajad SU, Miller JL, Chin NA, Trepanier LA. NADH cytochrome b5 
reductase and cytochrome b5 catalyze the microsomal reduction of xenobiotic 
hydroxylamines and amidoximes in humans. J Pharmacol Exp Ther. 2004;311:1171-8. 
 
[121] Mikula M, Gaj P, Dzwonek K, Rubel T, Karczmarski J, Paziewska A, et al. 
Comprehensive analysis of the palindromic motif TCTCGCGAGA: A regulatory element 
of the HNRNPK promoter. DNA Res. 2010;17:245-60. 
 
[122] Andersson S, Hofmann Y, Nordling A, Li X-q, Nivelius S, Andersson TB, et al. 
Characterization and partial purification of the rat and human enzyme systems active in 
the reduction of N-hydroxymelagatran and benzamidoxime. Drug Metab Dispos. 
2005;33:570-8. 
 167 
 
 
[123] Newton BW, Cologna SM, Moya C, Russell DH, Russell WK, Jayaraman A. 
Proteomic Analysis of 3T3-L1 Adipocyte Mitochondria during Differentiation and 
Enlargement. J Proteome Res. 2011;10:4692-702. 
 
[124] Abbenante G, Fairlie DP. Protease inhibitors in the clinic. Med Chem. 2005;1:71-104. 
[125] Shirk RA, Vlasuk GP. Inhibitors of Factor VIIa/Tissue Factor. Arterioscler, Thromb, 
Vasc Biol. 2007;27:1895-900. 
 
[126] Meyer JE, Brocks C, Gehrking E, Kovacs G, Neppert B, Gliemroth J, et al. 
Brachytherapy in combination with function-preserving surgery. An interdisciplinary 
challenge. HNO. 2008;56:471-8. 
 
[127] Fuller AT. Antibacterial action of some aromatic amines, amidines, amidoximes, 
guanidines, and diguanides. Biochem J. 1947;41:403-8. 
 
[128] Salom-Roig XJ, Hamze A, Calas M, Vial HJ. Dual molecules as new antimalarials. 
Comb Chem High Throughput Screening. 2005;8:49-62. 
 
[129] Werbovetz K. Diamidines as antitrypanosomal, antileishmanial and antimalarial 
agents. Curr Opin Invest Drugs (Thomson Sci). 2006;7:147-57. 
 
[130] Soeiro MNC, de Castro SL, de Souza EM, Batista DGJ, Silva CF, Boykin DW. 
Diamidine activity against trypanosomes: the state of the art. Curr Mol Pharmacol. 
2008;1:151-61. 
 
[131] Weller T, Alig L, Beresini M, Blackburn B, Bunting S, Hadvary P, et al. Orally active 
fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J Med Chem. 
1996;39:3139-47. 
 
[132] Clement B. Reduction of N-hydroxylated compounds: amidoximes (N-
hydroxyamidines) as pro-drugs of amidines. Drug Metab Rev. 2002;34:565-79. 
 
[133] Peterlin-Masic L, Cesar J, Zega A. Metabolism-directed optimisation of 
antithrombotics: The prodrug principle. Curr Pharm Des. 2006;12:73-91. 
 
[134] Clement B, Lopian K. Characterization of in vitro biotransformation of new, orally 
active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug 
Metab Dispos. 2003;31:645-51. 
 
 168 
 
[135] Cribb AE, Spielberg SP, Griffin GP. N4-hydroxylation of sulfamethoxazole by 
cytochrome P450 of the cytochrome P4502C subfamily and reduction of 
sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab 
Dispos. 1995;23:406-14. 
 
[136] Bonetta L. Protein-protein interactions: Interactome under construction. Nature 
(London, U K). 2010;468:851-4. 
 
[137] Thomas JA, Chovanec P, Stolz JF, Basu P. Mapping the protein profile involved in 
the biotransformation of organoarsenicals using an arsenic metabolizing bacterium. 
Metallomics. 2014;6:1958-69. 
 
[138] Szklarczyk D, Franceschini A, Wyder S, Heller D, Simonovic M, Roth A, et al. 
STRING v10: protein-protein interaction networks, integrated over the tree of life. 
Nucleic Acids Res. 2015;43:D447-52. 
 
[139] Von Mering C, Jensen LJ, Snel B, Hooper SD, Krupp M, Foglierini M, et al. STRING: 
Known and predicted protein-protein associations, integrated and transferred across 
organisms. Nucleic Acids Res. 2005;33:D433-D7. 
 
[140] Kim JH, Karnovsky A, Mahavisno V, Weymouth T, Pande M, Dolinoy DC, et al. 
LRpath analysis reveals common pathways dysregulated via DNA methylation across 
cancer types. BMC Genomics. 2012;13:526. 
 
[141] Lee C, Patil S, Sartor MA. RNA-Enrich: a cut-off free functional enrichment testing 
method for RNA-seq with improved detection power. Bioinformatics. 2016;32:1100-2. 
 
[142] Cornwall PL. Assertive outreach in Tyneside. Br J Psychiatry. 2003;183:461. 
 
[143] Martindale B. Cognitive-behavioural therapy as a treatment for psychosis. Br J 
Psychiatry. 2003;183:463. 
 
[144] Samarasekera N. Cognitive-behavioural therapy as a treatment for psychosis. Br J 
Psychiatry. 2003;183:462-3. 
 
[145] Howes O, Ohlsen R, Pilowsky LS. Effect of clozapine on mortality. Br J Psychiatry. 
2003;183:460. 
 
[146] Nunn CMH. Efficacy of antidepressant medication. Br J Psychiatry. 2003;183:463-4. 
 
 169 
 
[147] Wager E. Good practice in publication of clinical trial results. Br J Psychiatry. 
2003;183:464-5. 
 
[148] El-Nimr G. Health care contact and suicide. Br J Psychiatry. 2003;183:460-1. 
 
[149] Bola JR. Integrity and bias in academic psychiatry. Br J Psychiatry. 2003;183:464. 
 
[150] Summerfield D. Mental health of refugees. Br J Psychiatry. 2003;183:459-60; author 
reply 60. 
 
[151] Haw C. A new dawn for the yellow journal? Br J Psychiatry. 2003;183:459. 
 
[152] McGrath PJ, Elgar FJ, Johnston C, Dozois DJA, Reyno S. Treating maternal 
depression? Br J Psychiatry. 2003;183:461-2; author reply 2. 
 
[153] Shaw SY, Cheng S, Cupples LA, Larson MG, McCabe EL, Ngwa JS, et al. Genetic 
and clinical correlates of early-outgrowth colony-forming units. Circ: Cardiovasc Genet. 
2011;4:296-304. 
 
[154] Kaaij LTJ, van de Wetering M, Fang F, Decato B, Molaro A, van de Werken HJG, et 
al. DNA methylation dynamics during intestinal stem cell differentiation reveals 
enhancers driving gene expression in the villus. Genome Biol. 2013;14:R50/1-R/15,  pp. 
 
[155] Danielsen JMR, Sylvestersen KB, Bekker-Jensen S, Szklarczyk D, Poulsen JW, Horn 
H, et al. Mass spectrometric analysis of lysine ubiquitylation reveals promiscuity at site 
level. Mol Cell Proteomics. 2011;10:1-12. 
 
[156] Durand SVM, Hulst MM, Wit AAC, Mastebroek L, Loeffen WLA. Activation and 
modulation of antiviral and apoptotic genes in pigs infected with classical swine fever 
viruses of high, moderate or low virulence. Arch Virol. 2009;154:1417-31. 
 
[157] Hulst M, Kerstens H, de Wit A, Smits M, van der Meulen J, Niewold T. Early 
transcriptional response in the jejunum of germ-free piglets after oral infection with 
virulent rotavirus. Arch Virol. 2008;153:1311-22. 
 
[158] Altun M, Kramer HB, Willems LI, McDermott JL, Leach CA, Goldenberg SJ, et al. 
Activity-Based Chemical Proteomics Accelerates Inhibitor Development for 
Deubiquitylating Enzymes. Chem Biol (Cambridge, MA, U S). 2011;18:1401-12. 
 
 170 
 
[159] Cantu-Medellin N, Kelley EE. Xanthine oxidoreductase-catalyzed reactive species 
generation: A process in critical need of reevaluation. Redox Biol. 2013;1:353-8. 
 
[160] Chowdhury MM, Dosche C, Loehmannsroeben H-G, Leimkuehler S. Dual Role of 
the Molybdenum Cofactor Biosynthesis Protein MOCS3 in tRNA Thiolation and 
Molybdenum Cofactor Biosynthesis in Humans. J Biol Chem. 2012;287:17297-307. 
 
[161] Ghorbel MT, Mokhtari A, Sheikh M, Angelini GD, Caputo M. Controlled 
reoxygenation cardiopulmonary bypass is associated with reduced transcriptomic 
changes in cyanotic tetralogy of Fallot patients undergoing surgery. Physiol Genomics. 
2012;44:1098-106. 
 
[162] Wu CTB, Levine M, Homa F, Highlander SL, Glorioso JC. Characterization of the 
antigenic structure of herpes simplex virus type 1 glycoprotein C through DNA sequence 
analysis of monoclonal antibody-resistant mutants. J Virol. 1990;64:856-63. 
 
[163] Schrader M, Fahimi HD. The peroxisome: still a mysterious organelle. Histochem 
Cell Biol. 2008;129:421-40. 
 
[164] Bittner F. Molybdenum metabolism in plants and crosstalk to iron. Front Plant Sci. 
2014;5:28. 
 
[165] Wiese S, Gronemeyer T, Ofman R, Kunze M, Grou CP, Almeida JA, et al. Proteomics 
characterization of mouse kidney peroxisomes by tandem mass spectrometry and protein 
correlation profiling. Mol Cell Proteomics. 2007;6:2045-57. 
 
[166] Zhou M, Li Q, Wang R. Current Experimental Methods for Characterizing Protein-
Protein Interactions. ChemMedChem. 2016;11:738-56. 
 
[167] Miernyk JA, Thelen JJ. Biochemical approaches for discovering protein-protein 
interactions. Plant J. 2008;53:597-609. 
 
[168] Howell JM, Winstone TL, Coorssen JR, Turner RJ. An evaluation of in vitro protein-
protein interaction techniques: assessing contaminating background proteins. 
Proteomics. 2006;6:2050-69. 
 
[169] Luethy MH, David NR, Elthon TE, Miernyk JA, Randall DD. Characterization of a 
monoclonal antibody recognizing the E1α subunit of plant mitochondrial pyruvate 
dehydrogenase. J Plant Physiol. 1995;145:443-9. 
 
 171 
 
[170] Huang BX, Kim H-Y. Effective identification of Akt interacting proteins by two-step 
chemical crosslinking, co-immunoprecipitation and mass spectrometry. PLoS One. 
2013;8:e61430. 
 
[171] Tang X, Bruce JE. Chemical cross-linking for protein-protein interaction studies. 
Methods Mol Biol (Totowa, NJ, U S). 2009;492:283-93. 
 
[172] Guerrero C, Tagwerker C, Kaiser P, Huang L. An integrated mass spectrometry-
based proteomic approach. Quantitative analysis of tandem affinity-purified in vivo 
cross-linked protein complexes (QTAX) to decipher the 26 S proteasome-interacting 
network. Mol Cell Proteomics. 2006;5:366-78. 
 
[173] Vasilescu J, Guo X, Kast J. Identification of protein-protein interactions using in vivo 
cross-linking and mass spectrometry. Proteomics. 2004;4:3845-54. 
 
[174] Hall DB, Struhl K. The VP16 activation domain interacts with multiple 
transcriptional components as determined by protein-protein cross-linking in vivo. J Biol 
Chem. 2002;277:46043-50. 
 
[175] Li H, Chang L, Howell JM, Turner RJ. DmsD, a Tat system specific chaperone, 
interacts with other general chaperones and proteins involved in the molybdenum 
cofactor biosynthesis. Biochim Biophys Acta, Proteins Proteomics. 2010;1804:1301-9. 
 
[176] Matsunami H, Yoon Y-H, Meshcheryakov VA, Namba K, Samatey FA. Structural 
flexibility of the periplasmic protein, FlgA, regulates flagellar P-ring assembly in 
Salmonella enterica. Sci Rep. 2016;6:27399. 
 
[177] Wei X, Guo Y, Shao C, Sun Z, Zhurina D, Liu D, et al. Fructose Uptake in 
Bifidobacterium longum NCC2705 Is Mediated by an ATP-binding Cassette Transporter. 
J Biol Chem. 2012;287:357-67. 
 
[178] Mellacheruvu D, Wright Z, Couzens AL, Lambert J-P, St-Denis NA, Li T, et al. The 
CRAPome: a contaminant repository for affinity purification-mass spectrometry data. 
Nat Methods. 2013;10:730-6. 
 
[179] Andrew PJ, Harant H, Lindley IJD. Nitric oxide regulates IL-8 expression in 
melanoma cells at the transcriptional level. Biochem Biophys Res Commun. 1995;214:949-
56. 
 
 172 
 
[180] Kuo HP, Hwang KH, Lin HC, Wang CH, Lu LC. Effect of endogenous nitric oxide 
on tumor necrosis factor-α-induced leukosequestration and IL-8 release in guinea pigs 
airways in vivo. Br J Pharmacol. 1997;122:103-11. 
 
[181] Yoshizumi M, Perrella MA, Burnett JC, Jr., Lee ME. Tumor necrosis factor 
downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ 
Res. 1993;73:205-9. 
 
[182] Bernier SG, Haldar S, Michel T. Bradykinin-regulated interactions of the mitogen-
activated protein kinase pathway with the endothelial nitric-oxide synthase. J Biol Chem. 
2000;275:30707-15. 
 
[183] Du Q, Zhang X, Liu Q, Zhang X, Bartels CE, Geller DA. Nitric Oxide Production 
Upregulates Wnt/β-Catenin Signaling by Inhibiting Dickkopf-1. Cancer Res. 
2013;73:6526-37. 
 
[184] Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. 
Oncogene. 2006;25:7469-81. 
 
[185] Murohara T, Witzenbichler B, Spyridopoulos I, Asahara T, Ding B, Sullivan A, et al. 
Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler, 
Thromb, Vasc Biol. 1999;19:1156-61. 
 
[186] Venkatesh S, Ramachandran A, Zachariah A, Oommen A. Mitochondrial ATP 
synthase inhibition and nitric oxide are involved in muscle weakness that occurs in acute 
exposure of rats to monocrotophos. Toxicol Mech Methods. 2009;19:239-45. 
 
[187] Mery PF, Pavoine C, Belhassen L, Pecker F, Fischmeister R. Nitric oxide regulates 
cardiac calcium current. Involvement of cGMP-inhibited and cGMP-stimulated 
phosphodiesterases through guanylyl cyclase activation. J Biol Chem. 1993;268:26286-95. 
 
[188] Kurtz A, Gotz K-H, Hamann M, Wagner C. Stimulation of renin secretion by nitric 
oxide is mediated by phosphodiesterase 3. Proc Natl Acad Sci U S A. 1998;95:4743-7. 
 
[189] Sandner P, Kornfeld M, Ruan X, Arendshorst WJ, Kurtz A. Nitric oxide/cAMP 
interactions in the control of rat renal vascular resistance. Circ Res. 1999;84:186-92. 
 
[190] Wang L, Cummings R, Usatyuk P, Morris A, Irani K, Natarajan V. Involvement of 
phospholipases D1 and D2 in sphingosine 1-phosphate-induced ERK (extracellular-
 173 
 
signal-regulated kinase) activation and interleukin-8 secretion in human bronchial 
epithelial cells. Biochem J. 2002;367:751-60. 
 
[191] Ghosh S, Strum JC, Sciorra VA, Daniel L, Bell RM. Raf-1 kinase possesses distinct 
binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic acid 
regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol-13-acetate-stimulated 
Madin-Darby canine kidney cells. J Biol Chem. 1996;271:8472-80. 
 
[192] Andresen BT, Rizzo MA, Shome K, Romero G. The role of phosphatidic acid in the 
regulation of the Ras/MEK/Erk signaling cascade. FEBS Lett. 2002;531:65-8. 
 
[193] Rizzo MA, Shome K, Vasudevan C, Stolz DB, Sung T-C, Frohman MA, et al. 
Phospholipase D and its product, phosphatidic acid, mediate agonist-dependent Raf-1 
translocation to the plasma membrane and the activation of the mitogen-activated 
protein kinase pathway. J Biol Chem. 1999;274:1131-9. 
 
[194] Rizzo MA, Shome K, Watkins SC, Romero G. The recruitment of Raf-1 to 
membranes is mediated by direct interaction with phosphatidic acid and is independent 
of association with Ras. J Biol Chem. 2000;275:23911-8. 
 
[195] Denuc A, Nunez E, Calvo E, Loureiro M, Miro-Casas E, Guaras A, et al. New 
protein-protein interactions of mitochondrial connexin 43 in mouse heart. J Cell Mol Med. 
2016;20:794-803. 
 
[196] Vandermoere F, El Yazidi-Belkoura I, Demont Y, Slomianny C, Antol J, Lemoine J, 
et al. Proteomics exploration reveals that actin is a signaling target of the kinase Akt. Mol 
Cell Proteomics. 2007;6:114-24. 
 
